

# POSTER SESSION GUIDELINES

## OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

**NOTE:** Neither ISPE nor the Montreal Convention Center will be responsible for any poster that is left up overnight or is lost or damaged.

## POSTER SESSION

Posters will be displayed in Rooms 220BC of the Montreal Convention Center August 26-28. Each day will have a separate poster session. All posters for a specific day's session must be set-up and taken down that day.

- ▶ **Monday, August 26** ..... Poster Session A
- ▶ **Tuesday, August 27** ..... Poster Session B
- ▶ **Wednesday, August 28** ..... Poster Session C

### 1. Set Up:

- ▶ 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in rooms 220BC of the convention center.

### 2. Hours:

- ▶ Posters will be displayed from 8:00am-6:00pm on Monday and Tuesday, and from 8:00am-1:45pm on Wednesday.

### 3. Discussion Time:

- ▶ **General:** Presenters should be at their posters between 12:45-1:15pm on Monday (A) and Wednesday (C); and between 12:15-12:45pm on Tuesday (B)
- ▶ **Poster Walks:** Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters at the following times: Monday & Wednesday 12:45-1:30pm; Tuesday 12:15-1:00pm.

<b>Monday</b>	<ul style="list-style-type: none"> <li>• Adherence</li> <li>• Comparative Effectiveness Research (CER)</li> </ul>	<ul style="list-style-type: none"> <li>• Medications in Pregnancy</li> </ul>
<b>Tuesday</b>	<ul style="list-style-type: none"> <li>• Benefit Risk Assessment, Communications &amp; Evaluation (BRACE)</li> <li>• Databases</li> </ul>	<ul style="list-style-type: none"> <li>• Molecular Epidemiology-Biomarkers-Pharmacogenetics</li> <li>• Pediatrics</li> </ul>
<b>Wednesday</b>	<ul style="list-style-type: none"> <li>• Asian Pharmacoeconomics Network (AsPEN)</li> <li>• Biologics</li> </ul>	<ul style="list-style-type: none"> <li>• Drug Utilization/Health Services Research</li> <li>• Medical Devices</li> </ul>

The poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

A group of judges will select the best poster of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced during The Final Word session at 4:30pm, Wednesday, August 28.

### 4. Take Down:

- ▶ All posters must be taken down by 6:30pm on Monday and Tuesday, and by 5:00pm on Wednesday.

## NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board corresponding to the number assigned to their poster on that day in the Final Program. The **poster number is the first number listed**. The **abstract number** for use in locating abstracts in the Final Program is listed after the abstract title in brackets [ ]. The Abstracts2View site, accessible on a mobile device, also indicates the poster number and abstract number.

## POSTER SPECIFICATIONS

1. Posters must be designed to fit a free-standing fabric poster board approximately **3 feet WIDE x 7 feet HIGH (1 meter WIDE x 2.4 meters HIGH)**. Horizontal posters will not fit the boards; only **VERTICAL/PORTRAIT** posters will be allowed.
2. **Disclosure Statement**  
A disclosure statement must accompany each poster. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.
3. **Call4Posters**  
Pick-up posters ordered through Call4Posters® in the Exhibit Hall (Room 220BC).

## Classical Pharmacoepidemiology

- 1 Association between Antidepressant Use and Sleep Quality: A Population-Based Study [80]**  
Nikkie Aarts, Raymond Noordam, Lisette Zuurbier, Albert Hofman, Henning Tiemeier, Bruno H Stricker, Loes E Visser. (Netherlands)
- 2 Glyburide, in Contrast to Gliclazide, Has a Dose-Response Relationship with Adverse Cardiovascular Outcomes in Type 2 Diabetes Patients [81]**  
Ahmed Abdelmoneim, Dean Eurich, Ambikaipakan Senthilselvan, Weiyu Qiu, Scot Simpson. (Canada)
- 3 Calcium Channel Blockers and Esophageal Cancer: A Case-Control Analysis [82]**  
Claudia Becker, Susan S Jick, Christoph R Meier. (Switzerland)
- 4 Case-Control Analysis on Metformin and Cancer of the Esophagus [83]**  
Claudia Becker, Christoph R Meier, Susan S Jick, Michael Bodmer. (Switzerland)
- 7 The Effect of Statins on Influenza Morbidity and Mortality [86]**  
Paul Brassard, Jennifer Wu, Brielan Smiechowski, Sophie Dellaniello, Pierre Ernst, Samy Suissa. (Canada)
- 8 Diabetes and the Risk of Incident Gout [87]**  
Saskia G Bruderer, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)
- 9 Association of Antibiotic Use with Colorectal Cancer Risk in Type 2 Diabetes Mellitus [88]**  
Li-Chiu Wu, Chia-Hsui Chang, Jiun-Ling Wang, Jou-Wei Lin, Mei-Shu Lai. (Taiwan)
- 10 Risk of Tuberculosis and Influenza Associated with Use of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [89]**  
Yaa-Hui Dong, Chia-Hsui Chang, Fe-Lin Lin Wu, Li-Jiuan Shen, Claes-Göran Löfdahl, Mei-Shu Lai, Donald A Mahler. (Taiwan)
- 11 The 3.5-Year Mortality Impact of Drugs in Secondary Prevention of Myocardial Infarction in Real-Life (Interim Analysis of the EOLE Cohort) [90]**  
Cécile Droz, Caroline Dureau, Daniel Thomas, Nicolas Danchin, Jacques Tricoire, Jacques Bénichou, François Paillard, Serge Herberg, Igor Sibon, François Rouanet, Sahondra Rambelomanana, Hélène Maizi, Marie-Agnès Bernard, Patrick Blin, Nicholas Moore. (France)
- 12 Drug-Associated Acute Liver Failure Leading to Registration for Transplantation in France from the SALT Study, 2005-2007 [91]**  
Sinem Ezgi Gulmez, Dominique Larrey, George-Philippe Pageaux, Jeremy Jove, Régis Lassalle, Severine Lignot, Patrick Blin, Nicholas Moore. (France)
- 15 Breast Cancer and Postmenopausal Hormone Therapy in a Japanese Cohort of Women: An Interim Analysis of Japan Nurses' Health Study [95]**  
Kunihiko Hayashi, Hideki Mizunuma, Toshiro Kubota, Toshiyuki Yasui, Kota Katanoda, Jung-Su Lee, Kazue Nagai, Shosuke Suzuki. (Japan)
- 16 Trends in the Prevalence and Incidence of ADHD-Drugs among Children, Adolescents, and Adults in Sweden 2006-2012 [96]**  
Mikael Hoffmann, Gudrun Jonasdottir-Bergman, Katarina Baatz, Bengt Danielsson, Mårten Gerle, Birgitta Nordstedt Wikner, Peter Salmi. (Sweden)
- 17 Comparison of Validation Studies for the External Control for Confounding by Body Mass Index and Smoking When Assessing the Effects of Metformin Versus Sulfonylureas on Cancer Incidence [97]**  
Jin-Liern Hong, Virginia Pate, Michele Jonsson Funk, Emily Ko, Til Stürmer. (United States)
- 18 Comparing the Risk for Breast Cancer in Older Adults Initiating Metformin or Sulfonylureas [98]**  
Jin-Liern Hong, Michele Jonsson Funk, Emily Ko, Virginia Pate, Til Stürmer. (United States)
- 19 Ocular Safety of Intravitreal Injection of Age-Related Macular Degeneration (AMD) Treatments in a Prospective Observational Cohort Study in Europe [99]**  
Kui Huang, Marla B Sultan, Duo Zhou, Charles S Tressler, Jingping Mo. (United States)
- 20 What Is the Delay in Insulin Therapy Initiation in Patients with T2DM Not Responding to Oral Glucose Lowering Agents? [100]**  
Ruth M Mast, Danielle AP Jansen, Piet J Kostense, Iris Walraven, Amber van der Heijden, Rob J Heine, Jacqueline M Dekker, Jacqueline G Hugtenburg, Giel Nijpels. (Netherlands)
- 21 Antiepileptic Drugs and Suicide: A Systematic Review [101]**  
Pili Ferrer, Elena Ballarín, Mònica Sabaté, Xavier Vidal, Luisa Ibáñez. (Spain)
- 22 A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis [102]**  
Rachel Jawahar, Shijing Yang, Unsung Oh, Kate L Lapane. (United States)
- 24 Prevalence of Potentially Inappropriate Medication Prescribing among Older US Adults Using the New 2012 Beers Criteria [104]**  
Marcela Jirón, Virginia Pate, Laura Hanson, Michele Jonsson Funk, Til Stürmer. (Chile)
- 25 Replication Study on the Risk of Liver Injury Associated with the Use of Antibiotics Using a US Database with Linkage with Hospital Data [105]**  
Stephanie Tcherny-Lessenot, Yunxun Wang, Juhaeri Juhaeri, Xavier Kurz, Laurent Auclert, Patrick Caubel. (United States)
- 26 Risks of Venous Thromboembolism in Women Using Progestogen-Only Contraception [106]**  
Helle Kieler, Anders Sundström, Ingemar Persson, Annica Bergendal. (Sweden)
- 27 Clinical and Health Care Use Characteristics of Patients Newly Prescribed Allopurinol, Febuxostat and Colchicine for Gout [107]**  
Seoyoung C Kim, Bernhard MW Schmidt, Jun Liu, Daniel H Solomon, Sebastian Schneeweiss. (United States)
- 28 Aminoglycoside Ophthalmic Agents Use and Risk of Acute Renal Failure in Elderly Patients: A Case-Crossover Design [108]**  
Young-Jin Ko, Ji-Young Kim, Nam-Kyung Choi, Joongyub Lee, Hye-Min Kim, Byung-Joo Park. (Republic of Korea)
- 29 Relative Risk of Hip/Femur Fractures during the Initiation Period of alpha-Blockers Therapy in Male Elders [109]**  
Chao-Lun Lai, Raymond Nien-Chen Kuo, Ho-Min Chen, Ching-Fen Wu, Hui-Chun Huang, Chih-Hao Wang, Chiu-Lin Lai, Chia-Hsui Chang, Ming-Fong Chen, Mei-Shu Lai. (Taiwan)
- 31 Discontinuation of Statin Therapy Associates with Parkinson's Disease: A Population-Based Study [111]**  
Yen-Chieh Lee, Chin-Hsien Lin, Ruey-Meei Wu, Min-Shung Lin, Jou-Wei Lin, Chia-Hsui Chang, Mei-Shu Lai. (Taiwan)
- 32 Baseline Characteristics and Cardiovascular (CV) Comorbidities among United States Males Prior to Testosterone Treatment as Compared to Non-Users [112]**  
Hu Li, Karin Benoit, Jonathan Swain, Nancy Ostrowski, Stephen Motsko. (United States)
- 33 Baseline Characteristics and Comorbidities among United Kingdom Males Prior to Testosterone Treatment Compared to Non-Users Stratified by Body Mass Index (BMI) [113]**  
Hu Li, Jonathan Swain, Karin Benoit, Nancy Ostrowski, Stephen Motsko. (United States)
- 34 Statins for Prevention of Alzheimer's Disease: Systematic Review and Meta-Analysis [114]**  
Sandra Lopez-Leon, Elena Rivero-Ferrer. (Spain)
- 35 Serious Infections Associated with Anti-Tumor Necrosis Factor (anti-TNF) Agents among Rheumatoid Arthritis Patients in Brazil [115]**  
Cristiano S Moura, Felipe Ferre, Grazielle D Dias, Adriana M Kakehasi, Augusto A Guerra, Jr., Eli Iola G Andrade, Mariângela L Cherchiglia, Francisco A Acurcio. (Canada)

Monday, August 26  
**POSTER SESSION A**

- 37 Real-Life Usage Patterns and Effectiveness of Sunitinib in Patients with Clear Cell Metastatic Renal Cell Carcinoma: The SANTORIN Study [117]**  
Angela Grelaud, Alain Ravaud, Jacques-Olivier Bay, Céline Bairras-Martin, Aurélie Balestra, Christine Chevreau, Marie-Agnès Bernard, Emmanuelle Bignon, Stéphane Culine, Stéphanie Lamarque, Régis Lassalle, Magali Rouyer, Nicholas Moore, Pernelle Noize, Annie Fourrier-Réglat. (France)
- 38 Cetuximab with Irinotecan or Oxaliplatin for 1st-Line Metastatic Colorectal Cancer: Effectiveness in the EREBUS Cohort Compared to Pivotal Trials [118]**  
Pernelle Noize, Annie Fourrier-Réglat, Magali Rouyer, Angela Grelaud, Emmanuelle Bignon, Alise Le Monies de Sagazan, Régis Lassalle, Jérémy Jové, Alain Monnereau, Antonio Sa Cunha, Eric François, Emmanuel Mitry, Nicholas Moore, Denis Smith. (France)
- 39 Association of Acetylsalicylic Acid and the Risk of Hospitalization for Vascular Access-Related Infections and Septicemia among Hemodialysis Patients [119]**  
Isabelle Normand, Rachel Grinker, Hind Harrak, Naoual Elftouh, Jean-Philippe Lafrance. (Canada)
- 40 Using Epidemiological Registry Data To Provide Background Rate Context for Adverse Events in a Rheumatoid Arthritis (RA) Drug Development Program - A Coordinated Approach [120]**  
Fredrik Nyberg, Johan Askling, Jeffrey D Greenberg, Kaleb Michaud, Hisashi Yamanaka, Deborah Symmons, Meilien Ho. (Sweden)
- 41 Validation of the Health Improvement Network for the Study of Psoriatic Arthritis [121]**  
Alexis Ogdie, Thorvador Love, Kevin Haynes, Sean Hennessy, Hyon Choi, Joel Gelfand. (United States)
- 43 The Association between Obesity and Major Bleeding Risk in Warfarin Users in a Community Setting [123]**  
Joshua A Roth, Denise Boudreau, Kenneth E Thummel, David L Veenstra. (United States)
- 44 Psychiatric Comorbidity among Children, Adolescents, and Adults Treated with Methylphenidate [124]**  
Peter Salmi, Gudrun Jonasdottir-Bergman, Bengt Danielsson, Birgitta Norstedt Wikner, Mårten Gerle, Mikael Hoffmann. (Sweden)
- 45 Co-Prescription of Methylphenidate with Psychotropic Drugs among Children and Adults [125]**  
Peter Salmi, Gudrun Jonasdottir-Bergman, Bengt Danielsson, Birgitta Norstedt Wikner, Mårten Gerle, Mikael Hoffmann. (Sweden)
- 46 Evaluating the Impact of the Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain on Opioid Prescribing in Utah, 2002-2009 [126]**  
Brian C Sauer, Christy Porucznik, Chia-chen Teng, Jonathan Nebeker. (United States)

- 47 Anti-Malarial Chemoprophylaxis and the Risk of Developing Neuropsychiatric Disorders [127]**  
Cornelia Schneider, Miriam Adamcova, Susan S Jick, Mary K Miller, Patricia Schlagenhauf, Hans-Georg Rhein, Christoph R Meier. (Switzerland)
- 48 Risks of Adverse Events in Treated Chronic Hepatitis C Patients with Cirrhosis Compared to without Cirrhosis in Real-World Settings [128]**  
Sophie W Shen, Jennifer Wood Ives, Patricia Hines, Dessislava Dimitrova. (United States)
- 49 Use of Azithromycin and Cardiovascular Death [130]**  
Björn Pasternak, Henrik Svanström, Anders Hviid. (Denmark)
- 50 QT Interval Prolongation in Elderly Users of Selective Serotonin Reuptake Inhibitors [131]**  
Ingrid MM van Haelst, Wilton A van Klei, Hieronymus J Doodeman, Miriam J Warnier, Marie L De Bruin, Cor J Kalkman, Toine CG Egberts. (Netherlands)
- 51 The Association of Oral Fluoroquinolone Use with the Need for Retinal Detachment or Retinal Tear Repair [132]**  
Brian L VanderBeek, Kian Eftekhari, Devon Ghodasra, Jinbo Chen, John H Kempen, Kevin Haynes. (United States)
- 52 The SOS Project: Risk of Heart Failure and Use of Nonsteroidal Anti-Inflammatory Drugs—A Meta-Analysis of Observational Studies [133]**  
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Jordi Castellsague, Andrea Arfe, Susana Perez-Gutthann. (Spain)
- 53 Cardiovascular Risk with Glitazones and Metformin: Results from a Systematic Review of Observational Studies [134]**  
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Andrea V Margulis, Manel Pladevall, Miguel Gil, Silvana Romio, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 54 Beta Blockers and Breast Cancer: Results from a Collaborative Study [135]**  
Marco Villa, Stefano Boni, Simona Iodice, Magda Rognoni, Giuseppe Sampietro, Antonio Russo. (Italy)
- 55 Validity Threats in Multi-Center Retrospective Chart Abstraction Studies [136]**  
Nataliya Volkova, Lina Titievsky. (United States)
- 56 Effervescent, Dispersible and Soluble Medications Increase Cardiovascular Events [137]**  
Jacob George, Waseem Majeed, Thomas M MacDonald, Isla S Mackenzie, Li Wei. (United Kingdom)
- 57 An Epidemiological Study Examining the Risk of Malignancy in Patients with Inflammatory Bowel Disease [138]**  
Jessica C Wilson, Raoul I Furlano, Susan S Jick, Christoph R Meier. (Switzerland)

- 58 Factors and Characteristics for Medication Initiation in Type 2 Diabetes Patients in the UK [139]**  
Alison K Wright, Martin K Rutter, Richard Emsley, Darren M Ashcroft, Douglas Steinke. (United Kingdom)
- 60 Relative Risk of Myocardial Infarction for Canadian Patients with Psoriasis Treated Systemically as Compared to Patients Treated with Phototherapy [141]**  
Annie Levesque, Robert Bissonnette, Sophie Préfontaine, Marie-Eve Lapierre, Jean Lachaine. (Canada)

**Comparative Effectiveness Research**

- 62 Comparative Effectiveness and Safety of Concomitant Use of SSRIs in Combination with NSAIDs or Paracetamol [143]**  
Ole Köhler, Liselotte Petersen, Ole Mors, Christiane Gasse. (Denmark)
- 63 Comparative Effectiveness of Oxcarbazepine and Carbamazepine in Adult Patients with Epilepsy [144]**  
Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Yea-Huei Kao Yang. (Taiwan)
- 64 Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes Mellitus: A Pairwise and Network Meta-Analysis [145]**  
Feng Sun, Kai Yu, Shanshan Wu, Yuan Zhang, Zhirong Yang, Linong Ji, Luwen Shi, Siyan Zhan. (China)
- 65 Frequent Antibiotic Use and Breast Cancer Outcomes [146]**  
Heidi S Wirtz, Diana SM Buist, Julie R Gralow, William E Barlow, Shelly Gray, Jessica Chubak, Onchee Yu, Erin Bowles, Monica Fujii, Denise M Boudreau. (United States)

**Drug Safety in Pregnancy and Lactation**

- 66 ITP and Pregnancy [147]**  
Wendy J Carman, Diego Wyszynski, Cheryl Enger, John D Seeger. (United States)
- 67 Chats about Drugs and Pregnancy on Forum Websites: A French Descriptive Study [148]**  
Lucie Cantaloube, Isabelle Lacroix, Vanessa Rousseau, Haleh Bagheri, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 68 Medication Use during Pregnancy: A Multinational Perspective [149]**  
Angela Lupattelli, Olav Spigset, Michael J Twigg, Ksenia Zagorodnikova, Ann-Charlotte Mårdby, Myla Moretti, Mariola Drozd, Alice Panchaud, Katri Hameen-Anttila, Andre Rieutord, Romana Gjergja, Marina Odalovic, Debra Kennedy, Gorazd Rudolf, Herbert Juch, Anneke Passier, Ingunn Björnsdóttir, Hedvig Nordeng. (Norway)

*Monday, August 26*  
**POSTER SESSION A**

**Other**

- 69 Medication Discrepancy at Discharge in a Tertiary Hospital in Saudi Arabia [150]**  
Hisham Aljadhey, Isra Al-Rashoud. (Saudi Arabia)
- 70 The Number of Included Older People in Recent Pre-Authorization Trials [151]**  
Erna Beers, Dineke C Moerkerken, Toine CG Egberts, Hubert GM Leufkens, Paul AF Jansen. (Netherlands)
- 71 Expected Timelines To Set-Up an Observational Study in Europe: Example of 4 Pharmaco-Epidemiological Registries [152]**  
Sohéla Elkebir, Delphine Bayle, Denitza Muller. (France)
- 72 Evaluation of Knowledge and Use of Prescription Tools by Hospital Physicians in a Teaching Hospital [153]**  
Angeline Faucher, Driss Berdai, Claire Brotons, Annie Fourrier-Reglat, Nicholas Moore. (France)
- 73 A Cohort Study Examining Aspirin Use and Mortality in Men with Localised Prostate Cancer [154]**  
Evelyn M Flahavan, Kathleen Bennett, Linda Sharp, Thomas I Barron. (Ireland)
- 74 Clinical Pharmacy Interventions in a Tertiary Care Teaching Hospital in Southern India [155]**  
Parthasarathi Gurumurthy, Himanshu Patel, Gloria George, Ramesh Madhan. (India)
- 75 Use of Antidepressants and Risk of Developing First-Time Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Observational Studies [156]**  
Parthasarathi Gurumurthy, Krishna Undela, Sharon S John. (India)
- 76 Eight-Year Results from the US Osteosarcoma Surveillance Study [157]**  
David H Harris, Kirk D Midkiff, Alicia W Gilsenan, Nicole Kellier, Daniel Masica, Elizabeth B Andrews. (United States)
- 78 Medication Safety Resources Available through a New Public Access Repository: A Descriptive Analysis [159]**  
John Iskander, Robert Swain. (United States)
- 79 Medication Adherence in Pediatric Patients with Epilepsy Using Prescription Refilled Rate and Self-Reported Questionnaire [160]**  
Shih-Chieh Shao, Edward Chia-Cheng Lai, Yea-Huei Kao Yang, Pheng-Ying Yeh Liu. (Taiwan)
- 80 Methods Issues in Observational Studies of the Cardiovascular Risk Associated with Glucose-Lowering Medications: Results of a Systematic Review and Evaluation [161]**  
Nuria Riera-Guardia, Andrea V Margulis, Manel Pladevall, Cristina Varas-Lorenzo, Susana Perez-Gutthann. (Spain)

- 81 The Extent and Origin of Resistance to Antituberculosis Drugs in the Netherlands in the Period 1993-2011 [162]**  
Carolien Ruesen, Arianne B Van Gageldonk-Lafeber, Gerard de Vries, Connie GM Erkens, Job van Rest, Hester Korthals Altes, Han de Neeling, Miranda Kamst, Dick van Soolingen. (Netherlands)
- 82 Potential Predictors of Naltrexone Response in Alcohol Dependence: A Systematic Review [163]**  
James Garbutt, Amy Greenblatt, Suzanne L West, Laura Morgan, Alexei Kampov-Polevoy, Harmon Jordan, Georgiy Bobashev. (United States)
- 83 Reliability of Outcome Definitions Using Japanese Standardized Electronic Medical Records Data [164]**  
Kaori Yamada, Eiko Tada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)

**Pharmacovigilance**

- 85 Public Perception towards Adverse Drug Reaction Reporting in Saudi Arabia [166]**  
Hisham Aljadhey, Yaser Albogami. (Saudi Arabia)
- 86 Evaluation of Knowledge and Barriers among Physicians towards Adverse Drug Reactions (ADRs) Reporting in Saudi Arabia [167]**  
Hisham Aljadhey, Dalal Al-Abdulkarim. (Saudi Arabia)
- 87 Adverse Events Associated with Colchicine Drug Interactions: Analysis of the Public Version of the FDA Adverse Event Reporting System [168]**  
Ziyad S Almalki, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)
- 88 Risk of Major Bleeding with Dabigatran Versus Active Controls: A Systematic Review and Meta-Analysis of Randomised Clinical Trials [169]**  
Stefania Antoniazzi, Driss Berdai, Valentino Conti, Philip Robinson, Sonia Radice, Emilio Clementi, Nicholas Moore, Antoine Pariente, Francesco Salvo. (Italy)
- 89 Evaluation of Signal Scores over Time [170]**  
Robert Azadian, Naashika Quarcoo, Nancy Yuen, Greg Powell. (United States)
- 90 Reducing Words without Losing Clinical Meaning – Can Text Mining Accelerate Review of Spontaneous Reports? [171]**  
Bethany Baer, Michael Nguyen, Emily Jane Woo, Scott Winiecki, John Scott, David Martin, Taxiarchis Botsis, Robert Ball. (United States)
- 91 Pharmacovigilance from a Public Health Point of View – A Survey of Simplified Recording of Adverse Drug Reactions (ADR) in Medical Records [172]**  
Ulf Bergman, Erika Höglund, Ingegerd Odar-Cederlöf, Nina Pettersson. (Sweden)
- 92 Comparison of 7 Patient Information Leaflets (PILs) of Narcotic Pain Medications Marketed by Indian Generic Companies with Original SmPC from Innovator Companies [173]**  
Arun K Biswas, Pipasha N Biswas. (United Kingdom)

- 93 ENCePP Supporting Regulatory Decision Making [174]**  
Stella Blackburn, Kevin Blake, Xavier Kurz, Jim Slattery, Henry Fitt, Peter Arlett. (United Kingdom)
- 94 Post-Marketing Requirements in Diabetes Mellitus in Europe (EMA) and the USA (FDA) [175]**  
Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 95 Post-Marketing Requirements: An Overview of the Therapeutic Areas Targeted by the EMA and the FDA [176]**  
Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 97 Development of Systematic Target Drug Prioritization Process in Korea [178]**  
Sooyoun Chung, So-Hyeon Ahn, Sujin Kim, Joo young Cho, Je Yon Kim, Yeun Jung Choi, Byung-Joo Park. (Republic of Korea)
- 98 Effects of Opioid Analgesic Tablets Resistant to Breaking, Crushing and Dissolving on Patient Safety Outcomes [179]**  
Paul M Coplan, Carla A Green, Nancy Perrin, Cynthia I Campbell, Stevan G Severson, Becki Bucher-Bartelson, Richard Dart, Shannon L Janoff, Nelson E Sessler, Hrishikesh Kale, Jody Green, Howard D Chilcoat. (United States)
- 99 MIHARI – Medical Information for Risk Assessment Initiative Year 4 [180]**  
Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 100 Classification and Evaluation Algorithm of Drug Safety Information of KFDA [181]**  
Jihye Ha, Han Oll Kim, You Jung Kim, Han Sung Na, Myeon Woo Cheong. (Republic of Korea)
- 101 Reporting Patterns of Adverse Drug Reactions over Recent Years in China: Analysis from Publications [182]**  
Jia He, Xiao-fei Ye, Xiao-jing Guo. (China)
- 102 Post Authorization Safety Study Comparing Quetiapine to Risperidone and Olanzapine [183]**  
Edith M Heintjes, Jetty A Overbeek, Fernie JA Penning-van Beest, Gunnar Brobert, Ron MC Herings. (Netherlands)
- 103 Application of Propensity Score Methods to Japanese Claims Data [184]**  
Shingo Higa, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 104 Quinine Sulfate Use and Hematologic Adverse Events: Active Surveillance in Medicare [185]**  
Monika Houstoun, Marsha E Reichman, David J Graham, Sumathi Nambiar, Hala Shamsuddin, S Christopher Jones, Kelly Cao, Michael Wernecke, Chelsea Lam, Chris M Worrall, Thomas E MaCurdy, Jeffrey A Kelman. (United States)

Monday, August 26  
**POSTER SESSION A**

- 105 Outlier Removal Expedites Adverse Drug Reaction Surveillance – Evaluation of a Simple Unmasking Strategy [186]**  
Kristina Juhlin, Xiaofei Ye, Kristina Star, G Niklas Norén. (Sweden)
- 106 Comparison of 7 Patient Information Leaflets (PILs) of Anesthetic Drugs Marketed by Indian Generic Companies with Original SmPC from Innovator Companies [187]**  
Nilima Justice. (United States)
- 107 Survey of Demand to Postmarketing Adverse Drug Event Reporting Data [188]**  
Sujin Kim, Sun Mi Shin, Minsun Kim, Mi Hee Kim, So-Hyeon Ahn, Sooyoun Chung, Byung-Joo Park. (Republic of Korea)
- 108 Low Renal Function in Hospitalized Geriatric Patients: Potentially Serious for Use of Renal Risk Drugs [189]**  
Inga Klarin, Ingegerd Odar Cederlöf, Ulf Bergman, Anders Helldén. (Sweden)
- 109 Use of Antiepileptic Drugs and Risk of Infection in Taiwan and Denmark: A Collaborative Cross-National Sequence Symmetry Analysis [190]**  
Edward Chia-Cheng Lai, Anton Pottegård, Jesper Hallas, Yea-Huei Kao Yang. (Taiwan)
- 110 Strategies To Optimize Physician Survey Research: Results from a Survey of Urology and Oncology Practitioners in 19 Countries [191]**  
Alexander Liede, Kirsty Hope, Alex Graham, Jorge Arellano. (United States)
- 111 Evaluation of Drug Induced Liver or Renal Toxicity with National Health Insurance Claim Database [192]**  
Mei-Shu Lin, Ro-Fang Pu, K Arnold Chan, Nen-Chung Chang, Churn-Shiouh Gau. (Taiwan)
- 112 Risk of HBV Reactivation in Patient Receiving Rituximab: Results from Taiwan National Adverse Drug Reaction Reporting System [193]**  
Shan-Hu Lin, Pi Huei Chao, Wen-Wen Chen, Angela On. (Taiwan)
- 113 Post-Marketing Study of Denosumab in Male Osteoporosis: A Model Feasibility Assessment [194]**  
Angelika Manthripragada, Elizabeth Delzell, Paul Muntner, Jeffrey R Curtis, Wendy Carmen, Haijun Ma, Violetta Hennessey, Fei Xue, Cynthia D O'Malley. (United States)
- 114 Drug Safety and Corporate Governance [195]**  
Kathy Moscou. (Canada)
- 115 Pharmacovigilance of Oral Antituberculosis in Indonesian TB Patients [196]**  
Ully A Mulyani, Dyah A Perwitasari, Jarir Atthobari. (Indonesia)
- 117 Changes in Prescription Drug Opioid Abuse Following Reformulation of an Abuse Deterrent Product: A National Study of Substance Abuse Treatment Clients [198]**  
Scott P Novak, Nathaniel Katz. (United States)
- 118 Results of the Experience with the Use of Varenicline in Daily Practice Using Intensive Monitoring [199]**  
Ingrid Oosterhuis, Linda Harmark, Eugene van Puijenbroek. (Netherlands)
- 119 Improving Pharmacovigilance Knowledge and Practice amongst Health Care Providers: A Case Study of Community Pharmacists in Lagos, Nigeria [200]**  
Ibrahim Adekunle Oreagba, Ibrahim Abayomi Ogunyinka. (Nigeria)
- 120 Pattern of Adverse Drug Reactions Reported in a South Indian Tertiary Care Teaching Hospital, 2001-2011 [201]**  
Bishnu Regmi, Thiyagu Rajakannan, MK Unnikrishnan. (India)
- 121 Development and Validation of an Instrument Classifying Preventable Adverse Drug Events - A Pilot Study [202]**  
Linda Ring Eriksson, Anna K Jönsson, Katja Hakkarainen, Staffan Hägg, Thomas Bradley, Henrik Lövborg. (Sweden)
- 122 QT Prolongation and Ventricular Arrhythmias Related to Antidepressants: An Analysis of the French Spontaneous Reporting Database [203]**  
Francesco Salvo, Annie Fourrier-Reglat, Miriam Sturkenboom, Emanuel Raschi, Elisabetta Poluzzi, Ugo Moretti, Fabrizio De Ponti, Pascal Auriche, Nicholas Moore, Antoine Pariente. (France)
- 123 Geospatial Analysis of Adverse Event Reports [204]**  
Simon Semus, Robert Azadian, Nancy Yuen, Phillip Burstein, Gregory Powell. (United States)
- 124 A Cohort Study of Sitagliptin and Risk of Acute Renal Failure Using Standardized Electronic Medical Record Data [205]**  
Eiko Tada, Kaori Yamada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 125 Hit-Miss Model Detects Duplicates Missed by Rule-Based Screening of Individual Case Safety Reports [206]**  
Philip M Tregunno, Dorthe Bech Fink, Cristina Fernandez, Niklas G Norén. (United Kingdom)
- 126 Advantages of Using Well Fitting Models To Assess the Effects of Time-Varying Drug Exposures in Prospective Surveillance [207]**  
Rolina D van Gaalen, Michal Abrahamowicz, Marie-Pierre Sylvestre, Marie-Eve Beauchamp, David L Buckeridge. (Canada)
- 127 Asymptotic Limit to the Relative Reporting Ratio - A Measure of the Violation of Hidden Assumptions behind Some Disproportionality Measures Used in Signal Detection [208]**  
Lionel Van Holle, Vincent Bauchau. (Belgium)
- 128 Signal Detection Based on the Time-to-Onset: Extending a New Method from Spontaneous Reports to Observational Studies [209]**  
Lionel Van Holle, Vincent Bauchau. (Belgium)
- 129 Drug Exposure Registry To Monitor Safety of Investigational Product [210]**  
Vani Vannappagari, Amy Sessoms, David Margolis, Lloyd Curtis, Kenne Mountford, Elizabeth Villeponteaux, Tamara Murry, Margaret Richards. (United States)
- 130 Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis [211]**  
Shanshan Wu, Yuelun Zhang, Feng Sun, Siyan Zhan. (China)

**Risk Management / Risk Minimization/Communication**

- 131 The Opportunities and Challenges of Delivering the Quetiapine Post-Authorization Safety Studies (PASS); a Diverse Program of Work [212]**  
Robert S Brody, Leigh Jefferies, Sherry Liu, Charles L Liss, Phil Damstetter, Lei Chen, Raj Tummala, Dhaval G Desai. (United States)
- 132 Assessing Current Awareness, Perception and Knowledge of Pharmacists on Anti-Counterfeiting Efforts in Singapore [213]**  
Hsien Jie Earl Tan, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 133 Thalidomide Imported by the Individual Doctors and Its Use in Japan [214]**  
Yukari Kamijima, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 134 The Observational Safety Evaluation of Asenapine (OBSERVA) Study: Rationale and Design [215]**  
Deborah Layton, Felicity Mitchell, Saad AW Shakir. (United Kingdom)
- 135 Methodological Considerations in Evaluating the Safety of Novel Anticoagulants in Secondary Care Setting in the UK: Defining the Contextual Comparator Cohort [216]**  
Deborah Layton, Miranda Davies, Alison Evans, Saad AW Shakir. (United Kingdom)
- 136 First-Year Review of Implementation of the Legal Requirements for Labels and Package Inserts of Proprietary Chinese Medicines [217]**  
Ching-kan Jackie Leung, Chi-hang Kevin Lam, Man-kin Ronald Lam. (China)
- 137 Effectiveness of Risk Minimization Interventions in Drug Safety: An Assessment of Methodological Gaps [218]**  
Yola Moride, Lenhangbong Nkeng, Inna Gridchyna, Anne-Marie Cloutier, Camille Craig, Sarah Frise. (Canada)
- 138 Observational Methods and Post Authorization Studies: Lessons Learned from Bosentan European Risk Management [219]**  
Erwan Muros-Le Rouzic, Monika Brand, Per Nilsson, Daniel Rosenberg. (Switzerland)

Monday, August 26  
**POSTER SESSION A**

- 139 Characteristics of Patients with Aberrant Behaviours Using Fentanyl Citrate Buccal Tablets: Results from a Post-Marketing Cohort Study [220]**  
 Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 140 Number of Biochemical Tests as a Trigger for Adverse Drug Events [221]**  
 Rianne J Zaai, Anouk D Lindemans, Ryan R Boedhrum, Jasperien E van Doormaal, Jos GW Kosterink, Flora M Haaijer-Ruskamp, Arnold G Vulto, Patricia MLA van den Bemt, Peter GM Mol. (Netherlands)

**Adherence SIG**

- 141 Cost-Effectiveness of Statins for Primary Prevention in Newly Diagnosed Type 2 Diabetes Patients: An Illustration for the Netherlands [244]**  
 Folgerdiena M de Vries, Petra Denig, Sipke T Visser, Eelko Hak, Maarten J Postma. (Netherlands)
- 144 Metformin Use in Prostate Cancer and the Risk of Death and Metastasis in Patients with Type 2 Diabetes [225]**  
 Leah Bensimon, Hui Yin, Samy Suissa, Michael N Pollak, Laurent Azoulay. (Canada)
- 146 Self-Reported Visual Analogue Scale Has Poor Sensitivity for Antiretroviral Non-Adherence in Botswana [242]**  
 Paul D Sonenthal, Scarlett Bellamy, Xiaoyan Han, Bakgaki Ratskaa, Gilbert Chimbengo, Thelma Ngoni, Tumelo Rantleru, Mosepele Mosepele, Elizabeth Lowenthal, Andrew P Steenhoff, Brian L Strom, Gregory P Bisson, Robert Gross. (United States)
- 147 Association of Patient and Drug Characteristics with Adherence and Persistence [227]**  
 Nikkie Aarts, Raymond Noordam, Albert Hofman, Bruno H Stricker, Loes E Visser. (Netherlands)
- 149 Adherence Explored as Patient-Centered Medication Management: Results of a Literature Review and Stakeholder Workshop [234]**  
 Jennifer L Kuntz, Carmit K McMullen, Meredith L Vandermeer, Maureen H Rumpitz, Mark C Hornbrook. (United States)
- 150 Beliefs about Medicines in Dutch Acenocoumarol and Phenprocoumon Users [236]**  
 Talitha I Verhoef, William K Redekop, Marcel L Bouvy, Brenda Dorenbos, Zamiera Karwar, Rianne MF van Schie, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 151 Antidepressant Utilization after Hospitalization with Depression: A Comparison between Non-Western Immigrants and Danish-Born Residents [237]**  
 Helle Wallach Kildemoes, Louise Thirstrup Thomsen, Margit Kriegbaum, Marie Louise Norredam. (Denmark)

- 152 Guidelines Adherence in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes: Comparing the Use of Metformin in Quebec Pre and Post-Canadian Diabetes Association Guidelines [238]**  
 Ting-Yu Wang, Eguale Tewodros, Robyn Tamblyn. (Canada)
- 153 Access to Medicines among the Brazilian Adult Population with Chronic Diseases [239]**  
 Anamaria Zaccolo. (Brazil)
- 154 Antihypertensive Persistence in Older Americans: Intent-To-Treat vs As-Treated Analysis [241]**  
 Wendy Camelo Castillo, Xiaojuan Li, Ross J Simpson, Jr., Virginia Pate, Til Sturmer, Michele Jonsson Funk. (United States)
- 156 Tumor Necrosis Factor Treatment Patterns in Medicare Patients with Inflammatory Conditions [245]**  
 Li Wang, Ahong Huang, Elyse Fritschel, Onur Baser. (United States)
- 157 Factors Associated with Reported Difficulty Taking Antiretroviral Therapy in Brazilian Patients [246]**  
 Celline C Almeida, Maria das Graças B Ceccato, Maria Inês B Battistella, Mark DC Guimarães, Francisco A Acurcio. (Brazil)
- 158 The Evaluation of Various Published Scales To Assess the Patient's Adherence to Medication [247]**  
 Josip Culig, Marcel Leppee, Marija Skes, Mario Malovic. (Croatia)
- 159 Attitudes towards Medication Use in a General Population of Adolescents [248]**  
 ES Koster, ML Bouvy, C Hakkers, T Hosman, L Nelemans, ER Heerdink. (Netherlands)

**Comparative Effectiveness Research (CER) SIG**

- 160 Comparative Effectiveness of Biologic DMARDs in Older and Disabled Patients with Rheumatoid Arthritis (RA) in Medicare [249]**  
 Huifeng Yun, Fenglong Xie, Lang Chen, Shuo Yang, Kenneth G Saag, David Harrison, George Joseph, Jeffrey R Curtis. (United States)
- 161 Opioid Analgesic Dosage Strength as a Predictor of Overdose Risk in the UK [250]**  
 Paul Coplan, Charles Wentworth, Nelson Sessler, Jerod Downing, Louis Alexander, Howard Chilcoat. (United States)
- 162 Application of a Cox Model across a Refunds Database: A New Approach To Compare Selective Serotonin Reuptake Inhibitors (SSRI) [251]**  
 Emilie Peron, Jean-Benoit Hardouin, Véronique Sebillé, Anicet Chaslerie, Jacques Pivette, Pascale Jolliet, Caroline Victorri-Vigneau. (France)
- 163 Treatment in the Morning Versus Evening (TIME) with Antihypertensives: A Pilot Study [252]**  
 David A Rorie, Thomas M MacDonald, Robert Flynn, Isla Mackenzie, Claudine Jennings, Lewis McConnachie, Ian Ford. (United Kingdom)

- 164 Thiazolidinedione Use and Risk of Hospitalization for Pneumonia in Type 2 Diabetes: Population Based Matched Case-Control Study [253]**  
 Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan Weiner, Jeanne Clark, Jodi B Segal. (United States)
- 165 Long-Term Effectiveness of Ribavirin Plus Pegylated Interferon Combination Therapy for Patients with Dual Hepatitis C and B in Taiwan: A Population-Based Study [255]**  
 Yu-Tseng Chu, Chun-Jen Liu, Wen-Yi Shau, Yaa-Hui Dong, Raymond NC Kuo, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 166 The Effect of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy [256]**  
 Mirko Di Martino, Silvia Cascini, Nera Agabiti, Lisa Bauleo, Ursula Kirchmayer, Danilo Fusco, Luigi Pinnarelli, Valeria Belleudi, Claudio Voci, Riccardo Pistelli, Elisabetta Patorno, Marina Davoli, The OUTPUT Study Group. (Italy)
- 167 Prioritizing Comparative Effectiveness Research: Utility of Disease-Specific Spending Estimates [258]**  
 Daniel M Huse, William D Marder. (United States)
- 168 Does the Risk Reduction Provided by Longer Durations of Clopidogrel Use after Stent Placement in Taiwan's National Health Insurance [259]**  
 Yen-Yun Yang, Yi-Chun Yeh, Chao-Lun Lai, Chiu-Ling Lai, Mei-Shu Lai. (Taiwan)
- 169 Effectiveness of Cholinesterase Inhibitors for Mild to Moderate Alzheimer's Disease: A Systematic Review of Observational Studies [260]**  
 Marie-Laure Laroche, Laure Paravisini, Marion Lassalle, Louis Merle. (France)
- 170 Comparative Effectiveness Research (CER): Where to Begin? A Literature Review of CER Methods Guides [261]**  
 Robert O McConeghy, Nicolle M Gatto, Aisling R Caffrey. (United States)
- 171 Improving the Validity of CER through Principled Exploration of Data [262]**  
 Anne-Marie Meyer, Huan Liu, Christina Mack, William R Carpenter, M Alan Brookhart. (United States)
- 173 Do SSRIs Increase the Risk of Gastrointestinal Adverse Effects? [264]**  
 Koen Pouwels, Arno Kalkman, Daan Schagen, Sipke Visser, Eelko Hak. (Netherlands)
- 174 Angiotensin-Converting Enzyme Inhibitor Treatment and the Development of Urinary Tract Infection [265]**  
 Koen Pouwels, Sipke Visser, Jens Bos, Eelko Hak. (Netherlands)

Monday, August 26  
**POSTER SESSION A**

- 175 Feasibility of Linking Administrative Claims Data to Institution-Specific Laboratory and Electronic Health Record Data for Comparative Effectiveness Research [266]**  
John D Seeger, Andrew T Rothman, Marie D Gerhard-Herman, Jessica J Jalbert, Louis L Nguyen, Chi-Ying Chen, Lauren A Williams, Soko Setoguchi. (United States)
- 176 FDA's Partnership in Applied Comparative Effectiveness Sciences [267]**  
Jodi B Segal, Michael Rosenblum, Gary Rosner, Emily Little, Sam Ogunbo, Sonal Singh, Ravi Varadhan, Sean Tunis. (United States)
- 178 Comparative Effectiveness of Pharmacologic and Mechanical Strategies for Prevention of VTE among Special Populations [270]**  
Sonal Singh, Elliott Haut, Daniel Brotman, Ritu Sharma, Yohalakshmi Chelladurai, Kenneth Shermock, Sosena Kebede, Jodi Segal. (United States)
- 179 Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-Analysis [271]**  
Mina Tadrous, Lindsay Wong, David N Juurlink, Murray Krahn, Linda E Levesque, Muhammad M Mamdani, Suzanne M Cadarette. (Canada)
- 180 The Comparative Safety and Effectiveness of Sitagliptin in Patients with Type 2 Diabetes and Heart Failure [272]**  
Daniala L Weir, Finlay A McAlister, Sentil Senthilselvan, Jason R Dyck, Jasjeet K Sandhu-Minhas, Dean T Eurich. (Canada)
- 181 Adjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer Patients: A Meta-Analysis of Published Randomized Trials [273]**  
Ying Xia, Boyang Bian, Elizabeth Costea, Jeff Guo, Christina Kelton. (United States)
- 182 Comparative Effectiveness of Interferon and Pegylated Interferon Against Chronic Hepatitis B in Taiwan [274]**  
Chun-Jen Liu, Yi-Chun Yeh, Raymond NC Kau, Chiu-Ling Lai, Yen-Yun Yang, Mei-Shu Lai, Pei-Jer Chen. (Taiwan)
- 183 Comparative Effectiveness of Lamivudine and Interferon or Pegylated Interferon Against Chronic Hepatitis B in Taiwan [275]**  
Yi-Chun Yeh, Chun-Jen Liu, Chiu-Ling Lai, Raymond NC Kuo, Ho-Min Chen, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 184 Balance Measures for Determining Optimal Caliper Width in Propensity Score Matching: A Simulation Study [277]**  
M Sanni Ali, RHH Groenwold, Svetlana V Belitser, Wiebe R Pestman, Arno W Hoes, Kit CB Roes, A de Boer, Olaf H Klungel. (Netherlands)
- 186 Propensity Score Estimation To Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics [279]**  
Stacie B Dusetzina, Christina DeFilippo Mack, Til Stürmer. (United States)

- 187 The Complex Role of the Prescriber in Comparative Effectiveness Research [280]**  
Jessica M Franklin, Sebastian Schneeweiss, Krista F Huybrechts, Robert J Glynn. (United States)
- 188 Using Covariate Data To Inform Large-Scale Studies and Application in the Global Registry Program on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) [281]**  
Jessica M Franklin, Kristina Zint, Jeremy A Rassen, Sebastian Schneeweiss, Dorothee B Bartels. (United States)
- 189 Combined Disease Risk Score Stratification and Propensity Score Matching When Comparing Multiple Drugs [282]**  
Joshua J Gagne, Robert J Glynn, Sebastian Schneeweiss. (United States)
- 190 Differential Diagnostic Work-Up among Initiators of Antihypertensive Drugs [283]**  
Mugdha Gokhale, Virginia Pate, J Bradley Layton, Til Sturmer. (United States)
- 191 Confounding by Indication in Comparative Effectiveness Research: Does Adding Registry to Claims Data Make a Difference? [285]**  
Jessica J Jalbert, John D Seeger, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)
- 193 Severity Index for Rheumatoid Arthritis: Impact on Healthcare Costs and Utilization [288]**  
Onur Baser, Juan Du, Lin Xie, Anne H Dysinger, Li Wang. (United States)
- 194 A Validated Outcomes Measure To Assist the Pharmacoepidemiological Study of Opiate Maintenance Treatment [289]**  
Hannu Alho, Icro Maremmanni. (Finland)

**Medications in Pregnancy SIG**

- 195 Design and Feasibility of a Study Using the Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) To Assess the Risk of Spontaneous Abortion (SA) Following Administration of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvant [290]**  
Dominique Rosillon, Corinne Willame, John Logie, Sylvia Taylor, Vincent Bauchau, Maria-Genalin Angelo, Julia Zima, Judith van den Bosch, Tjeerd van Staa, Rachael Boggon, Christina Chambers, Sonia Hernandez-Diaz, Laurence Baril. (Belgium)
- 196 Lessons Learned from Implementation of a Prospective, Observational Cohort Study To Assess Risk of Spontaneous Abortion (SA) Following Administration of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine around Conception [291]**  
Christina Chambers, Diana Johnson, Ronghui Xu, Dominique Rosillon, Judith van den Bosch, Laurence Baril, Sylvia Taylor. (United States)

- 197 Is There Any Evidence for Fetal Harm with Prolonged Use of Magnesium Sulfate in Pregnant Women? [292]**  
Syed Rizwanuddin Ahmad, Mark S Miller, Shelley R Slaughter. (United States)
- 198 Impact of the FDAAA on Post-Marketing Commitments Related to Pregnancy and Lactation [293]**  
Jessica D Albano, Susan Sinclair Roberts. (United States)
- 199 The Use of Medications Pregnancy Categories among Healthcare Professionals in Saudi Arabia Hospitals [295]**  
Thamir M Alshammari, Adel A Alrwisani, Majed Aljeraiisy, Hisham Aljadhey. (Saudi Arabia)
- 200 Safety of Neuraminidase Inhibitors during Pregnancy: A Comparative Study in the EFEMERIS Database [296]**  
Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel, Isabelle Lacroix. (France)
- 201 First Trimester Exposure to Sertraline and the Risk of Major Congenital Malformations in a Cohort of Depressed Women [297]**  
Anick Berard, Odile Sheehy, Vivian Leung. (Canada)
- 202 Risk of Preterm Delivery in Women with Inflammatory Bowel Disease – Effects of Disease Activity and Drug Exposure [298]**  
Gabiella Bröms, Marie Linder, Fredrik Granath, Olof Stephansson, Maria Elmgren, Helle Kieler. (Sweden)
- 203 Use of Glyburide Versus Insulin for Treatment of Gestational Diabetes in the U.S., 2000-2010 [300]**  
Wendy Camelo Castillo, Kim Boggess, Til Sturmer, M Alan Brookhart, Daniel K Benjamin, Jr.. (United States)

- 204 Meta-Analysis of the Use of Assisted Reproductive Technologies and the Risk of Multiple Birth and Major Congenital Malformations [302]**  
Sonia Chaabane, Lucie Blais, Fraser William, François Bissonnette, Patricia Monnier, Seang Lin Tan, Jacquetta Trasler, Anick Bérard. (Canada)
- 205 Congenital Malformations in the Offspring of Women with Asthma [303]**  
Rachel Charlton, Julia Snowball, Kourtney Davis, Corinne de Vries. (United Kingdom)
- 206 Healthcare Databases in Europe for Studying the Safety of Medicine Use during Pregnancy [304]**  
Rachel Charlton, Amanda Neville, Sue Jordan, Anna Pierini, Kari Klungsoyr, Anne-Marie Nybo Andersen, Christine Damase-Michel, Lolkje de Jong-van den Berg, Corinne de Vries. (United Kingdom)

Monday, August 26  
**POSTER SESSION A**

- 207 Outcomes of Pregnancies for Women Prescribed Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists in Semester 2 or 3 [305]**  
Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)
- 208 Treatment of Acute Asthma Exacerbations during and outside Pregnancy at a Canadian Teaching Hospital [306]**  
Benoit Cossette, Amélie Forget, Marie-France Beauchesne, Catherine Lemière, Pierre Larivée, Évelyne Rey, Lucie Blais. (Canada)
- 209 EXPECT Enrollment: Impact of Recruitment Strategy on Enrollment in the Xolair® Pregnancy Registry [307]**  
Deborah Covington, Vivian Wang, Gillis Carrigan, Nicole Hurst, Joachim Veith, Hubert Chen. (United States)
- 210 Which Therapeutic Option Is the Safest for the Fetus in the Treatment of Maternal Asthma: Higher Dose Inhaled Corticosteroids or Long-Acting beta2-Agonists Plus Lower Dose Inhaled Corticosteroids? [309]**  
Sherif Eltonsy, Amélie Forget, Marie-France Beauchesne, Lucie Blais. (Canada)
- 211 Best Practices for Pregnancy Registries [310]**  
Richard Gliklich, Nancy Dreyer, Sonia Hernandez-Diaz, Janet Cragan, Melissa Tassinari, Deborah Covington, Sara Ephross, Christina Chambers, Elise Berliner, Michelle Leavy, Laura Khurana. (United States)
- 212 Use of Serotonin Reuptake Inhibitors in Late Gestation and Lactation Difficulties [311]**  
Luke E Grzeskowiak, Catherine Leggett, Lynn Costi, Janna L Morrison, Vicki L Clifton. (Australia)
- 213 Prenatal Antidepressant Exposure and Child Behavioural Outcomes at 7-Years of Age [312]**  
Luke E Grzeskowiak, Janna L Morrison, Tina B Henriksen, Bodil H Bech, Jorn Olsen, Carsten Obel, Lars H Pedersen. (Australia)
- 214 Use of Acid-Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Case-Crossover Study Using the General Practice Research Database [313]**  
Eelko Hak, Bianca Mulder, Nynke CM Schuiling-Veninga, Tjalling W De Vries, Susan S Jick. (Netherlands)
- 215 Prenatal Exposure to Antidepressants and Motor Development in the Three Years Old Child. Results from MoBa, a Large Population Based Pregnancy Cohort in Norway [314]**  
Marte Handal, Svetlana Skurtveit, Kari Furu, Eva Skovlund, Sonia Hernandez-Diaz, Wenche Nystad, Randi Selmer. (Norway)
- 216 Reproductive Calls to the Norwegian Poison Information Center - Women Are Frightened of Exposures to Gases and Household Chemicals, Not Only Medicines [315]**  
Gro C Havnen, Ann-Christin Olsen, Hedvig Nordeng. (Norway)
- 217 Pregnancy Outcome in Women Exposed to Dopamine Agonists during Pregnancy: A Study in EFEMERIS Database [316]**  
Caroline Hurault-Delarue, Jean-Louis Montastruc, Anna-Belle Beau, Isabelle Lacroix, Christine Damase-Michel. (France)
- 218 Antidepressant Medication Use during Pregnancy and the Risk of Preterm Birth [317]**  
Krista F Huybrechts, Reesha C Shah, Jerry Avorn, Adam C Urato. (United States)
- 219 In Utero Exposure to Antipsychotics and Congenital Malformations - A Nation Wide Cohort Study [318]**  
Espen Jimenez-Solem, Jon T Andersen, Nadia L Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)
- 220 Topical Pharmacological Treatment of Hemorrhoids during Pregnancy and Congenital Malformations – A Nation-Wide Cohort Study [319]**  
Espen Jimenez-Solem, Jon T Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)
- 221 Can We Rely on Pharmacy Claims Databases To Ascertain Maternal Use of Medications during Pregnancy? [320]**  
Katherine Jobin Gervais, Odile Sheehy, Anick Bérard. (Canada)
- 222 How Much Ortho-Phthalate May Be Present in Medications and Dietary Supplements? [321]**  
Katherine E Kelley, Mark Böhlke, Allen A Mitchell, Russ Hauser, Sonia Hernández-Díaz. (United States)
- 223 Veinotonics in Pregnancy: A Comparative Study in the EFEMERIS Database [322]**  
Isabelle Lacroix, Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 224 Safety of Influenza AH1N1 Pandemic Vaccination during Pregnancy: A Comparative Study in the EFEMERIS Database [323]**  
Isabelle Lacroix, Anna-Belle Beau, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 225 First Trimester Exposure to Bupropion and Cardiac Defects [325]**  
Carol Louik, Stephen Kerr, Allen A Mitchell. (United States)
- 227 The Fetal Safety of Macrolides – A Systematic Review and Meta-Analysis [327]**  
Hedvig Nordeng, Myla Moretti, Gideon Koren. (Norway)
- 228 Validity of Maternal and Infant Outcomes within Medicaid Data [328]**  
Kristin K Palmsten, Krista F Huybrechts, Mary K Kowal, Sonia Hernández-Díaz. (United States)
- 229 Antidepressant Use Late in Pregnancy and Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN) among Low-Income Women [329]**  
Kristin K Palmsten, Krista F Huybrechts, Mary K Kowal, Helen Mogun, Soko Setoguchi, Sonia Hernández-Díaz. (United States)
- 230 Drug Use in Pregnancy, Gestational Age and Date of Delivery: Comparison of Health Database and Self-Reported Information in a Cohort [330]**  
Federica E Pisa, Anica Casetta, Elena Clagnan, Elisa Michelesio, Fabio Barbone. (Italy)
- 231 Perception of Teratogenic Risk Related to Medications: Agreement between Two Techniques of Measuring [331]**  
Emília S Pons, Luciano P Guimarães, Daniela R Knauth, Tatiane S Dal-Pizzolo. (Brazil)
- 232 Validation of Pregnancy Information in the German Pharmacoepidemiological Research Database (GePaRD) [333]**  
Niklas Schmedt, Rafael T Mikolajczyk, Angela A Kraut, Edeltraut Garbe. (Germany)
- 234 Antimalarial Drug Use during Pregnancy and the Risk of Low Birth Weight (LBW): A Systematic Review [336]**  
Muanda MT Tsobo, Anick AB Bérard. (Canada)
- 235 Zidovudine Exposure during Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry [337]**  
Vani Vannappagari, Jessica Albano, Hugh Tilson, Conway Gee, Anisha Gandhi, Nana Koram, Catherine Ryan. (United States)
- 236 Health Beliefs, Attitudes and Knowledge of Expectant Mothers Regarding Medicine and Substance Use in Pregnancy: A Literature Review [338]**  
Mariam I Wahab, Alastair G Sutcliffe, Ian CK Wong, Yogini H Jani. (United Kingdom)
- 237 Complementary and Alternative Medicine Use in the First Trimester: Safety Perceptions and Preference of Pregnant Women [339]**  
Mariam I Wahab, Alastair G Sutcliffe, Ian CK Wong, Yogini H Jani. (United Kingdom)
- 238 Exposure to Inhalation Zanamivir during Pregnancy and Pregnancy Outcomes [340]**  
Alec Walker, Vani Vannappagari, Rebecca Buus, Deborah Covington, Emily Bratton, Mary Thompson. (United States)
- 239 Dispensing of Potential Teratogenic Drugs before and during Pregnancy: A Population Based Study [341]**  
Inge M Zomerdijk, Rikje Ruiters, Leanne MA Houweling, Ron MC Herings, Sabine MJM Straus, Bruno H Stricker. (Netherlands)
- 240 Drug Dispensing before and during Pregnancy and Congenital Malformations: A Population Based Study [342]**  
Inge M Zomerdijk, Rikje Ruiters, Leanne MA Houweling, Ron MC Herings, Sabine MJM Straus, Bruno H Stricker. (Netherlands)

Monday, August 26  
**POSTER SESSION A**

**241 Are Women with Major Depression in Pregnancy Identifiable in Population Health Data? [343]**

Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

**242 Relation between the Prevalence of Attention Deficit and Hyperactivity Disorders (ADHD) and Autism Spectrum Disorders (ASD), and Maternal Depression and Antidepressant Use during Pregnancy [345]**

Anick Berard, Odile Sheehy, Takoua Boukris. (Canada)

**243 Adverse Developmental Events Reported to FDA in Association with Maternal Use of Topiramate in Pregnancy [346]**

Sonia Tabacova, Ana Szarfman. (United States)

**244 Prenatal Antidepressant Exposure and Neurodevelopmental Outcomes in a Cohort of Typically-Developing Children [347]**

Mollie E Wood, David Kennedy, Jean A Frazier, PING Research Group. (United States)

**245 First Trimester Fluoxetine Use and Major Malformations: A Meta-Analysis of Epidemiological Studies [348]**

Yu Yan, Yingkai Cheng, Brenda Crowe, Rashna Chhabra-Khanna, Angelo Camporeale, Lauren Marangell. (United States)

**Poster Walk - Adherence SIG**

**246 Medication Adherence and Severe Asthma Exacerbations: Systematic Review [226]**

Marjolein Engelkes, Hettie M Janssens, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)

**247 Predicting Persistence with Antidepressant Treatment at 6 Months [228]**

Greta A Bushnell, Til Stürmer, Virginia Pate, Alice D White, Sonja Swanson, Deborah Azrael, Matthew Miller. (United States)

**248 Persistence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer – Accounting for Temporary Treatment Discontinuations [232]**

Laetitia Huiart, Cyril Ferdynus, Sophie Dell'Aniello, Roch Giorgi, Samy Suissa. (France)

**249 Adherence and Persistence to Hormonal Therapy in Breast Cancer: A Meta-Regression To Summarize the Available Data [233]**

Laetitia Huiart, Cyril Ferdynus, Roch Giorgi. (France)

**250 Effectiveness of the Persistence Telephone Assessment and Communication Program for Patients with Treated Depression: Pragmatic Randomized Controlled Trial [235]**

Yola Moride, Guillaume Galbaud du Fort, Marie Tournier, Marie-Eve Alary, Michel Rossignol, Thierry Ducruet, Jean Lachaine, Jean-Pierre Bonin, Jean-Paul Collet. (Canada)

**251 Guidelines Adherence in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes: Comparing the Use of Metformin in Quebec Pre and Post-Canadian Diabetes Association Guidelines [238]**

Ting-Yu Wang, Eguale Tewodros, Robyn Tamblyn. (Canada)

**252 Potential Impact of Errors in the Days Supply of Osteoporosis Medications on Estimates of Drug Adherence [240]**

Andrea M Burden, Michael J Patterson, Andrea Gruneir, Suzanne M Cadarette. (Canada)

**Poster Walk - Comparative Effectiveness Research (CER) SIG**

**253 Comparative Effects of Different Combination Antiretroviral Therapies on the Risk for Myocardial Infarction among HIV Patients Enrolled in Medicaid: A New User, Active Comparator Cohort Study [254]**

Emily S Brouwer, Sonia Napravnik, Joseph J Eron, Jr., Ross J Simpson, Jr., Brant Stalzer, Michelle Floris-Moore, Michael Vinikoor, Til Stürmer. (United States)

**254 Registry of Patient Registries (RoPR): Advancing Registries for Comparative Effectiveness Research [257]**

Richard E Gliklich, Daniel Levy, Daniel M Campion, Michelle Leavy, Jannette Karl, Elise Berliner, Laura Khurana, Willet Hossfeld. (United States)

**255 Confounding by Indication in Comparative Effectiveness Research: Does Adding Registry to Claims Data Make a Difference? [268]**

Jessica J Jalbert, John D Seeger, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)

**256 Dose and Duration Relationship between Pioglitazone and Associated Risk of Bladder Cancer: A Systematic Review and Meta-Analysis [269]**

Richard Turner, Chun S Kwok, Chen Chen-Turner, Chinedu Maduakar, Sonal Singh, Yoon K Loke. (United States)

**257 Assessment of Balance in Propensity Score Analysis in the Medical Literature: A Systematic Review [276]**

M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitser, Wiebe R Pestman, Arno W Hoes, Kit CB Roes, A de Boer, Olaf H Klungel. (Netherlands)

**258 Instrumental Variable Analyses Using Nursing Home Prescribing Preferences for Comparative Effectiveness Research [284]**

Krista F Huybrechts, Tobias Gerhard, Jessica M Franklin, Raisa Levin, Stephen Crystal, Sebastian Schneeweiss. (United States)

**259 Quantitative Verification of Instrumental Variables Assumption Using Balance Measures [287]**

M Jamal Uddin, M Sanni Ali, Rolf HH Groenwold, Wiebe R Pestman, Svetlana V Belitser, Arno W Hoes, Anthonius de Boer, Kit CB Roes, Olaf H Klungel. (Netherlands)

**Poster Walk - Medications in Pregnancy SIG**

**260 Public Perception of Risk Factors for Birth Defects: HealthStyles, 2010-2011 [299]**

Shenita R Peterson, Meghan T Frey, Suzanne M Gilboa, Cheryl S Broussard. (United States)

**261 Hypertension and Patterns of Prescription of Antihypertensive Medications during Pregnancy Using THIN Database [301]**

Lucia Cea Soriano, Brian T Bateman, Luis A Garcia Rodriguez, Sonia Hernandez-Diaz. (Spain)

**262 Prospective Enrollment in Pregnancy Registries: Definitions and Potential Impact on Birth Defect Prevalence [308]**

Deborah Covington, Amanda Golembesky, Deanna Hill, Nicole Hurst, Paige Churchill, Laura McKain. (United States)

**263 Risks and Safety of Pandemic H1N1 Vaccine in Pregnancy: Preterm Birth and Specific Defects [324]**

Carol Louik, Katherine Ahrens, Stephen Kerr, Junhee Pyo, Christina Chambers, Kenneth L Jones, Michael Schatz, Allen A Mitchell. (United States)

**264 Hypertensive Disorders and Antihypertensive Medication during Pregnancy and the Risk of Birth Defects: A Case-Control Study [332]**

Marleen MHJ van Gelder, Carla M Van Bennekom, Carol Louik, Martha M Werler, Nel Roeleveld, Allen A Mitchell. (Netherlands)

**265 Prenatal Exposure to Antidepressants and Language Competence at 3 Years of Age. Results from a Large Population Based Pregnancy Cohort in Norway [334]**

Svetlana Skurtveit, Randi Selmer, Christine Roth, Sonia Hernandez-Diaz, Marte Handal. (Norway)

**266 Identification of Pregnancy by a Coding Algorithm in a U.S. Administrative Healthcare Database [344]**

Hoa V Le, Chi T Truong, Charlotte F Carroll, Julie L Priest, Sara A Ephross, Carlyne M Averell. (United States)

**▶ END SESSION A**

**Benefit Risk Assessment and Risk Communication**

- 1 **Aspirin Use in Prostate Cancer and the Risk of Death and Metastasis [429]**  
Jonathan Assayag, Laurent Azoulay, Hui Yin, Michael N Pollak, Samy Suissa. (Canada)
- 2 **The Clinical Benefit of Warfarin in Patients with Atrial Fibrillation in Taiwan [430]**  
Chia-Hsien Chang, Yea-Huei Kao Yang, Li-Jen Lin, Swu-Jane Lin. (Taiwan)
- 3 **The Role of the thorough QT Study in Drug Development [431]**  
Frank A Holtkamp, Pieter A de Graeff, Peter GM Mol. (Netherlands)
- 4 **Use of Glucocorticoids and Risk of Breast Cancer Recurrence [432]**  
Lone W Lietzen, Deirdre P Cronin-Fenton, Thomas P Ahern, Henrik T Sørensen, Peer Christiansen, Anders B Jensen, Timothy L Lash. (Denmark)
- 5 **Acute Non-Steroidal Anti-Inflammatory Drug Exposure in Asthma: A Meta-Analysis of Clinical Trials [433]**  
Daniel R Morales, Virginia H Santiago, Brian Lipworth, Cathy Jackson, Peter Donnan, Bruce Guthrie. (United Kingdom)
- 6 **Acute  $\beta$ -Blocker Exposure in Asthma: A Meta-Analysis of Randomized Controlled Trials [434]**  
Daniel R Morales, Cathy Jackson, Peter T Donnan, Brian J Lipworth, Bruce Guthrie. (United Kingdom)

**Methods**

- 7 **Identification of Incident Cardiovascular Events Using a Computerized Hospital Database: A Feasibility Study [435]**  
Julien Bezin, Maelys Touya, Cécile Lebrun, Véronique Gilleron, Antoine Pariente, Annie Fourrier-Reglat, Nicholas Moore. (France)
- 8 **Are Patients Classified as Antiretroviral Therapy Naïve Using Administrative Data Truly Naïve Based on Comprehensive Medical Record Reviews? An Exploration Using an HIV Clinical Cohort [436]**  
Emily S Brouwer, Daniela C Moga, Joseph J Eron, Jr., Sonia Napravnik. (United States)
- 9 **Factors Affecting the Association of Cancer Risk among Patients Treated with Anti-Diabetic Medication [437]**  
Anna But, Haining Wang, Marie L De Bruin, Satu Männistö, Jari Haukka. (Finland)
- 10 **Comparison of Comorbidity Ascertainment Using the End-Stage Renal Disease Medical Evidence Form 2728 Versus Medicare Claims Data [438]**  
Anne M Butler, Abhijit V Kshirsagar, Lily Wang, M Alan Brookhart. (United States)

- 11 **Uptake of Methodological Innovation in Pharmacoepidemiology: Disease Risk Score Co-Authorship Network Analysis [439]**  
Patrick R Edwards, Giulia Consiglio, Mina Tadrous, Suzanne M Cadarette. (Canada)
- 12 **Identifying Patients in Electronic Healthcare Data When No Diagnostic Codes Are Available for the Disease of Interest: Critical Limb Ischemia Example [440]**  
Jennifer Campbell, George Geroulakos, Tjeerd van Staa. (United Kingdom)
- 13 **Changes in Daily Dose over Time from Longitudinal Data of Tianeptine Users: Convergence of Two Different Approaches [441]**  
Cedric Collin, Fanny Feuillet, Caroline Victorri-Vigneau, Marie-Anne Courne, Jean-Benoit Hardouin, Veronique Sebillle. (France)
- 14 **Artificial Intelligence for Drug-Drug Interaction Prediction - A Systematic Review [442]**  
Felipe Ferre, Vania E Araujo, Marina AA Machado, Francisco A Acurcio, Wagner Meira Junior. (Brazil)
- 15 **Confounding Control by Traditional Covariate Adjustment, Propensity Score Matching, and High Dimensional Propensity Score in a Cohort Study [443]**  
Shujun Gao, Wanju Dai, Ling Zhang, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 16 **Approaches to Long-Term Surveillance for Rare Cancer Events [444]**  
Alicia W Gilsenan, David H Harris, Kirk D Midkiff, Elizabeth B Andrews, Nicole A Kellier, Daniel N Masica. (United States)
- 17 **Impact of Censoring on Estimates of Adverse Drug Effects: A Simulation Study [445]**  
Rolf H Groenwold, Tjeerd P van Staa, Anthonius de Boer, Olaf H Klungel. (Netherlands)
- 18 **Measures of “exposure Needed for One Additional Patient To Be Harmed” in Population-Based Case-Control Studies [446]**  
Jesper Hallas, Rene Depont Christensen, Til Stürmer, Anton Pottegård. (Denmark)
- 19 **Impact of PSA Doubling Time (DT) Calculation Method on Estimate of Association with Bone Metastases in a Cohort of Prostate Cancer Patients Treated with Androgen Deprivation Therapy (ADT) [447]**  
Rohini K Hernandez, Jonas Banefelt, Johan Mesterton, Jan Ståhlhammar, Bo-Eric Persson, Chunlei Ke, Patrik Sobocki, Alexander Liede. (United States)
- 20 **Identification of Patients with Chronic Kidney Disease from National Health Insurance Claims Data in Taiwan: A Validation Study [448]**  
Cheng-Yang Hsieh, Chih-Hung Chen, Yea-Huei Yang Kao. (Taiwan)
- 21 **Doubly Robust Estimator: Effects of Variable Selection into Component Models on Efficiency [449]**  
Michele Jonsson Funk, Virginia Pate, Til Stürmer. (United States)

- 22 **Antidepressant Treatment (ADT) Following a Cancer Diagnosis: Investigation in a Cohort of Older Patients [407]**  
Sallie-Anne Pearson, Michal Abrahamowicz, Preeyaporn Srasuebkul, Nicholas Buckley. (Australia)
- 23 **The Impact of Methods Used for Case Ascertainment on the Association between Restless Legs Syndrome (RLS) and Cardiovascular Disease (CVD) [451]**  
Linda Kalilani, Erwin Schollmayer, Mahnaz Asgharnejad, Kimberly Moran, David Miller. (United States)
- 24 **Conformity between Protocol Eligibility Criteria for Electronic Patient Identification: A Comparison of Clinical Trials [452]**  
Allise G Kamaau, Stephen OT Agbor, Aaron WC Kamaau. (United States)
- 25 **Validation of the Telephone-Administered Age and Stage Questionnaire and the Revised-Prescreening Denver Questionnaire: Results from the OTIS Antidepressants in Pregnancy Study [453]**  
Fatiha Karam, Anick Bérard, Odile Sheehy, Marie-Claude Huneau, Gerald Briggs, Christina Chambers, Adrienne Einarson, Diana Johnson, Kelly Kao, Gideon Koren, Brigitte Martin, Janine Polifka, Sara Hammer Riordan, Mark Roth, Sharon Lavigne Voyer, Lori Wolfe, OTIS Research Committee. (Canada)
- 26 **A Comparison of Event-Based Versus Case-Based Methods for Detection of Signals of Disproportionality with Variable Age Distributions [454]**  
Nicole Kellier, Qianyi Zhang, Kenneth Hornbuckle. (United States)
- 28 **Is the Physician's Preference of Antipsychotic Medications a Valid Instrumental Variable in the German Pharmacoepidemiological Research Database? [456]**  
Bianca Kollhorst, Edeltraut Garbe. (Germany)
- 29 **Statistical Methods for Estimating Treatment Effects from Randomized Clinical Trials in the Presence of Non-Randomized Post-Study Therapies [457]**  
Larry F Leon, Bann-Mo Day, Sylvia Hu. (United States)
- 30 **Signal Refinement of Drug-Induced Thrombocytopenia Using the Health Information Network (THIN) Database [458]**  
Qing Liu, Manfred Hauben, Andrew J Bate. (United States)
- 31 **Quality Assessment of Observational Studies in a Drug-Safety Systematic Review—comparison of Two Tools, the Newcastle-Ottawa Scale and the RTI Item Bank [459]**  
Andrea V Margulis, Manel Pladevall, Nuria Riera-Guardia, Cristina Varas-Lorenzo, Lorna Hazell, Susana Perez-Gutthann. (Spain)
- 32 **Consequences of Violating Model Assumptions: An Example Using Healthcare Claims Data [460]**  
Rayna K Matsuno, Aditi Kadakia, Laura Wallace. (United States)

Tuesday, August 27  
**POSTER SESSION B**

- 33 Comparison of Covariate Selection Approaches for Propensity Score (PS) Derivation for Multiple Health Outcomes of Interest (HOIs): An Empirical Example [461]**  
 Ann Marie McNeill, Cynthia J Girman, Zhiwen Liu, Robert J LoCasale, Richard Wyss, Ying Su, Til Sturmer. (United States)
- 34 Comparison of Case-Cohort Data Analyses Using Data of Cases/Subcohort Members Only and Data of Entire Cohort [462]**  
 Nobuhiro Ooba, Akira Wakana, Tsugumichi Sato, Takuhiro Yamaguchi, Kiyoshi Kubota. (Japan)
- 35 Investigator-Specified vs. Empirical Covariate Selection for Confounding Adjustment in Studies with Infrequent Outcomes: Anticonvulsants and Cardiovascular Risk [463]**  
 Elisabetta Patomo, Robert Glynn, Sonia Hernandez-Diaz, Jun Liu, Sebastian Schneeweiss. (United States)
- 36 Validation of the Adjusted Sequence Ratio in Prescription Sequence Symmetry Analysis: A Simulation Study [464]**  
 Nicole Pratt, Jenni Ilomaki, Chris Raymond, Elizabeth Roughead. (Australia)
- 37 Defining a Denominator Population for Linked Datasets [465]**  
 Shivani Puri, Tim Williams, Susan Eaton. (United Kingdom)
- 39 Missing Data in Modified-PEM (M-PEM) Studies; an Application of Multiple Imputation [467]**  
 Ian Ratcliffe, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 40 Estimation of the Incidence Rate of Very Rare Diseases - A Case Study of Multicentric Castleman's Disease [468]**  
 Dana Y Teltsch, Richard S Swain, Don W Robinson, Jr., Marie-Pierre Desrosiers, Philip Rotella, Krista A Payne, Matthew W Reynolds. (United States)
- 41 Comparison of a Targeted Maximum Likelihood Estimator to Other Estimation Techniques for the One Year Risk of Myocardial Infarction among New Users of High vs. Low Potency Statins [469]**  
 Jonathan V Todd, Michele Jonsson-Funk, Bradley Layton, Virginia Pate, MA Brookhart. (United States)
- 42 TrialViz: A Feasibility Tool Based upon the CPRD GOLD Primary Care Database [470]**  
 Tim Williams, Shivani Puri, Joss Wickson, Rosemary Tate, Natalia Beloff, Tjeerd van Staa, Adrian Bleach, John Cuthbert. (United Kingdom)
- 43 Predicting a Missing Baseline Value in a Rare Disease Registry Using Extrapolation of Mixed Models Estimates [471]**  
 Amanda B Wilson. (United States)
- 44 Inclusion of Variables Associated with Exposure but Not Outcome Can Compromise Propensity Score-Based Adjustments – Examination of a Real-Life Example in Pediatric Psychopharmacology [472]**

- Almut G Winterstein, Joseph A Delaney, Paul Kubilis, Stephen Crystal, Tobias Gerhard. (United States)
- 45 Development of a Claims-Based Algorithm To Identify Prolia Use in Medicare Data [473]**  
 Nicole C Wright, Rui Chen, Tarun Arora, Huifeng Yun, Elizabeth S Delzell, Jeffrey R Curtis. (United States)
- 46 The Validity of Claims-Based Algorithms To Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw [474]**  
 Nicole C Wright, Tarun Arora, Wilson K Smith, Ashley N Milford, Mark Marchant, Boni Elewski, Jeffrey R Curtis, Meredith L Kilogre, Michael Morrissey, Kenneth G Saag, Monika M Safford, Elizabeth S Delzell. (United States)
- 47 Evaluation of Analytical Method Performance Using Observational Medical Dataset Simulator (OSIM2) [475]**  
 Jasmanda Wu, Ling Zhang, Juhaeri Juhaeri, Wanju Dai, Patrick Caubel. (United States)
- 48 Validation of Stroke in the Clinical Practice Research Datalink (CPRD) [476]**  
 Esther H Zhou, Kate Gelperin, David J Graham, Yulan Ding, Mark Levenson, Martin Rose, Shannin F Davillier, Tarek A Hammad. (United States)
- 49 A High-Performing, SEER-Validated Algorithm for Identifying Patients with Incident Cancer of the Esophagus or Cardia Using Medicare Claims Data [477]**  
 David J Graham, Katlyn Calia, Lorene Nelson, Jeff Yang, Jay Bhattacharya, Thomas E MacCurdy, Chris Worrall, Jeffrey A Kelman. (United States)
- 50 Algorithms To Identify Pancreatic Cancer and Thyroid Neoplasm from Health Insurance Claims Data [478]**  
 Caihua Liang, Bruce R Turnbull, Kathleen E Skerry, Kwame Appenteng, Stephen P Motsko, David D Dore. (United States)
- 51 Validation of Outcome Definition of Acute Renal Failure in Japanese Electronic Medical Records Data [479]**  
 Kaori Yamada, Eiko Tada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- Pediatrics**
- 52 Adverse Events Associated with Pediatric Use of Proton Pump Inhibitors: Analysis of the FDA Adverse Event Reporting System [480]**  
 Abdullah K Alahmari, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)
- 53 Do EMA and FDA Have Different Opinions/ Requirements in Terms of Pediatric Studies for Sitagliptin (Alone or in Combination)? [481]**  
 Martine Caron, Marie-Pierre Emery, Will Maier. (France)
- 54 Did the Dutch Pneumococcal Vaccination Campaign Decrease the Need for Antibiotics in Children? [482]**  
 Giedre Gefenaite, Maarten J Bijlsma, Jens Bos, Eelko Hak. (Netherlands)

- 56 Period Prevalence of Therapy Combination and Switching among Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) Treated with Stimulants in the Canadian Province of Quebec [484]**  
 Jean Lachaine, Vanja Sikirica, Martin Cloutier, Leila BenAmor, Paul Hodgkins, Judy van Stralen, Valeire Carter, Annie Guerin. (Canada)
- 57 Quantitative Vaccine Safety Signal Detection Techniques Using Vaccine Adverse Event Reporting System (VAERS) [485]**  
 Huifang Liang, Motonobu Sakaguchi. (United States)
- 58 Acne and Lifestyle: Results of a Survey on a Representative Sample of the French Population [486]**  
 Pierre Wolkeinstein, Sébastien Branchoux, Charles Taieb. (France)
- 59 Children with Atopic Dermatitis: Monitoring a French Cohort over a Nine-Year Period [487]**  
 Charles Taieb, Laurent Misery. (France)
- 60 Atopic Dermatitis: Evaluation of 2 Different Drug Related Managements [488]**  
 Charles Taieb. (France)

**Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG**

- 61 Entacapone Containing Drugs Use and Risk of Death: Analysis of FDA AERS (FAERS) Database [489]**  
 Thamir M Alshammari, Eman N Almutairi. (Saudi Arabia)
- 62 Risk of Severe Ventricular Arrhythmia among Outpatient Receiving Fluoroquinolones in Taiwan [490]**  
 Hsu-Wen Chou, Chao-Lun Lai, Jiun-Ling Wang, Chia-Hsueh Chang, Mei-Shu Lai. (Taiwan)
- 63 Impact of Previous Suicide Attempts and Family History of Psychiatric Disease on the Size of the Association between Antiepileptic Drugs and Suicide Related Events [491]**  
 Christiane Gasse, Aske Astrup, Henrik Støvring, Ole Mors, Jakob Christensen. (Denmark)
- 64 Estimating the Association between QT Prolongation and SSRI Utilization from the FDA's Adverse Event Reports [492]**  
 Jing Guo, Jeff J Guo, Christina ML Kelton, Patricia Wigle. (United States)
- 65 A Systematic Review of the Adverse Effects of Atypical Antipsychotics in the Elderly Population [494]**  
 Neeraja Krishnaswamy, Andrew Zullo, David D Dore. (United States)
- 66 A Pragmatic Score To Predict the Risk of Clostridium difficile Infection among Patients Receiving a Fluoroquinolone Antibiotic [495]**  
 Jennifer L Kuntz, Eric S Johnson, Xiuhai Yang, Micah L Thorp, David H Smith. (United States)

Tuesday, August 27  
**POSTER SESSION B**

- 67 Background Rates of Other New Primary Malignancies among Locally Advanced and Metastatic Melanoma Patients: A SEER-Medicare Study [496]**  
Haojie Li, Thao Vo, Samantha St. Laurent, Monica Kobayashi, Jeanenne Nelson. (United States)
- 68 New-Onset Non-Melanoma Malignant Skin Lesions and Non-Cutaneous Squamous-Cell Carcinoma among Metastatic Melanoma Patients in Denmark [497]**  
Haojie Li, Lars Pedersen, Mette Nørgaard, Sinna Ulrichsen, Sandra Thygesen, Henrik Sørensen, Jeanenne Nelson. (United States)
- 69 Does Research Design Predict Estimated Risks of Venous Thromboembolism with Drospirenone-Containing Oral Contraceptives? [498]**  
Barbara Mintzes, Anat Fisher, Guillermina Perez, Soufi Sam. (Canada)
- 70 Lay Media Attention for Serious Drug Safety Issues in the Netherlands [499]**  
Valerie Damoiseaux, Sigrid Piening, Sabine Straus, Flora M Haaijer-Ruskamp, Peter GM Mol. (Netherlands)
- 71 The Additional Value of an e-Mail To Inform Healthcare Professionals of a Drug Safety Issue [501]**  
Sigrid Piening, Pieter A de Graeff, Sabine MJM Straus, Flora M Haaijer-Ruskamp, Peter GM Mol. (Netherlands)
- 72 Pattern and Determinants of Self Medication in a Nigerian Urban Population- "The Silent Epidemics" [502]**  
Olayinka O Ogunleye, Adesola F Yinka-Ogunleye, Sunday O Ogundele, Kazeem A Oshikoya. (Nigeria)
- 73 Changes in Number of Spontaneous Adverse Event Reports of Drug Abuse, Intentional Drug Misuse, Medication Error, and Overdose after Reformulation of OxyContin [503]**  
Nelson E Sessler, Jared M Downing, Howard D Chilcoat, Todd F Baumgartner, Paul M Coplan. (United States)
- 74 Statin Therapy and Incident Cataract: A Meta-Analysis [508]**  
Carlos Alves, Ana F Macedo, Diogo Mendes, Francisco Batel Marques. (Portugal)
- 75 Comorbidities and Medication Use in Lupus Nephritis Patients – A Comparison of Result across Case Identification Algorithms [509]**  
Kathleen M McCarty, Douglas Clark, Wei-Shi Yeah. (United States)
- 76 Assessment of Tolerance of Pain Treatment in Cancer Management [510]**  
Zineb Mesbahi, Samir Ahid, Bouchra Meddah, Zakaria Belkhadir, Yahia Cherrah. (Morocco)
- 77 Health-Care Professionals' Perspectives on Multi-Dose Dispensed Medicines [511]**  
Carola Bardage, Anders Ekedahl, Lena Ring. (Sweden)
- 78 Drug Use and Polypharmacy in Rehabilitation Center Inpatients Following Acquired Brain Injury: A Cross-Sectional Survey in Italy [512]**  
Giorgia Cosano, Tullio Giorgini, Emanuele Biasutti, Fabio Barbone, Federica E Pisa. (Italy)
- 79 Relative Effectiveness of Paracetamol in Patient with Knee and Hip Osteoarthritis [513]**  
Lamiae Grimaldi-Bensouda, Raphaelle Beau-Ledjstrom, Michel Rossignol, Bernard Avouac, Lucien Abenheim. (United Kingdom)
- 80 Risk of Suicide Attempts Associated with Anti-epileptic Drugs: A Case-Control Study Looking at the Effect of Differing Design Options [514]**  
Lamiae Grimaldi-Bensouda, Frédéric Rouillon, Vincent Caillard, Nicolas Dantchev, Jean Louis Terra, Michel Lejoyeux, Xavier Kurz, Lucien Abenheim. (France)
- 81 Benefits of Different Propensity Score Methods for Evaluation of Associations and Channeling Bias over Time: Pneumonia and Inhaled Corticosteroid in a COPD New User Cohort [515]**  
Hoa V Le, Rachael L DiSantostefano, Tim Sampson, Chi T Truong, Kourtney J Davis. (United States)
- 82 Knowledge and Awareness of Healthcare Professionals (HCPs) toward Pharmacovigilance Concept in Saudi Arabia [516]**  
Thamir M Alshammari, Yazeed M Ghawaa, Khaled B Alamri, Noura A AlOhal. (Saudi Arabia)
- 83 Data Sources Supporting Safety Warnings and the Correspondence Scientific Evidence Published in Literature: A Descriptive Study [517]**  
Carlos Alves, Ana F Macedo, Francisco Batel Marques. (Portugal)
- 84 Feasibility of Using Australian GP Prescribing Data for Pharmacovigilance [518]**  
Malcolm B Gillies, Filippo Galgani, Guy Tsafnat, Adam Dunn, Nancy Huang, Margaret Williamson. (Australia)
- 85 Evaluation of General Public Perceptions Towards Adverse Drug Reactions Reporting [519]**  
Mohammed Ahmed Alshakka, Mohamed Izham Mohamed Ibrahim, Mohamed Azmi Ahmed Hassali. (Malaysia)
- 86 Cellulitis Reported to the Canadian Adverse Events Following Immunization Surveillance System (1987-2012) [520]**  
Barbara Law, Julie Lafleche. (Canada)
- 87 Reductions in Fatalities Following Introduction of a Reformulated Opioid with Abuse-Deterrent Properties [521]**  
Nelson E Sessler, Jared M Downing, Hrishikesh P Kale, Barbara Harding, Howard D Chilcoat, Todd F Baumgartner, Paul M Coplan. (United States)
- 88 Risk Minimization Plans in Developing Countries: A Cross Sectional Survey of Isotretinoin Use in Saudi Arabia [522]**  
Adel A Alrwisan, Thamir M Alshammari, Hisham S Aljadhey. (Saudi Arabia)
- 89 The Impact of Pharmacist-Led Educational Interventions on the Use of High-Risk Abbreviations in a Saudi Arabian Hospital and Emergency Centers [524]**  
Abdul Haseeb, Win W Watjana, AbdulRahman Baksh, Alaa A Mously, Rasha A Almubarak, Asmaa Z Gadibalban, Bashayir F Al-Ibrahim, Rawan A Ikram. (Saudi Arabia)
- 90 Development of a Clinical Prediction Model for an INR  $\geq$  4.5 in Hospitalized Patients Treated with Vitamin K Antagonists [525]**  
Anouk D Lindemans, Nico JC van Blijderveen, Marieke JHA Kruip, Miriam CJM Sturkenboom, Arnold G Vulto, Yvonne Vergouwe, Patricia MLA van den Bemt. (Netherlands)
- 91 Diabetes Screening of Adults Receiving Anti-psychotics: A U.S. State Survey of Prescribers [526]**  
Elaine H Morrato, Elizabeth J Campagna, Eva Dibert, Joseph Parks. (United States)
- 92 Adoption of a Clinical Checklist as a Risk Minimization Tool in China [527]**  
Meredith Y Smith, Ning Wang. (United States)
- 93 Characterization and Factors Associated with Post-Transplant Headaches: A Retrospective Survey Study [528]**  
Ying Xia, Elizabeth Costea, Boyang Bian, Carolyn Dosen, Gautham Mogilishetty, Jill Boone, Jeff Guo. (United States)
- 94 Attitudes and Beliefs on the Use of Non-Prescription Medicines in Singapore [529]**  
Yong Bing Ng, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 95 Methods To Evaluate Additional Risk Minimization Measures: A Systematic Review [531]**  
Inge M Zomerdijk, Kelly Mentink, Christine C Gispen-de Wied, Miriam CJM Sturkenboom, Sabine MJM Straus. (Netherlands)

**Database SIG**

- 96 Drospirenone and Risk for Venous Thromboembolism; a Comparison by Dosage of Ethinyl-Estradiol [532]**  
Steven T Bird, James M Brophy, Mahyar Etminan, Joseph AC Delaney, Abraham G Hartzema. (United States)
- 97 Fluoroquinolones and Risk for Acute Kidney Injury [533]**  
Steven T Bird, Mahyar Etminan, James M Brophy, Abraham G Hartzema, Joseph AC Delaney. (United States)
- 98 Need for Collaborative International Vaccine Benefit-Risk Studies in Low-Income Countries: A Pilot Project [534]**  
Daniel Weibel, Caitlin Dodd, Steve Black, Hector Izurieta, Osman Sankoh, Kayla Laserson, Robert Chen, Esperanca Sevens, Abraham Oduro, Jan Bonhoeffer, Miriam CJM Sturkenboom. (Netherlands)

Tuesday, August 27  
**POSTER SESSION B**

- 100 Creating Treatment Episodes for Biologic Medications from Pharmacy and Medical Claims [536]**  
 Kathy Hardis Fraeman, Dena Ramey, Vinay Mehta, Stephan Lanes. (United States)
- 101 Use of the French Claims and Hospitalisations Database To Estimate the Prevalence and Incidence of Parkinson's Disease in France [537]**  
 Patrick Blin, Caroline Dureau, Adeline Grolleau, Emmanuel Corbillon, Jérémy Jové, Régis Lassalle, Nathalie Poutignat, Alexandra Foubert-Samier, Cécile Droz, Nicholas Moore. (France)
- 102 Audit of the Effect of Relative Age on Morbidity among Children in the Health Improvement Network (THIN) UK Data [538]**  
 Michelle Johnson, Piers Mook, Mary Thompson, Alison Bourke. (United Kingdom)
- 103 Chronic Hepatitis B Virus Infection among U.S. Medicaid Enrollees, 2000-2007 [539]**  
 Dana D Byrne, Craig W Newcomb, Dena M Carbonari, Melissa S Nezamzadeh, Kimberly BF Leidl, Maximilian M Herlim, Yu-Xiao Yang, Sean Hennessy, Jay R Kostman, Mary B Leonard, Russell Localio, Vincent Lo Re III. (United States)
- 104 Seizure and Associated Factors in Patients with Different Types of Dementia [540]**  
 Yingkai Cheng, Paula T Trzepacz, Curtis Chang, Ann Marie Hake, Eric R Siemers. (United States)
- 106 Diabetes as a Risk Factor for Herpes Zoster: Results of an Insurance Claims Database Study in the United States [543]**  
 Adrienne P Guignard, Michael Greenberg, Chao Lu, Dominique Rosillon, Vani Vannappagari. (Belgium)
- 107 Profile of Patients with Gastric Cancer in the US Using Administrative Claims Data [544]**  
 C Hirst, J Ryan, O Tunceli, B Wu, DM Kern. (United Kingdom)
- 108 Posterior Reversible Encephalopathy Syndrome in the IMS Oncology Database: Case Definition, Epidemiology, and Patient Profile [545]**  
 Cinira Lefevre, Dale Quentin Marmaduke, Rohit Noghnan, Ben Cheng, Hugo Xavier, Yu Yan. (United Kingdom)
- 109 Prevalence of Depression in Patients with Type 2 Diabetes in Quebec: A Population-Based Cohort Study [546]**  
 Carlotta Lunghi, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
- 110 Agreement between Claims and Electronic Medical Records Data for CHF in Inpatients [547]**  
 Marc Rosenman, Jinghua He, Joel Martin, Kavitha Nutakki, Irmina Gradus-Pizlo, Siu L Hui. (United States)
- 111 Database Queries for Hospitalizations for Acute CHF: Flexible Methods and Validation Based on Set Theory [548]**  
 Marc Rosenman, Jinghua He, Joel Martin, Kavitha Nutakki, George Eckert, Kathleen Lane, Irmina Gradus-Pizlo, Siu L Hui. (United States)
- 112 Prevalence and Incidence of Idiopathic Pulmonary Fibrosis in UK Healthcare Databases, GPRD and THIN; Need for an IPF Registry [549]**  
 Paula L Thompson, Stephanie Chretien, Francoise Bugnard, William C Maier, Rory Cameron, Mark Fisher, Christophe Giot, Christian Hill, Imran Kausar. (United Kingdom)
- 113 Incidence, Co-Morbidities, and Risk Factors of Age-Related Macular Degeneration [550]**  
 Zdravko P Vassilev, Luis A García-Rodríguez, Montse Soriano-Gabarró, Ana Ruigomez. (United States)
- 114 The Epidemiology of Herpes Zoster (HZ) and Its Complications in Medicare Cancer Patients [551]**  
 Mihran A Yenikomshian, Ann S LaCasce, Arthur T Skarin, Alex Trahey, Adrienne Guignard, François F Haguinet, Paul E Karner, Mei S Duh. (United States)
- 115 Benzodiazepine Use and Risk of Dementia: A Case Control Study Using the Quebec Claims Database [552]**  
 Sophie Billioti de Gage, Yola Moride, Thierry Ducruet, Tobias Kurth, Helene Verdoux, Karine Peres, Antoine Pariente, Bernard Begaud. (France)
- 116 Validation of the National Health Insurance Research Database in Taiwan with Acute Myocardial Infarction Cases [553]**  
 Ching-Lan Cheng, Cheng-Han Lee, Po-Sheng Chen, Yi-Heng Li, Swu-Jane Lin, Yea-Huei Kao Yang. (Taiwan)
- 117 Adverse Events of Ribavirin Plus Pegylated Interferon Combination Therapy for Hepatitis C Patients in Taiwan: A Population-Based Study [554]**  
 Yu-Tseng Chu, Chun-Jen Liu, Wen-Yi Shau, Chi-Shin Wu, Yaa-Hui Dong, Raymond NC Kuo, Chiu-Ling Lai, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 118 Characteristics of Initiators of Asthma Maintenance Medications in 10 Health Care Populations [555]**  
 Catherine B Johannes, Lisa J McQuay, Patricia Tennis, Carlos A Camargo, Jr., Michael Schatz, Kirk D Midkiff, Stephan Lanes, Rachael DiSantostefano, Kourtney J Davis. (United States)
- 119 Using Automated Healthcare Databases To Study Insomnia in Real World [556]**  
 Zhiwen Liu, William Joseph Herring, Cynthia Silber, Edward A Bortnichak, Weifeng Xu, Jay D Pearson. (United States)
- 120 Risk of Upper Gastrointestinal Bleeding with Cyclo-Oxygenase-2 Inhibitors and Nonselective NSAIDs Plus Gastroprotective Agents: What To Prefer? [557]**  
 Gwen MC Masclee, Vera E Valkhoff, Eva M van Soest, R Schade, Giampiero Mazzaglia, Mariam Molokhia, Gianluca Trifiro, Jay L Goldstein, Sonia Hernández-Díaz, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)
- 121 Harmonization of Diagnoses for Acute Pancreatitis Identification from Different Databases in the SAFEGUARD Project [558]**  
 Gwen MC Masclee, Silvana Romio, Ingrid A Leal, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martín, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Miriam CJM Sturkenboom. (Netherlands)
- 122 Harmonization of Acute Myocardial Infarction Identification from Different Databases in the SAFEGUARD Project [559]**  
 Gwen MC Masclee, Miriam CJM Sturkenboom, Ingrid A Leal, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martín, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Silvana Romio. (Netherlands)
- 123 The Effect of Daily Dose of Individual NSAIDs on the Risk of HF in the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project [560]**  
 Federica Nicotra, Andrea Arfè, Antonella Zambon, Tania Schink, Bianca Kollhorst, Huub Straatman, Ron Herings, Miriam Sturkenboom, Giovanni Corrao. (Italy)
- 124 Use of Glucocorticoids and 30-Day Mortality after Colorectal Cancer Surgery; a Nationwide Cohort Study in Denmark [561]**  
 Eva B Ostenfeld, Anders H Riis, Ole Thorlacius-Ussing, Rune Erichsen, Henrik T Sørensen. (Denmark)
- 125 Validation of Hospital Discharge Diagnoses and Laboratory Measurements To Identify Patients with Idiopathic Acute Liver Injury [564]**  
 Renate Udo, Anke-Hilse Maitland-van der Zee, Toine CG Egberts, Hubert GM Leufkens, Wouter W van Solinge, Marie L De Bruin. (Netherlands)
- 126 A Cohort Analysis To Measure the Effect of Orlistat or Bariatric Surgery on Weight and Body Mass Index in a General UK Population Sample [565]**  
 Ian J Douglas, Krishnan Bhaskaran, Liam Smeeth. (United Kingdom)
- 127 Antidepressant Prescribing in Five European Countries: Application of Common Methods To Assess the Variation in Prevalence [566]**  
 V Abbing-Karahagopian, C Huerta, PC Souverein, F de Abajo, HGM Leufkens, J Slattery, Y Alvarez, M Montserrat, M Gil, U Hesse, G Requena, F de Vries, M Rottenkolber, S Schmiedl, R Reynolds, R Schlinger, M de Groot, OH Klungel, TP van Staa, L van Dijk, ACG Egberts, H Gardarsdottir, ML De Bruin. (Netherlands)

Tuesday, August 27  
**POSTER SESSION B**

- 128 Is the CPRD GOLD Population Comparable to the U.K. Population? [567]**  
Jennifer Campbell, Daniel J Dedman, Susan C Eaton, Arlene M Gallagher, Tim J Williams. (United Kingdom)
- 129 Effects of Glargine in Patients with Type 1 Diabetes in Belo Horizonte, Brasil [568]**  
Ana Luísa Caires de Souza, Francisco Assis Acurcio, Augusto Afonso Guerra, Júnior, Renata Cristina Rezende Macedo do Nascimento, Leonardo Maurício Diniz. (Brazil)
- 130 Translating Prescribing Data into Practice – Down Under [569]**  
Nancy PT Huang, Margaret Williamson, Reital Minogue. (Australia)
- 131 Times Trends in Antihypertensive Drug Use and Hypertension in Cohort Database 2005-2009 of Employees of Oil and Gas Mining in East Kalimantan, Indonesia [570]**  
Iwan Dwiprahasto, Erna Kristin, Dwi Indria Anggraini. (Indonesia)
- 132 Utilisation Patterns of Inhaled Corticosteroids in Patients with Asthma: A Study Using the UK Clinical Practice Research Datalink (CPRD) [571]**  
Alison L Nightingale, Julia Snowball, Rachel A Charlton, Corinne S de Vries. (United Kingdom)
- 133 Anticholinergic Load as a Modifiable Risk Factor of Sitter Use in Acute Care Hospitals [572]**  
Ariane Lessard, Anne-Marie Charbonneau-Allard, Fluet Jessicat, Christian M Rochefort, Robyn M Tamblin, Louise Mallet. (Canada)
- 134 Use of Antidepressant Drugs among Diabetic Population: A Prescription Sequence Symmetry Analysis [573]**  
Muhammad Saeed, Max Petzold, Morten Andersen, Anders Carlsen. (Sweden)
- 135 Therapeutic Consequences of Dextropropoxyphene Withdrawal in France [574]**  
Cheikh Tamberou, Catherine Cornu, Emilie Chretien, Laurent Letrilliart, François Gueyffier, Laurent Laforest, Elodie Chaissac, Eric Van Ganse, Comité Douleur-Anesthésie loco-Régionale French Society of Anesthesia and Intensive Care, Frederic Aubrun. (France)
- 136 Changes in Therapeutic Management of COPD between 2006 and 2001: French Claims Data [575]**  
Laurent Laforest, Cheikh Tamberou, Marine Ginoux, Chu-Philippe Ya, Gilles Devouassoux, Nicolas Roche, Cristos Chouaid, Eric Van Ganse. (France)
- 137 Comparison of Six Electronic Healthcare Databases in Europe Using Standardized Protocols: A Descriptive Study on the Incidence of Cancer [576]**  
Ana S Afonso, Mark CH De Groot, Rianne Van den Ham, Marie L Bruin, Consuelo Huerta Alvarez, Miguel Gil, Ulrik Hesse, Pernille F Rønn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Liset Van Dijk, Raymond
- G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda. (Netherlands)
- 138 Identifying Drug-Safety Signals in Electronic Health Records: An Evaluation of Automated Case-Detection Algorithms with Different Sensitivity and Specificity [577]**  
Zubair Afzal, Jan A Kors, Miriam C Sturkenboom, Martijn J Schuemie. (Netherlands)
- 139 Standard Method for Assessment of Electronic Health Record (EHR) Data Sources for Pharmacoepidemiology [578]**  
Stephen OT Agbor, Allise G Kamauu, Aaron WC Kamauu. (United States)
- 140 Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis [579]**  
Marloes T Bazelier, Frank de Vries, Peter Vestergaard, Ron MC Herings, Arlene M Gallagher, Hubert GM Leufkens, Tjeerd-Pieter van Staa. (Netherlands)
- 141 Validity of the Duration of Inhaled Corticosteroid Prescription and the Number of Allowed Refills Recorded in Québec Databases [581]**  
Lucie Blais, Anne Vilain, Fatima-Zohra Kettani, Amélie Forget, Geneviève Lalonde, Marie-France Beauchesne, Francine Ducharme, Catherine Lemièrè. (Canada)
- 142 A New Method To Get Fast Patient Reported Outcomes Data from Primary Care in the UK for Patients with Atrial Fibrillation (AF) in the Health Improvement Network (THIN) [582]**  
Michelle Johnson, Delphine Vial, Mary Thompson, Claire Cockbain, Simon Hogan, Alison Bourke. (United Kingdom)
- 143 Methods to Link a U.S Arthritis Cohort with Medicare Administrative Claims Data [583]**  
Lang Chen, Timothy Beukelman, Aseem Bharat, Fenglong Xie, Kenneth G Saag, Elizabeth S Delzell, Jeffrey R Curtis. (United States)
- 144 Antiepileptic Drug Use in Seven Electronic Health Record Databases in Europe: A Methodological Comparison [585]**  
Mark CH De Groot, Markus Schuerch, Frank De Vries, Ulrik Hesse, Belén Oliva, Consuelo Huerta Alvarez, Miguel Gil, Gema Requena, Francisco Abajo, Ana Afonso, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel. (Netherlands)
- 145 Comparison of Seven Electronic Healthcare Databases in EU Countries Using a Standardized Methodology; a Descriptive Study on the Exposure to Calcium-Channel Blockers (CCBs) [586]**  
Mark CH de Groot, Rianne Van den Ham, Marieke De Bruin, Consuelo Huerta Alvarez, Miguel Gil, Ana Afonso, Gema Requena, Ulrik Hesse, Pernille Falberg Rønn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda. (Netherlands)
- 146 Estimating Time-Specific Propensity Scores: A Case Study of the Effectiveness of Inhaled Long-Acting Beta-Agonists on Asthma Exacerbations [587]**  
Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk, Glen T Schumock, Todd A Lee. (Thailand)
- 147 Development and Validation of a Claims-Based Algorithm To Identify Urinary Retention in Patients Receiving Antiepileptic Drugs [588]**  
Mei Sheng Duh, Lianna Ishihara, Wendy Cheng, Scott C Quinlan, Yueqin Zhao, Michael Irizarry. (United States)
- 148 Determining Multiple Sclerosis Subtype from Electronic Medical Records [589]**  
Scott L DuVall, Jorie Butler, Joanne LaFleur, Aaron WC Kamauu, Markus Schuerch, Nadia Foskett, Richard E Nelson. (United States)
- 149 Characterization of Patients with ANCA-Associated Vasculitis by Subtype in the Veterans Affairs Database [590]**  
Scott L DuVall, Aaron WC Kamauu, Stephen OT Agbor, Tmirah Haselkorn, Pavel Napalkov, Iain D Tatt, Curry L Koening. (United States)
- 150 Analyzing Database Studies with Many Outcomes or Co-Morbidities: Using SAS® to Dynamically Generate Analytic Programs from Case Definitions Stored in Excel® [591]**  
Kathy Hardis Fraeman, Dena Ramey, Vinay Mehta, Stephan Lanes. (United States)
- 151 Study Designs in Pharmacoepidemiologic Studies on Electronic Healthcare Databases: A Systematic Review [592]**  
Nathalie Gault, Stéphanie Foulon, Sylvie Guillo, Florence Tubach. (France)
- 152 Potential for Early Pharmacoepidemiologic Studies and Monitoring Intake of a Biologic Treatment Using an Electronic Health Records Database Prior to Assigned J-Code [593]**  
Aaron WC Kamauu, Stephen Agbor, Emily Dastrup, Scott L DuVall, Debra Maldonato, Pavel Napalkov. (United States)
- 153 Utilization of New Diagnosis Codes for Basal Cell Carcinoma in 2 Large Nationwide EHR Databases [594]**  
Aaron WC Kamauu, Emily Dastrup, Yeun Mi Yim, Scott L DuVall. (United States)
- 154 Development and Validation of an Acute Liver Failure (ALF) Risk Prediction Model for Patients with Drug-Induced Hepatitis (DIH) [597]**  
Vincent Lo Re III, Kevin Haynes, James D Lewis, Dena M Carbonari, Kimberly BF Leidl, Kimberly A Forde, David Goldberg, Melissa S Nezamzadeh, K Rajender Reddy, Jason Roy, Daohang Sha, Amy R Marks, Jolanda De Boer, Brian L Strom, Douglas A Corley. (United States)

Tuesday, August 27  
**POSTER SESSION B**

- 155 Validity of Diagnostic Codes To Identify Cases of Severe Acute Liver Injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database [598]**  
Vincent Lo Re III, Kevin Haynes, David Goldberg, Kimberly A Forde, Dena M Carbonari, Kimberly BF Leidl, Sean Hennessy, Rajender Reddy, Pamala A Pawloski, Gregory W Daniel, T Craig Cheetham, Aarthi Iyer, Kara O Coughlin, Sengwee Toh, Denise M Boudreau, William O Cooper, Nandini Selvam, Mano S Selvan, Jeffrey J VanWormer, Mark I Avigan, Monika Houstoun, Gwen L Zornberg, Judith A Racosin, Azadeh Shoabi. (United States)
- 156 Developing Acute Coronary Syndrome Disease Cohorts Using Primary and Secondary Care Database Linkages [599]**  
Robert N Lubwama, Cathy A Pinto. (United States)
- 157 Distinguishing Incident and Prevalent Diabetes in an Electronic Medical Record Database [600]**  
Ronac Mamtani, Brian S Finkelman, Kevin Haynes, Frank I Scott, James D Lewis. (United States)
- 158 A Novel Process for the Identification, Development and Assessment of Database Coding Algorithms for 5 Psychiatric Conditions [601]**  
Vinay Mehta, Melissa Whipple, Natalie Jones, Juliana Lewis, Edward Bortnichak, Matthew Reynolds. (United States)
- 159 A Novel Process for the Identification, Development and Assessment of Database Coding Algorithms for 6 Cardiovascular Conditions [602]**  
Vinay Mehta, Melissa Whipple, Natalie Jones, Juliana Lewis, Edward Bortnichak, Matthew Reynolds. (United States)
- 160 Identifying Causes of Death in a Large Cohort of Asthma Patients [603]**  
Kirk D Midkiff, Catherine Johannes, Patricia Tennis, Brian Calingaert, Lisa J McQuay, David Harris, Elizabeth B Andrews. (United States)
- 161 Decision Rules for Microbiologically-Evaluable Complicated Urinary Tract Infection in an Electronic Medical Record-Linked Administrative Database [604]**  
Fanny Mitrani-Gold, Nittaya Suppapanya, Linda M Mundy. (United States)
- 162 An Assessment of How the Outputs from Signal Detection Can Be Affected by Variation of Database Profile by Analysing Adverse Events Reports of FDA and PMDA Received in 2010 [605]**  
Kaori Nomura, Kunihiro Takahashi, Yasushi Hinomura, Genta Kawaguchi, Yasuyuki Matsushita, Hiroko Marui, Tatsuhiro Anzai, Masayuki Hashiguchi, Mayumi Mochizuki. (Japan)
- 163 Validation of a Multiple Myeloma Algorithm in Administrative Data [606]**  
Susan Oliveria, Nancy Brandenburg, Syd Phillips, Karen Wells, Kimberley J Woodcroft, Marianne Ulcickas Yood. (United States)
- 164 Multiple Imputation of Missing Data in Longitudinal Electronic Health Records [607]**  
Irene Petersen, Catherine Welch, Jonathan Bartlett, Richard Morris, Kate Walters, Irwin Nazareth, Louise Marston, Ian White, James Carpenter. (United Kingdom)
- 165 Projection Methods Using Oncology Electronic Health Records To Produce Nationally Representative Estimates [608]**  
David Quach, Alexander Liede, Serapio Byekwaso, Daria Eremina, Bruce S Kossar, Li Zhou, Jane M Quigley, Joel Kallich, John Adams, Paul Smith. (United States)
- 166 The Identification of Incident Cancers in UK Primary Care Databases: A Systematic Review [609]**  
Michael E Rañopa, Ian Douglas, Tjeerd van Staa, Liam Smeeth, Krishnan Bhaskaran. (United Kingdom)
- 167 A Remote Research Environment for Collaborative Drug Safety Studies: The OCTOPUS Infrastructure [610]**  
Peter R Rijnbeek, Johan van der Lei, Miriam CJM Sturkenboom. (Netherlands)
- 168 Time Trends in Prevalence of Inhaled Long-Acting beta-2-Adrenoceptor Agonist Prescribing – A Comparison of Seven European Electronic Health Record Databases [611]**  
Marietta Rottenkolber, Eef Voogd, Liset van Dijk, Paola Primatesta, Raymond G Schlienger, Mark CH de Groot, Estel Plana Hortonedá, Yolanda Alvarez, Julie Durand, Jim Slattery, Ana S Afonso, Gema Requena, Miguel Gil, Consuelo Huerta, Arturo Alvarez, Francisco de Abajo, Ulrik Hesse, Rainald Fischer, Joerg Hasford, Roman Gerlach, Martin Tauscher, Robert Reynolds, Olaf H Klungel, Sven Schmiedl. (Germany)
- 169 A Detection Algorithm for Statin-Induced Myopathy Using Electronic Medical Records [612]**  
Kimie Sai, Tadaaki Hanatani, Yuichiro Azuma, Katsunori Segawa, Masahiro Tohkin, Hideaki Omatsu, Hiroo Makimoto, Midori Hirai, Yoshiro Saito. (Japan)
- 170 Test Data in General Practice Are Not Missing at Random – Can We Identify When They Are? [613]**  
Cormac J Sammon, Alison L Nightingale, Anne Miller, Kamal R Mahtani, Tim A Holt, Neil McHugh, Raashid A Luqmani, Corinne S de Vries. (United Kingdom)
- 171 Harmonisation of Event Definitions across Electronic Healthcare Databases; Pancreatic and Bladder Cancer as a Case Study [614]**  
Cormac J Sammon, Georgia De Berardis, Antonio Nicolucci, Irene Bezemer, Gema Requena, Miguel Gil, Elisa Martin, Ingrid Leal, Gwen MC Masclee, Giampiero Mazzaglia, Peter Rijnbeek, Silvana Romio, Niklas Schmedt, Lorenza Scotti, John D Seeger, Mark Smits, Cristina Aras-Lorenzo, Miriam CJM Sturkenboom, Corinne de Vries. (United Kingdom)
- 172 Validation of Mortality Information in the German Pharmacoepidemiological Research Database (GePaRD) [615]**  
Christoph Ohlmeier, Niklas Schmedt, Kathrin Hillebrand, Ingo Langner, Rafael Tadeusz Mikolajczyk, Edeltraut Garbe. (Germany)
- 173 Harmonization of Outcome Extraction for Ischemic and Hemorrhagic Stroke across Data Sources in the SAFEGUARD Project [616]**  
Niklas Schmedt, Miguel Gil, Elisa Martin, Gema Requena, Irene Bezemer, Giorgia De Berardis, Corine de Vries, Ingrid Leal, Gwen Masclee, Giampiero Mazzaglia, Peter Rijnbeek, Silvana Romio, Cormac Sammon, Lorenza Scotti, John Seeger, Mark Smits, Tania Schink, Christina Varas-Lorenzo, Miriam Sturkenboom, Edeltraut Garbe. (Germany)
- 174 Identification of Seizures among Adults and Children Following Influenza Vaccination Using Health Insurance Claims Data [617]**  
Veena Thyagarajan, Sue Su, Julianne Gee, Jonathan Duffy, Natalie L McCarthy, K Arnold Chan, Eric Weintraub, Nancy D Lin. (United States)
- 175 When Follow-Up Time Cannot Be Assigned: Chronic Kidney Disease and It's Diagnosis [618]**  
Jan C van Blijderveen, Sabine M Straus, Miriam C Sturkenboom, Bruno C Stricker, Katia M Verhamme. (Netherlands)
- 176 Spending with Infliximab Versus Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis Treatment in SUS, from 2003 to 2006 [619]**  
Juliana O Costa, Augusto AG Júnio, Alessandra M Almeida, Mariangela L Cherciglija, Eli Iola G Andrade, Francisco A Acurcio/ Research Group in Pharmacoepidemiology. (Brazil)
- 177 Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study [620]**  
Tony Antoniou, Hong Zheng, Samantha Singh, David N Juurlink, Muhammad M Mamdani, Tara Gomes. (Canada)
- 178 Assessing the Completeness and Quality of Saudi Adverse Event Reporting System (SAERS) [621]**  
Wa'ad H Alkathiri, Thamir M Alshammari, Hisham S Aljadhey. (Saudi Arabia)
- 179 Strengthening Pharmacovigilance Capabilities in Canada by Using MedDRA Coding and Medical Case Review in Parallel To Classify Reports of Adverse Events Following Immunization Received by the Public Health Agency of Canada [622]**  
Julie Lafèche, Helen Anyoti, Barbara Law. (Canada)
- 180 Evaluation of a Standardised MedDRA Query (SMQ) in Administrative and Electronic Medical Record (EMR) Databases [623]**  
Brian Dreyfus, Jasmine Marwaha, Allison Lee. (United States)

Tuesday, August 27  
**POSTER SESSION B**

- 181 Risk Identification in Healthcare Records - Comparison to Epidemiological Studies [624]**  
I Ralph Edwards, Ghazaleh Karimi, Tomas Bergvall, Ola Caster, Alex Asiimwe, Kristina Star, Fatima Bhayat, Montse Soriano-Gabarro, Bharat Thakrar, Mary Thompson, Andrew Bate, G Niklas Norén. (Sweden)
- 182 Safety Signal Surveillance Study of Adverse Events of Special Interest for Intradermal Influenza Vaccine Using THIN Database [625]**  
Shujun Gao, Catherine A Panozzo, Larissa Mege, Marie Miossec, Alena Khromava. (United States)
- 184 Positive Predictive Value of ICD-10 Discharge Diagnoses of Infection among Cancer Patients in Denmark [628]**  
Louise Holland-Bill, Hairong Xu, Henrik T Sorensen, John Acquavella, Claus Sværke, Henrik Gammelager, Vera Ehrenstein. (Denmark)
- 185 Incidence of Opioid Intoxications in Patients with or without Alcohol Related Disorders Treated with High-Potency Opioid Analgesics in 2004-2009 [629]**  
Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)
- 186 Quantitative Analysis of Gender Based Risk in Macrolide-Related QT Prolongation and Cardiovascular Events [630]**  
Jung E Lee, Samina Qureshi. (United States)
- 187 Influence of Computing Power for Time-Dependent Analysis in Large Cohorts Using SAS [631]**  
Lewis McConnachie, David A Rorie, Rob Flynn, Tom M MacDonald, Isla S Mackenzie, Adrian Hapca, Jonathan Monk, Aaron Hoolachan. (United Kingdom)
- 188 Adverse Drug Reaction Reports of Patients and Healthcare Professionals; How Different Are They? [632]**  
Leàn Rolfes, Florence van Hunsel, Eugène van Puijtenbroek, Kees van Grootheest. (Netherlands)
- 189 Hallucinations: A Case/Noncase Study in the French Pharmacovigilance Database [633]**  
Malak Abou Taam, Paul De Boissieu, Sylvain Dukic, Emmanuelle Herlem, Thierry Trenque. (France)
- 190 Leveraging Multiple EHR Databases in Parallel as an Innovative Means for Active Postmarketing Hepatotoxicity Monitoring in Oncology Patients [634]**  
Sumitra Shantakumar, Susan A Hall, Beth Nordstrom, Kristen Snow, Elizabeth Lawler, Irene Bezemer, Jeanette J Nelson. (United States)
- 191 Incidence of Cardiovascular Events in the Real World Population of Cancer Patients with Solid Tumors [635]**  
Jonathan G Zaroff, Douglas A Corley, Wei K Zhao, Lina Titievsky. (United States)
- 192 Cause of Death Recording in the Health Improvement Network (THIN) UK Data among the Afloat Study Population (n=56508) [636]**  
Michelle Johnson, Mary Thompson, Piers Mook, Simon Hogan, Alison Bourke. (United Kingdom)

- 193 Data Elements in Inpatient Databases to Enhance Safety & Health Outcomes Research [637]**  
Anokhi J Kapasi, Sharmila A Kamani, Bao Nguyen-Khoa, Judith K Jones. (United States)
- 194 Prevalence, Selected Co-Morbidities and Systemic Therapies in a U.S. Population-Based Cutaneous Psoriasis Cohort [638]**  
Hoa V Le, Chi T Truong, Julie Priest, Carlyne Averell, Joe Eastman, Martin Crane. (United States)
- 195 The Risk of Tetrazepam To Induce Severe Cutaneous Adverse Reactions [639]**  
Maja Mockenhaupt, Peggy Sekula, Benedicte Lebrun-Vignes, Jean-Claude Roujeau. (Germany)
- 196 Total Mortality Rates across Multiple Databases: Benchmarking Results from a Distributed Data Network - The SAFEGUARD Project [640]**  
John D Seeger, Silvana Romio, Cristina Varas-Lorenzo, Lorenza Scotti, Andrea Arfè, Antonella Zambon, Miguel Gil, Gema Requena, Irene Bezemer, Georgia De Berardis, Corinne DeVries, Ingrid Leal, Gwen Masclee, Gianluca Trifiró, Peter Rijnbeek, Cormac Sammon, Niklas Schmedt, Mark Smits, Giovanni Corrao, Miriam Sturkenboom. (United States)

**Molecular Epidemiology/Biomarkers/  
Pharmacogenetics SIG**

- 197 Evaluation of the Effect of SNPs in CYP3A4 and CYP4F2 on the Stable Phenprocoumon and Acenocoumarol Maintenance Dose [654]**  
Rianne van Schie, Judith Wessels, Amin Aoussar, Talitha Verhoef, Tom Schalekamp, Saskia le Cessie, Felix van der Meer, Frits Rosendaal, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 198 Pharmacogenomics in Primary Care: Expanding Our Understanding with Deliberations [643]**  
Gillian Bartlett, Cristina Longo, Annyck Besso, Brenda MacGibbon, Martin Dawes. (Canada)
- 199 CARING: Tumour Characteristics of Diabetic and Non-Diabetic Breast Cancer Patients [644]**  
Heleen K Bronsveld, Peter Vestergaard, Vibeke Jensen, Jakob Starup Linde, Sten Cornelissen, Peer Christensen, Marie L De Bruin, Marjanka K Schmidt. (Netherlands)
- 200 Interactions of Human Papillomavirus and Host Genetic Polymorphisms in Carcinogenesis: A Systematic Review and Meta-Analysis [646]**  
Steven Habbous, Vincent Pang, Lawson Eng, Eitan Amir, Geoffrey Liu. (Canada)
- 201 Breast and Colorectal Cancer Patients Decision Making for Pharmacogenomic Diagnostics [647]**  
Amalia M Issa, Waqas Tufail, Nelson Atehortua, Jose Tenorio. (United States)
- 202 Racial Differences Affect Patients Willingness in Providing Additional Biospecimens for Pharmacogenomic Testing [649]**  
Tenneille T Loo, Sinead Cuffe, Henrique Hon, Petra Martin, M Catherine Brown, Shabbir Alibhai, Xin Qiu, Wei Xu, Geoffrey Liu. (Canada)

- 203 Effect of BRM Promoter Polymorphisms on Survival Outcomes of Platinum-Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients [651]**  
Sinead Cuffe, Lu Cheng, Abul Kalam Azad, Yonathan Brhane, Dangxiao Cheng, Zhuo Chen, Xiaoping Qiu, Kevin Boyd, Wei Xu, Frances A Shepherd, Ming-Sound Tsao, David Reisman, Geoffrey Liu. (Canada)
- 204 Polymorphisms of Organic Cation Transporter1 (OCT1) in Indonesian Cancer Patients [652]**  
Dyah Aryani Perwitasari, Jarir Atthohari. (Indonesia)
- 205 The Opportunities and Challenges of Generating Evidence on Medical Device Associated Biomarkers and Implementing the Biomarker-Based Regulatory Research Applications [653]**  
Yelizaveta Torosyan, Danica Marinac-Dabic. (United States)
- 206 Influence of Genetic and Non-Genetic Factors on the Plasma Concentrations of the Clopidogrel Metabolite (SR26334) among Chinese Patients [656]**  
Haoming Zhou, Shu Meng, Jun Zhao, Junfen Xin, Weimin Cai. (China)
- 207 Beat-to-Beat Variability of the QT Interval: A Systematic Review [658]**  
Maartje N Niemeijer, Marten E van den Berg, Mark Eijgelsheim, Jan A Kors, Bruno H Stricker, Peter Rijnbeek. (Netherlands)

**Pediatrics SIG**

- 208 Latrogenic Aluminum and General Intelligence of Moroccan Children [659]**  
F-Z Azzaoui, M El Hioui, S Boulbaroud, A Ahami. (Morocco)
- 209 Exploration of Defined Daily Dose and Days of Therapy in Paediatrics and ob-gyn – A Descriptive Analysis of Antifungals [660]**  
Justine Guillot, Héléne Roy, Denis Lebel, Philippe Ovetchkine, Jean-François Bussièrès. (Canada)
- 210 Comorbid Conditions and Drug Utilization of Pediatric-Onset Multiple Sclerosis Patients in a Large US Health-Claims Database [696]**  
Made Wenten, Gary Bloomgren, Jin Wang, Anne Dilley. (United States)
- 211 Exploration of Defined Daily Dose and Days of Therapy in Paediatrics and ob-gyn – A Descriptive Analysis of Antivirals [661]**  
Justine Guillot, Héléne Roy, Philippe Ovetchkine, Denis Lebel, Jean-Francois Bussièrès. (Canada)
- 212 Obesity and Metabolic Abnormalities in Antipsychotic Exposed Youth [663]**  
Robert B Christian, Asheley C Skinner, Kathleen Moran, Joel F Farley, Jerry Mckee, Trista Pfeiffenberg, Troy Trygstad, Steve Wegner, Brian C Sheitman. (United States)

Tuesday, August 27  
**POSTER SESSION B**

- 213 Analgesic and Psychiatric Co-Medication in Commercially Insured Pediatric Inflammatory Bowel Disease Patients [664]**  
 Jessie P Buckley, Michael D Kappelman, Jeffery K Allen, Bhavani Muppidi, Susan A VanMeter, Suzanne F Cook. (United States)
- 214 Increasing Utilization of Proton Pump Inhibitors in Children: A Cohort Study in 3 European Countries [666]**  
 Sandra de Bie, Katia MC Verhamme, Miguel Gil Garcia, Gino Picelli, Sabine MJM Straus, Belen Oliva, Mariagrazia Felisi, Bruno HC Stricker, Francisco J de Abajo, Miriam CJM Sturkenboom. (Netherlands)
- 215 Pediatric Pharmacoepidemiology Safety Study with Long-Term Use of Sertraline: The SPRITES Study [667]**  
 Cynthia de Luise, Francesca Kolitsopoulos, Alejandra E Nieto, John F Curry, John S March. (United States)
- 216 Using PMSI Database To Identify Adverse Drug Reactions in a Pediatric University Hospital [668]**  
 Genevieve Durrieu, Arnaud Batz, Emmanuelle Bondon-Guitton, Vanessa Rousseau, Leila Chebane, Dominique Petiot, Jean-Louis Montastruc. (France)
- 217 Teething Symptoms and Their Evolution over Time: Data Collected from Parents [669]**  
 Soh la Elkebir, Laurence Terzan, Remi Gauchoux, Anne-Laure Fayard. (France)
- 218 Treatment of Teething Symptoms: Evaluation of Parent's Compliance to Pediatricians Prescriptions [670]**  
 Soh la Elkebir, Laurence Terzan, Remi Gauchoux, Anne-Laure Fayard. (France)
- 219 Prescription Patterns and Treatment Adherence of Asthma Controller Therapies in Children in a Dutch Primary Care Database [671]**  
 Marjolein Engelkes, Hettie M Janssens, Zubair Afzal, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)
- 220 Prevalence and Patterns of Anti-Infective Medication Use in Children with Type 1 Diabetes Mellitus [672]**  
 Soulmaz Fazeli Farsani, Patrick C Souverein, Maria MJ van der Vorst, Catherijne AJ Knibbe, Antonius de Boer. (Netherlands)
- 221 Medication Use and Disease History as Risk Factors for the Clinical Manifestation of Type 1 Diabetes Mellitus [673]**  
 Soulmaz Fazeli Farsani, Patrick C Souverein, Maria MJ van der Vorst, Catherijne AJ Knibbe, Antonius de Boer. (Netherlands)
- 222 Demographic and Clinical Characteristics Prior to Clozapine Initiation in Early Onset Schizophrenia: A Study Based on the Danish Population-Based Registers [674]**  
 Stephen Papachristou, Carolina Schneider, Christiane Gasse, Theresa Wimberley, Sophia Frangou. (Denmark)
- 223 Maternal Smoking in Early Pregnancy Increases Risk of Childhood Overweight [675]**  
 Luke E Grzeskowiak, Nicolette A Hodyl, Michael J Stark, Janna L Morrison, Vicki L Clifton. (Australia)
- 224 2nd Immunization Against Measles, Mumps, Rubella with MMRV, MMR or MMR+V [676]**  
 Sabrina Hense, Tania Schink, Edeltraut Garbe. (Germany)
- 225 Trends in Prevalence of Antibacterial Drug Use among Dutch Children from 2005 until 2010 [677]**  
 Stephan GL Joosten, Leanne MA Houweling, Fernie JA Penning-van Beest. (Netherlands)
- 226 Characteristics and Determinants of Palivizumab Use in the Netherlands [678]**  
 Leanne MA Houweling, Fernie JA Penning-van Beest, Irene D Bezemer, Richard A van Lingen, Ron MC Herings. (Netherlands)
- 227 Trends in Prevalence of Drug Use among Dutch Children from 2005 until 2010 [679]**  
 Stephan GL Joosten, Leanne MA Houweling, Fernie JA Penning-van Beest. (Netherlands)
- 228 Prevalence of Childhood Asthma and Asthma-Related Health Services Utilization in the Province of British Columbia, Canada [680]**  
 Ricardo Jimenez, TingTing Zhang, Hao Luo, Ran Goldman, Anne Smith, Bruce Carleton. (Canada)
- 229 Misuse of Short Courses of Oral Glucocorticoids in Children: A Prospective Observational Study [682]**  
 Marie-Laure Laroche, Emily Bennett, Adelilah Tahir, Vincent Guignonis, Louis Merle. (France)
- 230 Distribution and Development of Co-Morbidities in Pediatric Patients with ADHD [683]**  
 Xinyue Liu, Paul Kubilis, Dandan Xu, Regina Bussing, Almut G Winterstein. (United States)
- 231 Influence of Drug Prescription Status in Pediatric Adverse Drug Reaction: Review of Spontaneous Reports Registered to the Pharmacovigilance by a Regional Pharmacovigilance Center [684]**  
 Mathieu Maupiler, Charlotte Bezzina, Vanessa Rousseau, Leila Chebane, Emmanuelle Bondon-Guitton, Genevieve Durrieu, Jean Louis Montastruc. (France)
- 232 Antipsychotic Use for Youth with ADHD and Psychiatric Comorbidities [686]**  
 Xinyi Ng, Sharmila Das, Annie Guan, Susan dosReis. (United States)
- 233 Medication Administration Errors among Paediatric Nurses in Lagos Public Hospitals: An Opinion Survey [687]**  
 Kazeem A Oshikoya, Ibrahim A Oreagba, Olayinka O Ogunleye, Idowu O Senbanjo, GL MacEbong, Sunday O Olayemi. (Nigeria)
- 234 Creating a Reference Set for Comparing Data Mining Methods and Evaluating Database Performance in Children – The GRiP Project [688]**  
 Osemeke Osokogu, Federica Fregonese, Daniel Weibel, Katia Verhamme, Mariana Catapano, Sandra De Bie, Miriam Sturkenboom, Carmen Ferrajolo, Preciosa Coloma, Geert 't Jong, Martijn Schuemie, Ian Wong, Yingfen Hsia, Madlen Gazarian, Hide Nakamura. (Netherlands)
- 235 Use of SSRIs among Children: A Danish Drug Use Study [689]**  
 Anton Potteg rd, Helga Zo ga, Jesper Hallas, Per Damkier. (Denmark)
- 236 Relative Age in Class and Stimulant Drug Utilization for ADHD [690]**  
 Anton Potteg rd, Jesper Hallas, Sonia Hern ndez-D az, Helga Zo ga. (Denmark)
- 237 National Trends in Psychotropic Medications Prescribed for Pediatric Bipolar Disorder with and without Comorbid Behavioral Disorders, 1999-2010 [691]**  
 Thiyagu Rajakannan, Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 238 Pediatric Exclusivity: Evolving Legislation and Novel Complexities within Pediatric Therapeutic Development [692]**  
 Donna R Rivera, Abraham G Hartzema. (United States)
- 239 Automated Information Retrieval for Constructing Evidence-Based Pediatric Formularies [693]**  
 Bharat Singh, Gina Ayala, Peter R Rijnbeek, Erik M van Mulligen, Jan A Kors, Miriam CJM Sturkenboom. (Netherlands)
- 240 Results from a Novel and Proactive Program To Evaluate the Safety of Celecoxib in Juvenile Idiopathic Arthritis (JIA) Patients [695]**  
 Rachel E Sobel, Staci Abramsky, Carol A Wallace, Sarah Ringold, Audrey Hendrickson, Daniel J Lovell, Edward H Giannini, James Young, Sharon Mallen. (United States)
- 241 Evaluation of Long-Term Safety of Latanoprost in Pediatric Populations: Design and Rationale of an Ongoing Non-Interventional Cohort Study [697]**  
 Wanning Xu, Kui Huang, Marla Sultan, Min Zhang. (United States)
- 242 Pediatric Information in Cough/Cold Medication Product Labeling [698]**  
 Boon Hou Chua, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

**Poster Walk - Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG**

- 243 Development and Optimization Process of Benefit/Risk Balance Assessment (BRBA) Model of Medicine for KFDA [493]**  
 Jihye Ha, Sung Young Lee, Ji Eun Kang, Han Sung Na, Myeon Woo Chung. (Republic of Korea)

Tuesday, August 27  
**POSTER SESSION B**

- 244 Does Media Attention Affect Impact of DHPs in the Netherlands? [500]**  
Peter GM Mol, Valerie Damoiseaux, Katrin Reber, Sigrid Piening, Jaap Wieringa, Sabine MJM Straus, Flora M Haaijer-Ruskamp. (Netherlands)
- 245 Balancing Individual Benefits and Risks of Warfarin in Patients with Atrial Fibrillation [504]**  
Rianne van den Ham, Olaf H Klungel, Hubert GM Leufkens, Tjeerd P van Staa. (Netherlands)
- 246 A Systematic Review of Randomized Controlled Trials of New Oral Anticoagulants: The Search for a Net Clinical Benefit [505]**  
Martin Viau, Raana Haj Najafi, Jason R Guertin, Jacques LeLorier, Madeleine Durand. (Canada)
- 247 Information on QTc-Interval Prolongation in the Summary of Product Characteristics [506]**  
Miriam J Warnier, Frank A Holtkamp, Frans H Rutten, Arno W Hoes, Anthonius de Boer, Peter GM Mol, Marie L De Bruin. (Netherlands)
- 248 Using Multi-Criteria Decision Analysis for Quantitative Benefit Risk Assessment of Afibercept as a Second Line Treatment in Adults with Metastatic Colorectal Cancer [507]**  
Jasmanda Wu, Lawrence Phillips, Mengyang Wang, Wanju Dai, Sheikh Usman Iqbal, Manu Sondhi, Christopher Kripas, Pankaj Bhargava, Amy Freedman, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 249 Medication Guide Reading Behaviors and Attitudes among Patients with Migraine, Asthma, or COPD [523]**  
Kristen B Bibeau, Rachael L DiSantostefano. (United States)
- 250 Pregnancy and Lactation Labeling Information in Cough and Cold Related Medications [530]**  
Si Mei Shermaine Sue, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

**Poster Walk - Database SIG**

- 251 Incidence of, and Risk Factors for Herpes Zoster in the HAART Era: An Analysis of the CHORUS Cohort [542]**  
Adrienne P Guignard, François Haguined, Samantha St. Laurent, Vani Vannappagari. (Belgium)
- 252 Use of Disulfiram and Risk of Cancer: A Population-Based Case-Control Study [562]**  
Anton Pottegård, Søren Friis, Lau C Thygesen, Jesper Hallas, Gro Askgaard. (Denmark)
- 253 Harmonization of Outcome Extraction for Heart Failure across Data Sources in the SAFEGUARD Project [563]**  
Lorenza Scotti, Andrea Arfè, Antonella Zambon, Silvana Romio, Niklas Schmedt, Giorgia De Berardis, Cormac Sammon, Miguel Gil, Elisa Martin, Gema Requena, Corine de Vries, John D Seeger, Giampiero Mazzaglia, Irene Bezemer, Cristina Varas-Lorenzo, Mark Smits, Peter Rijnbeek, Miriam Sturkenboom, Giovanni Corrao. (Italy)

- 254 Using Natural Language Processing To Identify US Veterans with Binge Eating Disorder [580]**  
Brandon K Bellows, Scott L Duvall, Thomas Ginter, Aaron WC Kamauu, Dylan Supina, Paul Hodgkins, Haim Erder, Joanne LaFleur. (United States)
- 255 Multiple Database Approach for Study of Associations between Frequently Used Drugs and Community-Acquired Pneumonia [584]**  
Mark CH de Groot, Olaf H Klungel, Hubert GM Leufkens, Liset Van Dijk, Diederick E Grobbee, Ewoudt MW Van de Garde. (Netherlands)
- 256 Potentially Missing Prescription Medication Claims in Administrative Databases: Angioedema Prior to New Angiotensin Receptor Blocker Use [595]**  
J Bradley Layton, Mugdha Gokhale, Til Stürmer, M Alan Brookhart. (United States)
- 257 Sensitivity Analysis of Methods for Active Surveillance of Acute Myocardial Infarction Using Electronic Databases [596]**  
Xiaochun Li, Cynthia J Girman, Susan Ofner, Changyu Shen, Kimberly G Brodovitz, Linas Simonaitis, Nancy Santanello. (United States)
- 258 Development of an Algorithm for Detecting Heparin-Induced Thrombocytopenia and Assessment of the Risk Factors Using a Medical Information Database [627]**  
Tadaaki Hanatani, Kimie Sai, Masahiro Tohkin, Katsunori Segawa, Michio Kimura, Katsuhito Hori, Junichi Kawakami, Yoshiro Saito. (Japan)

**Poster Walk - Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG**

- 259 Hepatitis C Virus Genotype Coinfection and Distribution in Different Regions of Mexico [641]**  
Ricardo Jimenez, Adriana Loza, Kirvis J Torres, Ricardo Montiel, Laura Cisneros, Vicente Madrid. (Canada)
- 260 Serum Phosphate Variability and Phosphate Binder Usage in Patients New to Hemodialysis [642]**  
Kimberly Farrand, J Brian Copley, Jamie Heise, Moshe Fridman, Michael Keith, Arthur Silverberg. (United States)
- 261 Genetic Association between Variants in Genes for sPLA2 and Cardiovascular Biomarkers [645]**  
Bo Ding, Eva Hurt-Camejo, Audrey Y Chu, Daniel I Chasman, Paul M Ridker, Fredrik Nyberg. (Sweden)
- 262 Cholesteryl Ester Transfer Protein (CETP) Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events [648]**  
Maarten Leusink, N Charlotte Onland, Folkert W Asselbergs, Bo Ding, Salma Kotti, Natalie R van Zuydam, Audrey C Papp, Nicolas Danchin, Louise Donnelly, Andrew D Morris, Daniel I Chasman, Olaf H Klungel, Paul M Ridker, Wiek H van Gilst, Tabassome Simon, Fredrik Nyberg, Colin NA Palmer, Wolfgang Sadee, Pim van der Harst, Paul de Bakker, Anthonius de Boer, Celine Verstuyft, Anke-Hilse Maitland-van der Zee. (Netherlands)

- 263 Patient Willingness To Provide Different Types of Biological Samples for Pharmacogenomic Testing [650]**  
Tenneille T Loo, Sinead Cuffe, Henrike Hon, Petra Martin, M Catherine Brown, Shabbir Alibhai, Xin Qiu, Wei Xu, Geoffrey Liu. (Canada)
- 264 Associations between Overall Survival and Response to Standard of Care and Biomarker Status in Ovarian Cancer Patients Using an Observational Tumor-Linked Database [655]**  
Mellissa Yong, Michael Nebozhyn, Reshma Rangwala, Kimberly Wilson, Timothy Yeatman, Agnes Baffoe-Bonnie, Guochun Xie, Andrey Loboda, Mark Ayers, Theresa Zhang, Daniel Sullivan, James Hardwick. (United States)
- 265 Cost-Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation [657]**  
Talitha I Verhoef, William K Redekop, David L Veenstra, Rahber Thariani, Peter A Beltman, Rianne MF van Schie, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)

**Poster Walk - Pediatrics SIG**

- 266 Trends in Oral Antidiabetic Medication Use among Children and Adolescents: 2003-2010 [662]**  
Mona Cai, M Alan Brookhart. (United States)
- 267 Description of Psychoactive Drug Utilization in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec [665]**  
Caroline Croteau, Laurent Mottron, Marc Dorais, Sylvie Perreault. (Canada)
- 268 Drug-Induced Adverse Reactions Via Breast-feeding: A Study in the French Pharmacovigilance Database [681]**  
Isabelle Lacroix, Caroline Soussan, Ghislaine Portolan, Jean-Louis Montastruc and the French Association of Regional Pharmacovigilance Centres. (France)
- 269 Analysis of Method To Capture Adverse Events in Neonates and Children in Tertiary Care Pediatric Hospitals [685]**  
Ann W McMahon, Pamela Weinel, Gerold T Wharton, Barbara Abrams, Cecilia P Damilano, Diva DeLeon, Phuong Lieu, Lilly Yen, Carol K Taketomo, Paul S Thornton, Beena Sood, Edwin Doe, Robin L Baker, William Rodriguez, M Diane Murphy. (United States)
- 270 Results from a Registry To Monitor the Safety of Celecoxib and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Juvenile Idiopathic Arthritis (JIA) [694]**  
Rachel E Sobel, Daniel J Lovell, Hermine I Brunner, Jennifer E Weiss, Paula W Morris, Beth S Gottlieb, Elizabeth C Chalom, Lawrence K Jung, Karen B Onel, Lisa Petiniot, Donald P Goldsmith, Kabita Nanda, Michael Shishov, Staci Abramsky, James Young, Edward H Giannini. (United States)

▶ **END SESSION B**

**Biologics, including Vaccines**

- 1 **An Algorithm To Predict Biologic DMARD Use in the THIN Database [778]**  
 Bing Cai, Qing Liu, Jamie Geier, Andrew Bate. (United States)
- 2 **Narcolepsy and H1N1 Vaccination in France: A Case-Control Sub-Analysis Focusing on the Risk of Narcolepsy with Cataplexy [779]**  
 Yves Dauvilliers, Isabelle Arnulff, Michel Lecendreux, Abdelilah Abouelfah, Basma Ambrosino, Sophie Micon, Severine Lignot, Christel Saussier, Antoine Pariente. (France)

**Burden of Disease/Epidemiology of Illness**

- 5 **Trends in the Antimicrobial Susceptibility of Bacteremias over the past Decade: A Regional Antibiogram of the ESKAPE Pathogens [782]**  
 Ajinkya M Pawar, Kerry L LaPlante, Aisling R Caffrey. (United States)
- 6 **Antibiotic Resistance and Differences by Culture Site in Staphylococcus aureus [783]**  
 Duncan P Stiller, Ajinkya M Pawar, Kerry L LaPlante, Aisling R Caffrey. (United States)
- 7 **Identification and Treatment of Recurrent Ovarian Cancer in a Large Administrative Claims Database [784]**  
 Victoria M Chia, Jan Lethen, Lori Cyprien, Michael Kelsh. (United States)
- 8 **Management of Depression in Taiwan: Unmet Needs in Advanced Pancreatic Cancer Patients? [785]**  
 Hsu-Chih Chien, Yan-Shen Shan, Chia-Jui Yen, Yea-Hue Kao Yang. (Taiwan)
- 9 **Developing a Model for Type 2 Diabetes Mellitus Medication Use Prevalence at Local Level [786]**  
 Aletta Dijkstra, Fanny Janssen, Jens Bos, René Lub, Leo JG van Wissen, Eelko Hak. (Netherlands)
- 10 **Depression and Anxiety Diagnoses and Treatment in Hemophilia Patients: A US Claims Database Study [787]**  
 Anne Dilley, Nydjie Payas, Jin Wang, Lynda M Cristiano. (United States)
- 11 **Baclofen for Alcohol Dependence in France: Incidence of Treated Patients and Patterns of Prescribing [788]**  
 Julie Dupouy, Jean-Pascal Fournier, Emilie Jouanjus, Jean-Christophe Poutrain, Stéphane Oustric, Maryse Lapeyre-Mestre. (France)
- 12 **Background Rates of Anaphylaxis in General and Allergic Populations [789]**  
 Daina B Esposito, Linda Nelsen, Debra F Eisenberg, April Grant, Jennifer CL Hawes, Crystal N Holick, Xuehua Ke, Rakesh Luthra, Jennifer Maloney, Vinay Mehta, Daniel Mines. (United States)

- 13 **Parkinson's Disease and Risk of Retinal Degeneration [790]**  
 Joan Fortuny, Estel Plana. (Spain)
- 14 **Incidence Rates of Pneumonia in Solid Tumor Cancer Patients in the UK [791]**  
 Victor M Gastanaga, Charles E Wentworth, Oswald L Bracco, Alexander Liedt. (United States)
- 15 **Contextualization of Safety Endpoints in a Rheumatoid Arthritis (RA) Development Program: Collaboration with the Consortium of Rheumatology of North American Registry (CORONA) [792]**  
 Jamie L Geier, Kate Saunders, George Reed. (United States)
- 16 **Sickle Cell Disease Prevalence in a Large US Administrative Claims Database [793]**  
 Elsie L Grace, Alex Asimwe, Meghan Jones, James A Michael. (United States)
- 17 **Statin Therapy Is Associated with Decreased Risk of First Intracerebral Hemorrhage and Reduced 30-Day Fatality: Results of a Nationwide Observational Study Including 7696 Cases and 14 670 Controls [794]**  
 Karin M Henriksson, Marie Eriksson, Signild Åsberg. (Sweden)
- 18 **Demographics of the Patient Population Recruited into the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [795]**  
 Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 19 **Prevalence of Treated Gout in Scotland, England and Denmark and Summary of Recruitment into the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [796]**  
 Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)
- 20 **Healthcare Utilization and Treatment Patterns for Patients (pts) with Gastric Cancer (GC) in China [797]**  
 Jeff Jianfei, Wenmin Du, Laura Chu, Xiaopei Wang, Jane Prumer. (United States)
- 21 **Risk of Seizures among Patients with Schizophrenia as Compared to the General Population in the Clinical Practice Research Datalink (CPRD) [798]**  
 Meghan Jones, Jonathan Swain, Frank DeLisle, Ludmila Kryzhanovskaya, Bruce J Kinon. (United States)
- 22 **CARING: Does Subgroup Analysis by Gender Modify the Potential Association between Diabetes Mellitus and Cancer?- A Meta-Analysis [799]**  
 Jakob Starup-Linde, Peter Vestergaard, Oystein Karlstad, Stine A Eriksen, Heleen K Bronsveld, Paul JHL Peeters, Frank De Vries, Marie L De Bruin. (Norway)

- 23 **CARING: Diabetes Mellitus and Risk of Cancer - A Systematic Review and Meta-Analysis [800]**  
 Jakob Starup-Linde, Peter Vestergaard, Oystein Karlstad, Stine A Eriksen, Heleen K Bronsveld, Frank De Vries, Anthonius De Boer, Marie L De Bruin. (Norway)
- 24 **Burden of Human Respiratory Syncytial Virus (RSV) Infection [801]**  
 Harshila Patel, Hanane Khoury, Myra Widjojatmodjo, Ida Kolte, Antoine El Khoury. (Canada)
- 25 **Out-of-Pocket Prescription Drug Expenditures among the Korean Elderly: Who Is Vulnerable to Cost Burden? [802]**  
 Eun-Ja Park, Hyun Soon Sohn, Jin-Won Kwon. (Republic of Korea)
- 26 **Long-Term Follow Up of Concomitant Medication Use in Type 2 Diabetes Patients: A Cohort Study [803]**  
 Egbert JF Lamberts, Jacqueline G Hugtenburg, Giel Nijpels, Marcel L Bouvy, Patrick C Souverein. (Netherlands)
- 27 **Case-Mix in General Practice in Italy: Score Development and Validation [804]**  
 Francesco Lapi, Elisa Bianchini, Iacopo Cricelli, Federico Spandonaro, Claudio Cricelli. (Italy)
- 28 **An Efficient Way To Estimate Disease Prevalence Rates by Extrapolation of Data from Several Small Studies [805]**  
 Nikolay V Matveev, Jeffrey Vietri. (Russian Federation)
- 29 **Rheumatoid Arthritis (RA) in Quebec: Baseline Demographics, Co-Morbidity and Physician Use in an Incident Sample of Provincial Drug Plan Beneficiaries [806]**  
 Cristiano Moura, Sasha Bernatsky, Marie-Eve Beauchamp, Hassan Behlouli, Debbie Feldman, Gilles Boire, Louis Bessette, Paul R Fortin, Michal Abrahamowicz. (Canada)
- 30 **Multiple Sclerosis Subtypes and Infections Resulting in a Hospitalization in the Veterans Health Administration [807]**  
 Richard E Nelson, Yan Xie, Scott L DuVall, Jorie Butler, Aaron WC Kamauu, Markus Schuerch, Nadia Foskett, Joanne LaFleur. (United States)
- 31 **Exacerbation Recurrence Rates in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-Life Study [808]**  
 Jetty A Overbeek, Maria-Magdalena Balp, Fernie JA Penning-van Beest, PN Richard Dekhuijzen, Ron MC Herings. (Netherlands)
- 32 **Incidence of Colorectal Cancer in Association with Diagnosed Hypertension [809]**  
 Estel Plana, Ying Zhu, Christoph R Meier, Raymond G Schlienger. (Spain)

**34 Trends in Incidence Rates (IR) of Hip/Femur Fractures in 5 European Countries: A Comparison Using Electronic Health Care Records (e-HCR) [811]**

Gema Requena, Victoria Abbing-Karahagopian, Consuelo Huerta, Marieke L De Bruin, Yolanda Alvarez, Montserrat Miret, Ulrik Hesse, Helga Gardarsdottir, Patrick Souverein, Jim Slattery, Cornelia Schneider, Marietta Rottenkolber, Sven Schmiedl, Miguel Gil, Mark CH De Groot, Andrew Bate, Ana Ruigómez, Luis A García, Saga Johanson, Frank De Vries, Dolores Montero, Raymond Schlienger, Robert Reynolds, Olaf H Klungel, Francisco J De Abajo. (Spain)

**35 Patient Preferences for Antihypertensive Medications in General Practice [812]**

Maribel Salas, Martin Rosas, Gustavo Pastelin. (United States)

**36 Incidence of Giant Cell Arteritis in Clinical Practice Research Datalink and Cumulative Use of Prednisolone in Patients Treated for GCA [813]**

Hans Petri, Alan Nevitt, Khaled Sarsour, Neil Collinson, Pavel Napalkov. (United States)

**37 Thromboembolic Events among Older Ovarian Cancer Patients: A SEER-Medicare Analysis [814]**

Sumitra Shantakumar, Alexandra C Frost, Li Li. (United States)

**38 The Burden Imposed by Atopic Dermatitis on Families: Creation of a Specific Questionnaire [815]**

Cecile Meni, Sebastien Branchoux, Charles Taieb. (France)

**39 Hemangioma Family Burden: Creation of a Specific Questionnaire [816]**

Olivia Boccara, Sébastien Branchoux, Jean Jacques Voisard, Charles Taieb. (France)

**40 Burden of Chronic Kidney Disease [817]**

Jan C van Blijderveen, Sabine M Straus, Miriam C Sturkenboom, Bruno C Stricker, Katia M Verhamme. (Netherlands)

**41 A Decision Aid for Initiating a Registry Study [818]**

Priscilla Valentgas, Jaclyn L Bosco, Allison Bryant, Stephen Arcona, Kristijan Kahler, Nancy A Dreyer. (United States)

**42 Overview of the Clinical and Economic Burden of Prostate Cancer in the U.S. Veteran Population [819]**

Li Wang, Lu Li, Elyse Fritschel, Onur Baser. (United States)

**43 Longitudinal Patterns of Complications of Cystic Fibrosis (CF): An Analysis of a Claims Database in the United States [820]**

Yan Bai, Winifred Werther, Brooke Harrow, Claus Becker, Ami Buikema. (United States)

**Drug Utilization Research/  
 Health Services Research**

**45 Cost and Utilization Trends of Antiemetic Drug in US Using Medicaid Database, 1991-2011 [823]**

Ziyad S Almalki, Jeff J Guo, Christina ML Kelton, Patricia R Wigle. (United States)

**46 Co-Prescription of Gastroprotective Agents in Patients Taking Non-Selective NSAIDs or COX-2 Selective Inhibitors: A Hospital Based Retrospective Study [824]**

Jarir At Thobari. (Indonesia)

**47 Drug Utilization of Patients Admitted with Conditions Wholly Attributable to Alcohol in Friuli Venezia Giulia, Italy [825]**

Fabio Barbone, Valentina Rosolen, Marco Giordani, Federica Edith Pisa, Francesco Piani. (Italy)

**48 User and Treatment Characteristics of Oral Contraceptives in the European Union [826]**

Irene D Bezemer, Katia MC Verhamme, Rosa Gini, Mees BMT Mosseveld, Peter R Rijnbeek, Miriam CJM Sturkenboom, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)

**49 Characteristics of Selective Serotonin Re-Uptake Inhibitor (SSRI) Initiators 1999-2009 [827]**

Greta A Bushnell, Til Stürmer, Virginia Pate, Alice White, Sonja Swanson, Deborah Azrael, Matthew Miller. (United States)

**50 The Medical Management and Expenditure of Dry Eye Syndrome in Taiwan [828]**

Chia-Hsien Chang, Yea-Huei Kao Yang, Fung-Rong Hu, Po-Ting Yeh, Kwang Ng, Emily Cheng. (Taiwan)

**51 Prevalence of Aliskiren Use among Patients with Hypertensive Diabetes in Taiwan: A Nationwide Population-Based Study [829]**

Chi Wen Chiang, Li Chai Chen, Yaw Bin Huang. (Taiwan)

**52 Characteristics of Incident Statins Users in Maccabi Healthcare Services 2000-2010 [830]**

Gabriel Chodick, Raanan Raz, Varda Shalev. (Israel)

**53 Adherence and Persistence with Type 2 Diabetes (T2DM) Medications: Saxagliptin, Sulfonylureas (SU), Thiazolidinediones (TZD), and Glucagon-Like Peptide 1 (GLP-1) Agonists [831]**

Suellen M Curkendall, Nina Thomas, Kelly F Bell, Katy Pan, Paul Juneau. (United States)

**54 Metastatic Castration-Resistant Prostate Cancer: Treatment Pathway and Associated Cost in Canada [832]**

Alice Dragomir, Daniela Dinea, Marie Vanhuysse, Fabio Cury, Armen Aprikian. (Canada)

**55 Influence of Life-Saving Drugs Use before Acute MI and during Acute MI Phase on Mortality: LISS (Lyubertsy Infarct Survival Study) Registry Data [833]**

Sergey Yu Martsevich, Natalia P Kutishenko, Liubov Yu Drozdova, Moisey L Ginzburg, Alexander D Deev. (Russian Federation)

**56 Differences in Use of Pharmacologic Smoking Cessation Aids between Lung and Other Cancer Patients [834]**

Lawson Eng, Xin Qiu, Prakruthi R Palepu, Henrique Hon, Steven Habbous, Dan Pringle, Chongya Niu, Luke Harland, Mary Mahler, Oleksandr Halysky, M Catherine Brown, Sinead Cuffe, Jennifer M Jones, Shabbir MH Alibhai, Doris Howell, Peter Selby, Wei Xu, Geoffrey Liu. (Canada)

**57 Patient Activation by DTCA Influences Primary Care Physicians' Prescriptions of Celebrex for Osteoarthritis [835]**

Michael A Fischer, Jeffrey N Katz, Lisa D Marceau, Felicia L Trachtenberg, Jing Yu, John B McKinlay. (United States)

**58 Pharmacy-Based Interventions To Reduce Primary Medication Non-Adherence [836]**

Michael A Fischer, Katsiaryna Bykov, Niteesh K Choudhry, Gregory Brill, Gregory Bopp, Aaron M Wurst, William H Shrank. (United States)

**59 Experience of Using Gout Flare Prophylaxis in the FAST Trial [837]**

Robert WV Flynn, Claudine Jennings, Isla S Mackenzie, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)

**60 Adherence to Cardiovascular Drugs in Urban and Farmers Elders in the 3C and AMI Cohorts [838]**

Claire Brotons, Fabienne Bazin, Catherine Helmer, Karine Peres, Antoine Pariente, Philippe Robinson, Pernelle Noize, Jean Francois Dartigues, Annie Fourrier-Reglat. (France)

**61 Use of NSAIDs with Increased Risk of Cardiovascular Events in Low and Middle Income Countries [840]**

Patricia McGettigan, David Henry. (Canada)

**62 Interactive Medication Reconciliation by Secure Messaging [841]**

Leonie Heyworth, Justice Clarke, Max Stewart, Tracey Martin, Steven R Simon. (United States)

**63 A Tablet a Day or a Tablet a Week - Does It Affect Refill Adherence to Bisphosphonates in Sweden? [842]**

Anna K Jönsson, Linus Schiöler, Eva Lesén, Karolina A Sundell, Anne-Charlotte Mårdby. (Sweden)

**64 Up-Titration of Allopurinol in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [843]**

Claudine Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)

Wednesday, August 28  
**POSTER SESSION C**

- 66 **Development of Prescription Quality Indicators among Diabetic Patients in Taiwan [845]**  
Shu-Ting Chen, Li-Chiu Wu, Chia-Hsuin Chang, Mei-Shu Lai. (Taiwan)
- 67 **Comparison of ATC/DDD Utilization Data of Nervous System Medications with Potential for Abuse and/or Dependence in Bulgaria [846]**  
Hristina V Lebanova, Ilko N Getov, Evgeni E Grigov. (Bulgaria)
- 68 **Methotrexate and Anti-TNF Drug Use in Seniors with New-Onset Rheumatoid Arthritis (RA) in Quebec [847]**  
Cristiano Moura, Sasha Bernatsky, Marie-Eve Beauchamp, Hassan Behloul, Michal Abrahamowicz. (Canada)
- 69 **What Attitudes Could Influence Antibiotic Dispensing without Prescription? [848]**  
Fátima Roque, Sara Soares, Luiza Breitenfeld, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 70 **Assessing Physician Knowledge and Attitudes Regarding Antibiotic Prescribing and Microbial Resistances [849]**  
António Teixeira Rodrigues, Mónica Ferreira, Fátima Roque, Amílcar Falcão, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 71 **Validity and Reliability of a Questionnaire To Assess Knowledge and Attitudes Regarding Antibiotic Prescribing and Resistances [850]**  
António Teixeira Rodrigues, Mónica Ferreira, Fátima Roque, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 72 **Variation in Nursing Home Antipsychotic Use across Psychiatric Consultant Providers [851]**  
Jennifer Tjia, Becky A Briesacher, Kathleen M Mazor, Celeste Lemay, Terry Field, Daniel Peterson, Michelle Pandolfi, Abir O Kanaan, Jennifer L Donovan, Leslie R Harrold, Jerry H Gurwitz. (United States)
- 73 **Do Antidepressant Drug Treatments Increase the Probability of Receiving an Antipsychotic Treatment in General Population? [852]**  
Marie Tournier, Manon André, Héléne Lepouriel, Yoan Gaudron, Bernard Bégau, Héléne Verdoux. (France)
- 75 **Trends in the Use of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs in the General U.S. Population [854]**  
Yingjun Zhou, Denise M Boudreau, Andrew N Freedman. (United States)

### Medical Devices

- 76 **Ectopic Pregnancies under IUD Use: Interim Results from the EURAS-IUD Study [855]**  
Klaas Heinemann, Suzanne Reed, Sabine Moehner. (Germany)

### Pharmacoeconomics / Outcomes Research in Pharmacology

- 80 **Cost-Effectiveness of Intermittent Preventive Treatment in Pregnancy (IPTp) with Sulfadoxine-Pyrimethamine in the Light Increasing Resistance [859]**  
Obinna Ikechukwu Ekwunife. (Nigeria)
- 81 **Risk of Venous Thromboembolism Complications Associated with Recurrent Venous Thromboembolism [860]**  
Patrick Lefebvre, François Laliberté, Edith Nutescu, Mei Sheng Duh, Joyce C LaMori, Brahim K Bookhart, William H Olson, Katherine Dea, Yvonnick Hossou, Jeff R Schein, Scott Kaatz. (Canada)
- 82 **The Medicines Benefits Package of National Health Insurance Fund in Sudan [NHIF] The Access, Effectiveness and Use [861]**  
Isam Eldin Mohammed Ali Mustafa, Ismail Salim Haroun. (Sudan)
- 83 **Validity and Reliability of Indonesian Version of ST George Respiratory Questionnaire in Tuberculosis Patients [862]**  
Dyah Aryani Perwitasari, Adnan Adnan, Uly Adhi Mulyani, Jarir Athobari, Ad A Kaptein. (Indonesia)

### Biologics SIG

- 85 **Association of Anti-TNF- Agents and Fractures in Rheumatoid Arthritis Patients [866]**  
Nam-Kyong Choi, Joongyub Lee, Xue-Mei Jin, Young-Jin Ko, Byung-Joo Park. (Republic of Korea)
- 86 **Occurrence of Hemolytic Reactions (HRs) on the Same Day as Immune Globulin (IG) Product Administrations during 2008-2012 [868]**  
Hozefa A Divan, Mikhail Menis, Gayathri Sridhar, Nandini Selvam, Richard Forshsee, Hector S Izurieta. (United States)
- 87 **Patient Reported Health Outcomes from Well-Controlled Trials of Biologic Therapies: A Systematic Review [869]**  
Daniel M Frenkl, Mikel Strom, John E Ware, Jr. (United States)
- 89 **Evaluation of Protective Effect of TNF- Inhibitors Against Ischemic Stroke in Patients with Rheumatoid Arthritis [872]**  
Joongyub Lee, Nam-Kyong Choi, Xue-Mei Jin, Young-Jin Ko, Byung-Joo Park. (Republic of Korea)
- 90 **Effectiveness of the Pandemic H1N1 Influenza Vaccines in Preventing Hospitalization for Influenza and Pneumonia: A Population-Based Case-Control Study [873]**  
Salaheddin M Mahmud, Songul Bozat-Emre, Laura H Thompson, Lawrence J Elliott, Paul Van Caesele. (Canada)

- 91 **Hospitalization and Skilled Nursing Care Are Predictors of Influenza Vaccination: Evidence of Confounding by Frailty [874]**  
Leah J McGrath, Stephen R Cole, Abhijit V Kshirsagar, Lily Wang, David J Weber, Til Stürmer, Alan Brookhart. (United States)
- 92 **Risk of Guillain-Barré Syndrome Following Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccination: Self-Controlled Case Series Study in Germany [876]**  
Jürgen Prestel, Peter Volkers, Dirk Mentzer, Helmar C Lehmann, Hans-Peter Hartung, Brigitte Keller-Stanislawski. (Germany)
- 93 **Exacerbation of Herpes Zoster Ophthalmicus (HZO) Following Zoster Vaccine, Live, Attenuated [Oka/Merck]: A Case Series [879]**  
Elaine Taylor, C Légaré, Duc Vu. (Canada)
- 94 **Population Characteristics, Treatment Patterns and Medical Events in Patients with Psoriatic Arthritis [880]**  
Rolin L Wade, Sylvia L Kindermann, Qingjiang Hou. (United States)
- 95 **Identification of Newly Approved Medications Using Non-Specific Drug Codes in Medicare Administrative Claims Data: Tocilizumab as a Case Study [882]**  
Fenglong Xie, Rui Chen, Huifeng Yun, Meredith L Kilgore, James Lewis, Jie Zhang, Nicole C Wright, Elizabeth S Delzell, Jeffrey R Curtis. (United States)
- 96 **Sex-Specific Association between Antidepressant Drug Use and Body Mass Index in Ambulatory Elderly: Results from the Rotterdam Study [883]**  
Raymond Noordam, Nikkie Aarts, Albert Hofman, Bruno H Stricker, Loes E Visser. (Netherlands)
- 97 **Strengthening Vaccine Lot Safety Surveillance [884]**  
Robert P Wise, Anand M Iyer, Douglas A Domalik, Robert T Miday, Patricia A Price-Abbott, Michael D Blum. (United States)
- 98 **Development of Safety Concerns within RMPs after Approval: A Cohort Study of Biologicals [885]**  
NS Vermeer, RG Duijnhoven, SMJM Straus, S Blackburn, WE Hoogendoorn, AK Mantel-Teeuwisse, ACG Egberts, HGM Leufkens, ML De Bruin. (Netherlands)
- 99 **Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis in the U.S. and the Influence of TNF Inhibitors [886]**  
Melissa Mannion, Fenglong Xie, Jeffrey R Curtis, Timothy Beukelman. (United States)
- 100 **Applicability of the Brighton Collaboration Case Definition for Seizure after Immunization in Active and Enhanced Passive Surveillance in Canada [889]**  
Karina A Top, Cora M Constantinescu, Julie Lafèche, Julie A Bettinger, David W Scheifele, Wendy Vaudry, Scott A Halperin, Barbara J Law. (Canada)

**Drug Utilization/  
 Health Services Research SIG**

- 101 Life-Style Characteristics of Elderly Persons Who Receive Seasonal Influenza Vaccination [890]**  
 Christian F Christiansen, Rikke B Nielsen, Finn B Larsen, Henrik Toft Sørensen, Reimar W Thomsen. (Denmark)
- 102 Impact of Censoring at or Truncating Risk Time of Hospitalizations on the Effect Measure of the Association between Antiepileptic Drugs and Suicide Attempt [891]**  
 Aske Astrup, Christiane Gasse, Liselotte Petersen, Henrik Støvring. (Denmark)
- 103 Impact of Regulatory Warnings on Concomitant Use of Oxycodone and Macrolide Antibiotics [927]**  
 Richard A Epstein, William V Bobo, Peter R Martin, James A Morrow, Wei Wang, Rameela Chandrasekhar, William O Cooper. (United States)
- 104 Prevalence of Antibiotic Use: A Methodological Comparison across Various European Health Care Data Sources [912]**  
 Ruth Brauer, Ana Ruigómez, Gerry Downey, Andrew Bate, Luis Alberto Garcia Rodriguez, Consuelo Huerta, Belen Oliva, Miguel Gil, Francisco de Abajo, Gema Requena, Yolanda Alvarez, Jim Slattery, Mark de Groot, Patrick Souverein, Ulrik Hesse, Marietta Rottenkolber, Sven Schmiedl, Frank de Vries, Maurille Feudjo Tepie, Raymond Schlienger, Liam Smeeth, Ian Douglas, Robert Reynolds, Olaf Klungel. (United Kingdom)
- 105 Clinical Characteristics, Quality Measure Attainment, and Diabetes-Related Healthcare Costs in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Metformin (MET) and Sulfonylurea (SU) [893]**  
 Marie-Helene Lafeuille, Jonathan Gravel, Robert A Bailey, Silas Martin, Lawrence Garber, Mei Sheng Duh, Patrick Lefebvre. (Canada)
- 106 Evaluation of the Efficacy and Safety of Bitherypy on Moroccan Patients Treated from Hepatitis C [894]**  
 Ghassan Elmalki, Samir Ahid, Yahia Cherrah. (Morocco)
- 107 Correlates of Nonmedical Use of ADHD-Type Stimulants Versus Nonmedical Use of Other Stimulants in a U.S. National Sample [895]**  
 Lian-Yu Chen, Christopher N Kaufmann, Caleb Alexander, Ramin Mojtabai, Silvia S Martins. (United States)
- 108 Case Series of Patients with Reported Renal Events in a Prescription Event-Monitoring (PEM) Study of Aliskiren [1017]**  
 Claire Doe, Carole Fogg, Deborah Layton, Saad Shakir. (United Kingdom)
- 109 High Use of Opioids in Patients with Dementia [896]**  
 Christina Jensen-Dahm, Christiane Gasse, Aske Astrup, Preben Bo Mortensen, Gunhild Waldemar. (Denmark)

- 111 Combination Antihypertensive Therapy in Older Americans [898]**  
 Xiaojuan Li, Wendy Camelo-Castillo, Til Stürmer, Christine L Gray, Soko Setoguchi-Iwata, Virginia Pate, Laura C Hanson, Michele Jonsson Funk. (United States)
- 112 Validaton of a Cohort of New Users of Oral Antidiabetic Agents Free of Microvascular Complications in the RAMQ Database [899]**  
 Patrice Simard, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Râkel, Sylvie Perreault. (Canada)
- 113 Pharmaco-Epidemiological Study of Treatment Resistant Schizophrenia and Clozapine Treatment [900]**  
 Theresa Wimberley, Henrik Støvring, Christiane Gasse. (Denmark)
- 114 Trends of Utilization of and Spending on Anti-Tuberculosis Medications in the United States Medicaid Program from 1991 to 2011 [901]**  
 Abdullah K Alahmari, Mohammed F Aldawsari, Heidi R Luder, Patricia R Wigle, Christina ML Kelton, Jeff J Guo. (United States)
- 115 Prescription Patterns of Antihypertensives in a Community-Health Center in Mexico City. A Drug Utilization Study [902]**  
 A Alba-Leonel, A Carvajal, F Castillo-Nájera, J Molina-Guarneros. (Mexico)
- 116 Glucocorticoid-Induced Osteoporosis Management: A Systematic Review [903]**  
 Jordan M Albaum, Soyoun Youn, Suzanne M Cadarette. (Canada)
- 117 The Prescribing of Simvastatin in the UK - A Drug Utilisation Study in the Clinical Practice Research Datalink (CPRD) [904]**  
 Craig Allen, Katherine L Donegan, Andrew Thomson. (United Kingdom)
- 118 Provider Contact and Antidepressant Fills Prior to Suicide Attempt: A Retrospective Case Series of 32,000 Attempters [905]**  
 Heather D Anderson, Robert J Valuck. (United States)
- 119 The Effect of Adherence on Treatment Change among HIV/AIDS Patients at the Korle-Bu Teaching Hospital in Ghana [906]**  
 Daniel NA Ankrah, Margaret Lartey, Irene Agyepong, Hubert GM Leufkens, Aukje K Mantel-Teeuwisse. (Ghana)
- 120 A Pregabalin Drug Utilization Study Report [907]**  
 Kofi Asomaning, Staci Abramsky, Qing Liu, Xiaofeng Zhou, Rachel Sobel, Stephen Watt. (United States)
- 121 Trends in Antibacterial Use in a German Intensive Care Unit (ICU) [908]**  
 Ümniye Balaban, Holger A Lindner, Christel Weiß, Thomas Friedrich, Thomas Kirschning, Manfred Thiel, Verena Schneider-Lindner. (Germany)

- 122 Trends in Prevalent and Incident Use of Blood Glucose-Lowering Agents in Norway: No Increase in Incidence 2006-2011 [909]**  
 Hanne Strøm, Christian Berg, Randi Selmer, Lars Christian Stene. (Norway)
- 123 Prevalence, Incidence, Treatment Patterns and Mortality in Patients with Acute Coronary Syndrome in France from 2004 to 2009 [910]**  
 Julien Bezin, Régis Lassalle, Abdelilah Abouelfath, Caroline Dureau-Pournin, Annie Fourier-Reglat, Nicholas Moore, Cecile Droz-Perroteau. (France)
- 125 Variation in 12-Lead Electrocardiography for Chest Pain Patients Transported in North Carolina by Emergency Medical Service [913]**  
 Montika Bush, Lawrence T Glickman, Antonio R Fernandez, J Lee Garvey, Seth W Glickman. (United States)
- 126 Audit of Dabigatran Use at a Canadian Tertiary Care Centre [914]**  
 Aleesa Carter, Kori LeBlanc, Amita Woods, Rita Selby, Donna Lowe. (Canada)
- 127 Development of Evidence Based Medication Related Indicators of Potentially Preventable Hospitalisations [915]**  
 Gillian E Caughey, Lisa M Kalisch. (Australia)
- 128 Incidence in Use of Carotid Artery Stenting in Taiwan, 2005-2009: A Nationwide Study [916]**  
 Hsi-Chieh Chen, Chia-Hsui Chang, Mei-Shu Lai. (Taiwan)
- 129 Medication-Related Problems of Elders in Long-Term Care Facilities in Taipei in Taiwan [917]**  
 Pei-Chen Chen, Lih-Chi Chen, Chi-Hung Lin. (Taiwan)
- 130 Pattern of Use and Costs of Osteoporosis Drugs in an Italian Sub-Population: Data from ARNO Observatory [918]**  
 Elisa Cinconze, Maurizio Rossini, Elisa Rossi, Marisa De Rosa, Silvano Adami. (Italy)
- 131 Polypharmacy among Medicaid Recipients with Inflammatory Bowel Disease [919]**  
 Jessie P Buckley, Michael D Kappelman, Jeffery K Allen, Susan A VanMeter, Suzanne F Cook. (United States)
- 132 Prevalence and Correlates of Polypharmacy among Men and Women with Mental Illness in Brazil: PESSOAS Project [920]**  
 Juliana O Costa, Cristiano S Moura, Francisco A Acurcio, Mark DC Guimarães. (Brazil)
- 133 Utilization Patterns of Cabergoline for Prolactin Reduction in Europe Following the Strengthening of Prescribing Information - The SUCRE Study [921]**  
 Cynthia de Luise, Gianluca Trifirò, Miriam Sturkenboom, René Schade, Ron Herings, Lars Pederson, Douglas Ross. (United States)

Wednesday, August 28  
**POSTER SESSION C**

- 135 Preliminary Results of the Impact of the Use of Pillbox on the Stabilization of the INR among Patients Initiating Warfarin Treatment from a Prospective Cohort [923]**  
Stephanie Dumas, Etienne Rouleau-Mailoux, Marie-Pierre Dubé, Jean-Claude Tardif, Mario Talajic, Sylvie Perreault. (Canada)
- 136 Validity of Self-Reported Regimen of Dose by Patient Initiating Warfarin Treatment: Population-Based Study [924]**  
Stephanie Dumas, Etienne Rouleau-Mailoux, Amina Bardhadi, Marie-Pierre Dubé, Jean-Claude Tardif, Mario Talajic, Sylvie Perreault. (Canada)
- 138 Patient's Views on Multi-Dose Dispensed Medicines [926]**  
Lena Ring, Carola Bardage, Anders Ekedahl. (Sweden)
- 139 Dispensing Pattern of Blood Glucose-Lowering Drugs in New Diabetic Patients in Real Practice [928]**  
Carmen Ferrajolo, Gianluca Trifirò, Francesco Giorgianni, Concetta Rafaniello, Liberata Sportiello, Vincenzo Arcoraci, Giuseppe Pozzuoli, Claudia Pagliaro, Claudio Linguiti, Daniele U Tari, Achille P Caputi, Francesco Rossi, Dario Giugliano, Katherine Esposito, Annalisa Capuano. (Italy)
- 140 Intervention To Reduce Adverse Outcomes among Older Adults Discharged from Skilled Nursing Facilities to Home [929]**  
Terry S Field, Jessica Ogarek, Abir O Kanaan, Jennifer L Donovan, Peggy Preusse, Devi Sundaresan, Shawn J Gagne, Lawrence Garber, Jennifer Tjia, Sarah L Cutrona, Jerry H Gurwitz. (United States)
- 141 Continuation Rates of Long-Acting Reversible Contraceptives: A UK Primary Care Study [930]**  
Lucia Cea-Soriano, Mari-Ann Wallander, Susan Andersson, Anna Filonenko, Luis Alberto García Rodríguez. (Germany)
- 142 Antiretroviral Outpatient Drug Utilization in Portugal (2007-2012) [931]**  
Claudia Furtado. (Portugal)
- 143 Development of Two Patient Decision Aids To Increase Inhaled Corticosteroids Use in Asthma [932]**  
Myriam Gagné, France Légaré, Jocelyne Moisan, Louis-Philippe Boulet. (Canada)
- 144 Metabolic Risk and Screening in CMHC Patients Starting SGAs in MO Medicaid [933]**  
Lauren D Garfield, Elizabeth Campagna, Ginger E Nicol, Jeffrey F Scherrer, Neeraja Ganeshraj, Joseph Parks, Elaine H Morrato. (United States)
- 145 Medicine Safety Issues from within Hospital Distribution of Medicines [934]**  
Alice V Gilbert, Andrew L Gilbert. (Australia)
- 146 Prevalence and Potential Preventability of Adverse Drug Events – A Population-Based Medical Record Study of 4995 Adults [936]**  
Katja M Hakkarainen, Karolina Andersson Sundell, Anna K Jönsson, Max Petzold, Staffan Hägg. (Sweden)
- 147 Use of Pharmaceutical and Non-Pharmaceutical Complementary and Alternative Medicine in Cancer Patients [937]**  
Oleksandr Halysky, Lawson Eng, Osvaldo Espin-Garcia, Christine Lam, Kyoko Tiessen, Jodie Villeneuve, Rebecca Charow, Ravi M Shani, Chongya Niu, Dan Pringle, Mary Mahler, Shabbir MH Alibhai, Doris Howell, Jennifer M Jones, M Catherine Brown, Wei Xu, Geoffrey Liu. (Canada)
- 148 Use of Prescription Weight-Loss Drugs in the United States, 1993-2011 [938]**  
Christian Hampp, Elizabeth M Kang, Vicky Borders-Hemphill. (United States)
- 149 Factors Associated with Utilization of Saxagliptin in the US and UK [939]**  
Melissa S Nezamzadeh, Kevin Haynes, Dena M Carbonari, Craig Newcomb, Jason Roy, Serena Cardillo, Kimberly BF Leidl, Jennifer Wood Ives, Stephanie DeVore, Laura Horne, Betina Blak, Daina Esposito, Crystal Holick, Tjeerd Van Staa, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re III, Eileen E Ming, Sean Hennessy, Peter P Reese, K Rajender Reddy, David Margolis, Andrea Apter, Stephen E Kimmel, Cristin P Freeman, Hanieh Razzaghi. (United States)
- 151 Antipsychotic and Antidepressant Use and Mortality among Nursing Home Residents with Alzheimer's Disease and Related Dementias [941]**  
Ting-Ying J Huang, Yu-Jung J Wei, Patience Moyo, Ilene H Zuckerman, Judith Lucas, Linda Simoni-Wastila. (United States)
- 152 Prevalence of Use of Benzodiazepines and Related Drugs in Seven European Databases: A Cross-National Descriptive Study from the PROTECT-EU Project [942]**  
Consuelo Huerta, Victoria Abbing-Karahagopian, Gema Requena, Belén Oliva, Yolanda Alvarez, Helga Gardarsdóttir, Montserrat Miret, Comelia Schneider, Miguel Gil, Patrick Souverein, Jim Slattery, Mark CH De Groot, Ulrik Hesse, Marietta Rottenkolber, Sven Schmiedl, Dolores Montero, Andrew Bate, Ana Ruigomez, Luis A García, Saga Johanson, Frank De Vries, Raymond G Schlienger, Robert F Reynolds, Olaf H Kungel, Francisco J De Abajo. (Spain)
- 153 Epidemiologic Measures of Drug Use: Antiepileptic Drugs, Benzodiazepines, and Antidepressants in Four European Countries [943]**  
Elena Ballarin, Pili Ferrer, Mónica Sabaté, Joan-Ramon Laporte, Joan Fortuny, Marieke Schoonen, Iain Tatt, Joerg Hasford, Luisa Ibáñez. (Spain)
- 154 Educational Intervention and Knowledge Assessment in Patients on Oral Anticoagulant Treatment [944]**  
Consuelo Izazola-Conde, Abraham Majluf-Cruz, Juan Mandoki, Juan Molina-Guarneros. (Mexico)
- 155 Time Series Methods Applied in Drug Utilization Research: A Systematic Review [945]**  
Racquel Jandoc, Andrea M Burden, Suzanne M Cadarette. (Canada)
- 156 Drug Use Pattern of Rivaroxaban in Germany [946]**  
Kathrin Jobski, Dirk Enders, Ute Amann, Kiliana Suzart-Woischnik, Mari-Ann Wallander, Tania Schink, Edeltraut Garbe. (Germany)
- 158 Urinary Incontinence: A Poorly Recognised Adverse Effect of Medicines [948]**  
Lisa M Kalisch Ellett, Nicole L Pratt, John D Barratt, Elizabeth E Roughead. (Australia)
- 159 Trends in the Use of Non-Benzodiazepine Sleep-Aid Medications in the United States, 1996-2010 [949]**  
Christopher N Kaufmann, Lian-Yu Chen, Adam P Spira, Sarah L Canham, G Caleb Alexander, Ramin Mojtabai. (United States)
- 160 Sex-Based Differences in the Use of Evidence-Based Treatment for Heart Failure in Québec [950]**  
Jeanne Françoise Kayibanda, Catherine Girouard, Eric Demers, Jean-Pierre Grégoire, Jocelyne Moisan. (Canada)
- 161 Optimizing Medication Use among Patients with Advanced Alzheimer Disease in Long-Term Care - A Scoping Review [951]**  
Edeltraut Kröger, Marcel Arcand, Johanne Monette, Mabelle Wilchesky, Nathalie Champoux, Philippe Voyer, Michèle Aubin, Pierre Durand, René Verrault. (Canada)
- 162 Patterns of Relapse and Associated Cost Burden in Schizophrenia Patients Receiving Atypical Antipsychotics [952]**  
Marie-Helene Lafeuille, Jonathan Gravel, Patrick Lefebvre, John Fasteneau, Erik Muser, Dilesh Doshi, Mei Sheng Dug. (Canada)
- 163 Meta-Analysis of the Efficacy and Safety of Bortezomib (BTZ) Retreatment in Patients (pts) with Multiple Myeloma (MM) [953]**  
Kevin B Knopf, Mei Sheng Duh, Marie-Helene Lafeuille, Jonathan Gravel, Patrick Lefebvre, Liviu Niculescu, Abbie Ba-mancini, Esprit Ma, Hongliang Shi, Raymond L Comenzo. (Canada)
- 164 Sociodemographic Correlates of Glucosamine/Chondroitin Use over 4 Years in the National Osteoarthritis Initiative [954]**  
Kate L Lapane, Shbing Yang, Tim McAlindon, Charles Eaton. (United States)
- 166 Predictors of Non-Vaccination Against Human Papillomavirus among US Women Aged 18-26: Data from the 2010 National Health Interview Survey [957]**  
H Elsa Larson, Aisling Caffrey, Andrea Paiva, Cynthia Willey. (United States)
- 168 Effect of Computerized Clinical Decision Support on Appropriate Laboratory Monitoring of Medications [960]**  
Amy Linsky, Lynn Volk, Nivethietha Maniam, Steven R Simon. (United States)

Wednesday, August 28  
**POSTER SESSION C**

- 169 Profiling Chronic Opioid Use for Non-Cancer Pain in the United States [962]**  
Robert J LoCasale, David M Kern, Siting Zhou, Soheil Chavoshi, Ozgur Tunceli, Mark Sostek. (United States)
- 170 Does Weight Status Affect Antibiotic Prescribing Patterns? [963]**  
Cristina Longo, Gillian Bartlett, Brenda Macgibbon, Nancy Mayo, Ellen Rosenberg, Stella Daskolopoulou. (Canada)
- 171 Profile of Use of Anti-Tumor Necrosis Factor (Anti-TNF) Agents and Disease Modifying Anti Rheumatic Drugs (DMARD) in Ankylosing Spondylitis Patients in a Brazilian Healthcare Database [964]**  
Marina AA Machado, Felipe Ferre, Cristiano S Moura, Alessandra M Almeida, Iola G Andrade, Mariângela A Cherchiglia, Augusto A Guerra, Junior, Francisco A Acurcio. (Brazil)
- 172 Bladder Antimuscarinics Use in Veterans Affairs Community Living Centers [965]**  
Daniela C Moga, Ryan M Carnahan, Brian C Lund, Jane Pendergast, Robert Wallace, James Torner, Yue Li, Elizabeth A Chrischilles. (United States)
- 173 Practice Pattern Changes in Small Dialysis Organizations Following 25% Phase-In v 100% Opt-In to the Dialysis Capitated Payment System [966]**  
Keri L Monda, Brian D Bradbury, Robert J Rubin. (United States)
- 174 Usage Patterns of "OTC" Versus "Prescription" NSAIDs in France [967]**  
Nicholas Moore, Mai Duong, Abdelilah Abouelfath, Francesco Salvo, Antoine Pariente, Regis Lassalle, Cécile Droz, Patrick Blin. (France)
- 175 The Enigma of Appropriate Antimicrobial Use: A Model Antimicrobial Stewardship Program (ASP) [968]**  
Haley J Morrill, Aisling R Caffrey, Melissa M Gaitanis, Patricia A Cristofaro, Tanya Ali, Kerry L LaPlante. (United States)
- 176 Identifying Older Adults with Major Depressive Disorder from Medicare Current Beneficiary Survey Data [969]**  
Eunsun Noh, Brian J Quilliam. (United States)
- 177 Patterns of Antibiotic Use and Dose Adjustment in Patients with Chronic Kidney Disease at Kenyatta National Hospital, Kenya [970]**  
Mary Atieno Onyango, Faith A Okalebo, George O Osanjo, David G Nyamu. (Kenya)
- 178 Geographic Variation of Chronic Opioid Use in Fibromyalgia [971]**  
Jacob T Painter, Jeffery Talbert, Leslie J Crofford. (United States)
- 179 Medical and Mechanical Prophylaxis for Venous Thromboembolism after Total Hip and Knee Replacement [972]**  
Elisabetta Patorno, Brian Bateman, Niteesh Choudhry, Joan Landon, Sebastian Schneeweiss. (United States)
- 180 Drug Utilization and Safety Evaluations: Lessons Learned from International Multi-National Retrospective Chart Review Study Applications [973]**  
Krista A Payne, Dara Stein, Annette Stemhagen. (Canada)
- 181 Non-Prescription Medicines -The Missing Pieces of the Drug Utilization Puzzle [974]**  
Lisa G Pont, Hanane Jomaa, Gerard Stevens, Andrew J McLachlan. (Australia)
- 182 Medication Characteristics and Disparities in the Underuse of Prescription Medications among Chronically Ill Adults in the U.S. [975]**  
Dima M Qato, Wendy Cheng. (United States)
- 183 Sulfonylurea Use Associated with Higher Emergency Room Utilization among Elderly Patients with Type 2 Diabetes [976]**  
Swapnil Rajpathak, Chunmay Fu, Kimberly Brodovicz, Samuel Engel. (United States)
- 184 Lack of Therapeutic Efficacy on Type 2 Diabetic Patients Treated with Glibenclamide and Metformin in Mexico City [977]**  
Mauricio Ramos-Coss, Nidia Rodriguez-Rivera, Juan A Molina-Guarneros, Fernando Castillo-Najera. (Mexico)
- 185 Performance of Three Brands of Drug Interaction Programs for Use in Geriatrics [978]**  
Thais M Guedes, Adriano Max M Reis. (Brazil)
- 186 Agreement among Published Explicit Criteria for Inappropriate Medications in Elderly People [979]**  
Tárcita P Figueredo, Maria Auxiliadora P Martins, Adriano Max M Reis. (Brazil)
- 187 Evaluation of Drug Interaction Screening Programs in Oncology [980]**  
Kirla B Detoni, Maria Auxiliadora P Martins, Adriano Max M Reis. (Brazil)
- 188 INN Mandatory Prescription in Portugal Mainland [981]**  
Mafalda Ribeirinho, Óscar Carvalho. (Portugal)
- 189 Antimicrobial Utilization in Hospital and Primary Care in Portugal Mainland [982]**  
Mafalda Ribeirinho. (Portugal)
- 190 Prognostic Value of Chronic Anxiety and Depression and Utilization of Anti-Depressant Medication in Patients with Coronary Heart Disease [983]**  
Dietrich Rothenbacher, Andrea Kleiner, Ute Mons, Harry Hahmann, Bernd Wüsten, Thomas Becker, Wolfgang Koenig, Hermann Brenner. (Germany)
- 191 Association between Bronchodilator Treatment and Myocardial Infarction in COPD Patients: A Structured Assessment of Systematic Reviews and Meta-Analyses [984]**  
Marietta Rottenkolber, Dominik Rottenkolber, Luisa Ibañez, Joerg Hasford, Sven Schmiedl. (Germany)
- 192 Post Fracture Osteoporosis Care in Rheumatoid Arthritis (RA) [985]**  
Jean-Pascal Roussy, Louis Bessette, Sasha Bernatsky, Elham Rahme, Jean Lachaine. (Canada)
- 193 Rates of Non-Vertebral Osteoporotic Fractures in Rheumatoid Arthritis (RA) and Impact of Clinical Practice Guidelines for the Management of Osteoporosis [986]**  
Jean-Pascal Roussy, Louis Bessette, Sasha Bernatsky, Elham Rahme, Jean Lachaine. (Canada)
- 194 Characteristics of Antipsychotic Dispensations after First Admission to a Long-Term Care Facility (LTCF) in Saskatchewan, Canada [987]**  
Nianping Hu, David Blackburn, Yvonne Sevchuck, Gary Teare, Lisa Lix, Verena Schneider-Lindner. (Germany)
- 196 Sales Trends of Rosiglitazone and Pioglitazone after Safety Alert in Portugal (2002-2012) [989]**  
Sara Soares, António Teixeira Rodrigues, Tânia Silva, Fátima Roque, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 197 The Effect of a Training-Programme on Intravenous Preparation and Administration Errors in a Vietnamese Hospital [990]**  
Katja Taxis, Huong T Nguyen, TD Nguyen, Edwin van den Heuvel, Floor M Haaijer-Ruskamp. (Netherlands)
- 198 Errors in Medication Preparation and Administration in Vietnamese Hospitals [991]**  
Katja Taxis, Huong T Nguyen, TD Nguyen, Edwin vd Heuvel, Floor M Haaijer-Ruskamp. (Netherlands)
- 199 Effectiveness of Interventions by Community Pharmacists To Reduce Risk for Gastrointestinal Side Effects in NSAID Users [992]**  
Martina Teichert, Fabienne Griens, Edgar Buijs, Michel Wensing, Peter de Smet. (Netherlands)
- 200 Low Persistence with Oral Bisphosphonate Treatment in Portuguese Women with Postmenopausal Osteoporosis [993]**  
Carla Torre, José Guerreiro, Zilda Mendes, Ana Miranda, Helena Canhão, Jaime Branco, Manuela Machado, I Ferreira, M Feudjo-Tepie, Joaquim Cristino. (Portugal)
- 201 Comparison of the Antidepressant Treatment Patterns in Younger and Older Adults Using the French Health Insurance Claims Database [994]**  
Fanny Etchepare, Thibaut Sanglier, Manon André, Héléne Verdoux, Marie Tournier. (France)
- 203 Trends in Buprenorphine and Methadone Sales and Utilization in the United States, 1997-2012 [996]**  
Lydia Turner, Stefan Kruszewski, Ramin Mojtabai, Daniel Webster, Suzanne Nesbit, Randall Stafford, G Caleb Alexander. (United States)
- 204 Quality and Pattern of Use of Psychotherapeutic Agents in a Nigerian Referral Hospital [997]**  
Chukwuemeka M Ubaka, Maxwell O Adibe, Sunday O Nduka, Chinwe V Ukwé. (Nigeria)
- 205 Characteristics Associated with Initiation of Intravenous Versus Subcutaneous Injection Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis Patients [998]**  
Onur Baser, Li Wang, Lu Li, Lin Xie. (United States)

Wednesday, August 28  
**POSTER SESSION C**

- 206 Comparative Prevalence of Some Antipsychotic-Containing Drug Combinations in Geriatric Inpatients with Hospital-Acquired Pneumonia [999]**  
Jean Frederic Westphal, Cathy Nonnenmacher. (France)
- 207 Benzodiazepine Use in the HIV-Infected Population [1000]**  
Sarah E Wixson, Emily S Brouwer. (United States)
- 208 Assessment of Dronedrone Utilization Using US MarketScan Database [1001]**  
Jasmanda Wu, Jane Thammakhoune, Wanju Dai, Andrew Koren, Stephanie Tcherny-Lessenot, Shujun Gao, Chuntao Wu, Laurent Auclert, Patrick Caubel, Juhaeri Juhaeri. (United States)
- 209 Time Trends in Assessment of Dronedrone Utilization in the US [1002]**  
Jasmanda Wu, Juhaeri Juhaeri, Jane Thammakhoune, Shujun Gao, Heather Schiappacasse, Gary Wiecezorek, Andrew Koren, Laurent Auclert, Patrick Caubel. (United States)
- 211 Trends in the Use of Guideline-Recommended Medication Treatment and In-Hospital Mortality of Patients with Acute Myocardial Infarction in China [1004]**  
Jing Hu, Zheng Shu, Yanming Xie, Siyan Zhan. (China)
- 212 Effects of Changing from Suboptimal to Optimal Asthma Regimens on Asthma-Related Health Services Utilization [1005]**  
TingTing Zhang, Ricardo Jimenez, Hao Luo, Anne Smith, Bruce Carleton. (Canada)
- 213 Age and Sex Patterns of Drug Prescribing in a Defined American Population [1006]**  
Wenjun Zhong, Hilal Maradit-Kremers, Jennifer L St. Sauver, Barbara P Yawn, Jon O Ebbert, Veronique L Roger, Debra J Jacobson, Michaela E McGree, Scott M Brue, Walter A Rocca. (United States)
- 214 Trends in Antidepressant Prescribing: A Population-Based Study [1007]**  
Wenjun Zhong, Hilal Maradit-Kremers, Jennifer L St. Sauver, William V Bobo, Lila J Rutten, Barbara P Yawn, Walter A Rocca. (United States)
- 215 Birth Cohort Confounds Effect Estimates of Guideline Changes on Prevalence of Statin Use in Diabetic Patients [1008]**  
Eelko Hak, Maarten J Bijlsma, Fanny Janssen, Rene Lub, Jens Bos, Dianna de Vries. Netherlands)
- 216 A Chart Review Methodology To Characterize Treatment Patterns and Clinical Outcomes in Patients with Multicentric Castleman's Disease [1009]**  
Marie-Pierre Desrosiers, Noreen Lordan, Matthew W Reynolds, Donald W Robinson, Jr., Krista A Payne. (Canada)
- 217 Using the RIFLE Classification System To Categorise Severity of Adverse Renal Events in a Prescription Event-Monitoring Study [1010]**  
Claire Doe, Deborah Layton, Saad Shakir. (United Kingdom)
- 218 Latent Class Analysis: A New Approach To Characterize Psychotropic Drug Consumption [1011]**  
Fanny Feuillet, Caroline Victorri-Vigneau, Jean-Benoit Hardouin, Jacques Pivette, Anicet Chaslerie, Véronique Sebillé, Pascale Jolliet. (France)
- 219 Assessing Quality in Systematic Reviews of Adverse Effects [1012]**  
Mònica Sabaté, Pili Ferrer, Elena Ballarín, Marietta Rottenkolber, Sven Schmiedl, Marieke Schoonen, Joan Fortuny, Iain Tatt, Joan-Ramon Laporte, Joerg Hasford, Luisa Ibáñez. (Spain)
- 220 The Effect of Misclassification of the Outcome on the Relationship between an Increase in Anticholinergic Drug Burden and Memory Impairment in Older Adults [1013]**  
Mandavi Kashyap, Sylvie Belleville, Benoit Mul-sant, Sarah Hilmer, Cara Tannenbaum. (Canada)
- 221 Comparison of Methods for the Estimation of Drug Prevalence in a Dynamic Cohort [1014]**  
Tania Schink, Edeltraut Garbe. (Germany)
- 222 Utilization and Expenditure Trends for Anti-Allergic Agents in the Medicaid Program [1015]**  
Jing Guo, Jeff J Guo, Christina ML Kelton, Patricia Wigle. (United States)
- 223 Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder (PERFORM): Design and Characteristics of First 1000 Patients [1016]**  
Josep Maria Haro, J Chollet, Jean-Philippe Boulenger, Bengt Jönsson, Martin Knapp, Benoît Rive, Delphine Saragoussi. (France)
- 224 Post-Authorization Surveys To Evaluate Physician Knowledge: Contract Research Organization (CRO) Evaluation Case Study [1018]**  
Alexander Liede, Scott Stryker, Oliver Günther, John F Acquavella, J Michael Sprafka. (United States)
- 226 Endotoxin-Associated Sterile Peritonitis Observational Study (e-STEPS): Safety Findings [1020]**  
Dara Stein, Cory Sise, Matthew Sherwood, Örjan Mortimer. (Canada)
- 227 Using Forensic Toxicology Registers in Combination with Drug Dispensing Databases To Identify Prescription Drug Abuse: The Example of Tramadol [1021]**  
Micaela Tjäderborn, Anna K Jönsson, Staffan Hägg, Johan Ahlner. (Sweden)
- 228 Web Traffic: A New Tool in Pharmacovigilance? [1022]**  
Thierry Trenque, Malak Abou Taam, Paul De Boissieu, Emmanuelle Herlem. (France)
- 229 Quantitative Evaluation of Metformin Safety Warning on Drug Utilization and Clinical Adverse Effect in Taiwan [1023]**  
Jason C Hsu, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 230 Observational Assessment of Safety in Seroquel (OASIS) – Design, Recruitment and Baseline Patient Characteristics [1024]**  
Sarah Clarke, Deborah Layton, Saad Shakir, Joe Reilly, Anthony Hale. (United Kingdom)
- 231 Trends in Utilization of Cabergoline for Neurological Indications in Four European Countries. Do Doctors Comply with Risk Minimization Activities Concerning Heart Valve Fibrosis? A Population-Based Analysis [1025]**  
René Schade, Gianluca Trifirò, Ron Herings, Giampiero Mazzaglia, Lars Pedersen, Miriam Sturkenboom. (Netherlands)
- 232 Why Are the Myelosuppression as Adverse Reactions of Linezolid Often Reported in Japan? [1026]**  
Yukie Yamauchi, Shiro Hinotsu, Shiro Tanaka, Jun Morikawa, Yasunori Ichiba, Koji Kawakami. (Japan)
- 233 Antipsychotic Duration of Use among Medicaid-Insured Preschoolers, Young Children, and Adolescents [1027]**  
Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 234 Interaction of Age and Psychiatric Diagnosis on Antipsychotic Use among Publicly-Insured Youth with ADHD or Disruptive Behavior Disorders [1028]**  
Mehmet Burcu, Julie M Zito, Daniel J Safer. (United States)
- 235 Use of Glucagon-Like Peptide 1 Analogues and the Risk of Fracture in Type 2 Diabetes Patients [1029]**  
Johanna HM Driessen, Hein A van Onzenoort, Arief Lal Mohamed, Corinne Klop, Marloes Bazelier, Kees Neef, Frank de Vries. (Netherlands)
- 238 Utilization of Antipsychotic Medications in the Youth Population of Manitoba [1032]**  
Sarita Jha, Robert G Biscontri, Laurence Y Katz, Shawn Bugden, David M Collins, Silvia Alessi-Severini. (Canada)
- 239 Changes in Antibiotic Prescribing in Infants and Young Children in Denmark, 1999-2011 [1033]**  
Alan Kinlaw, Til Stürmer, Henrik Toft Sørensen, Jennifer L Lund. (United States)
- 240 Incidence of Stimulant Augmentation among Children and Adolescents with Attention/Deficit Hyperactivity Disorder (ADHD) during 2010 [1034]**  
Keith A Betts, Vanja Sikirica, Paul Hodgkins, Ella Du, Zhou Zhou, Haim M Erder, Eric Q Wu. (United States)

Wednesday, August 28  
**POSTER SESSION C**

- 241 Use of Medication among Young People with Intellectual Disability in Quebec [1035]**  
Caroline Sirois, Hubert Gascon, Mirella Faubert, Marie-Eve Gagnon. (Canada)
- 242 Use of Medication by Young People with Autism-Spectrum Disorders in Quebec [1036]**  
Caroline Sirois, Hubert Gascon, Mirella Faubert, Marie-Eve Gagnon. (Canada)
- 243 Persistent Antipsychotic Treatment and the Impact on Outpatient, Inpatient, and Emergency Department Services for Youth in Foster Care [1037]**  
Ming-Hui Tai, Susan dosReis, Bansri Desai, Gloria Reeves, Terry Shaw. (United States)
- 244 Age-Related Emergency Department Reliance (EDR) and Healthcare Resource Utilization in Patients with Sickle Cell Disease (SCD) [1038]**  
Morey A Blinder, Francis Vekeman, Medha Sasane, Alex Trahey, Carole Paley, Matthew Magestro, Mei Sheng Duh. (Canada)
- 245 Predictors of Stopping Medication Use in Pregnancy among Women with Chronic Conditions [294]**  
Nisha Almeida, Robyn Tamblyn. (Canada)
- 246 Regional Variations in Complex Antipsychotic Medication Regimens in U.S. Foster Care Youth [1040]**  
Julie M Zito, Mehmet Burcu, Salma Lemtouni, Daniel J Safer, Ian Schmid, Carol Pamer, Stephen McKean, Chelsea Lam, Dale Slavin. (United States)

**Poster Walk - Asian  
Pharmacoepidemiology Network  
(AsPEN) SIG**

- 248 Prescription Audit of Indian Elderly Ambulatory Patients Using WHO Prescribing Indicators [863]**  
Mandavi Kashyap, Sanjay D'Cruz, Atul Sachdev, Pramil Tiwari. (Canada)
- 249 Community Pharmacists' Knowledge, Behaviors and Experiences about Adverse Drug Reactions Reporting in Saudi Arabia [865]**  
Mansour A Mahmoud, Yazeed Alswaida, Thamer Alshammari, Mohamed Azmi Hassali, Hisham Aljadhey. (Saudi Arabia)

**Poster Walk - Medical  
Devices Poster SIG**

- 250 An Evaluation of Three Methods To Identify Adverse Event Signals Associated with Marketed Drugs and Devices [1041]**  
Dorian Villegas, Wendy Ye, Fred Schneeweiss, Ayela-Uwangue Osas. (United States)
- 251 Long Acting Reversible Contraceptives and Female Sterilization in Medicaid Population, 1999-2009 [1042]**  
Colin Anderson-Smits, Allison O'Neill, Julia Corrado, Danica Marinac-Dabic. (United States)

- 252 The Development of the Pelvic Floor Disorder Registry (PFDR) [1043]**  
Colin Anderson-Smits, Julia Corrado, Veronica Sansing, Danica Marinac-Dabic. (United States)
- 253 Outcomes after Carotid Artery Stenting in Medicare Beneficiaries, 2005-2009 [1044]**  
Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, Andrew T Rothman, Hiraku Kumamaru, Lauren A Williams, Chih-Ying Chen, Jun Liu, John D Seeger, Soko Setoguchi. (United States)
- 254 The Development and Opportunities of a Transcatheter Aortic Valve Replacement Therapy (TVT) Registry [1046]**  
Veronica V Sansing, Daniel Canos, Collin Anderson-Smits, Danica Marinac-Dabic. (United States)
- 255 Cohort Profile of Privately Insured Working Adults Undergoing Total Hip Arthroplasty [1047]**  
Jonathan Schelfhout. (United States)

**Poster Walk - Drug Utilization  
Research/Health Services  
Research SIG**

- 256 The Effect of the Financial Crisis in the Use of Psychotropics Drugs in Portugal [839]**  
Claudia Furtado. (Portugal)
- 257 Clinical Provider Perceptions of Intentional Medication Discontinuation [911]**  
Amy Linsky, Steven R Simon, Barbara Bokhour. (United States)
- 258 The Effect of Non-Dihydropyridine Calcium Channel Blocker Therapy among Patients with Supraventricular Tachyarrhythmias Hospitalized for Systolic Heart Failure [935]**  
Regina C Grebla, Gregory A Wellenius, Charles B Eaton, Constantine Gatsonis, Wen-Chih Wu. (United States)
- 259 Potentially Inappropriate Medications in the Elderly with Alzheimer's Disease and Related Dementia [955]**  
Marie-Laure Laroche, Marion Lassalle, Jean-Pierre Charmes, Jean Doucet, Muriel Rainfray, Régis Gonthier, Amina Lahlou, Emmanuel Alix, Jean-Marc Eyche. (France)
- 260 Factors Associated with Compliance with Inhaled Corticosteroids in Asthma [958]**  
Moulikatou A Lawani, Marie-Claude Breton, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
- 261 Long-Acting Beta2-Adrenergic Agonists (LABA) Use in Pediatric and Adolescent Asthma Patients, 2003-2011 [1039]**  
Esther H Zhou, Elizabeth M Kang, Sally Seymour, Solomon Iyasu. (United States)

**Poster Walk - Biologics SIG**

- 262 Impact of Influenza Vaccination on Risk of Myocardial Infarction, Pneumonia, and Death in Elderly Patients Surviving Intensive Care: A Cohort Study [867]**  
Christian F Christiansen, Reimar W Thomsen, Morten Schmidt, Lars Pedersen, Martin B Johansen, Henrik Toft Sørensen. (Denmark)
- 263 Risk of Lymphoma in Rheumatoid Arthritis (RA) Patients Treated with Certolizumab Pegol (CZP) Compared to World and US General Populations [870]**  
Jennifer D Guo, Amanda Golembesky, Theresa Rosario-Jansen, David P Miller. (United States)
- 264 Feasibility Evaluation for a Rituximab (RTX) Utilization Study To Be Conducted in Infusion Centers [875]**  
Manel Pladevall, Laurie Zografos, Iain Tatt, Pavel Napalkov, Elizabeth Andrews, Susana Perez-Gutthann. (Spain)
- 265 Immune Globulins (IGs) and Risk for Thrombotic Adverse Events (TEs) during 2008-2012 Study Period [877]**  
Gayathri Sridhar, Mikhail Menis, Hector S Izurieta, Hozefa A Divan, Richard Forshee, Nandini Selvam. (United States)
- 266 Characterization of Patients with Rheumatoid Arthritis Treated with Rituximab or Tocilizumab in Post-Marketing Patient Registries [878]**  
Iain D Tatt, Khaled Sarsour, Jamie Robinson, Eric Low, Pavel Napalkov. (Switzerland)
- 267 Comparative Risks of Recurrent Hospitalized Infection Associated with Biologics in RA Patients at High Risk [881]**  
Huifeng Yun, Fenglong Xie, Elizabeth S Delzell, Lang Chen, Emily Levitan, James D Lewis, Kenneth G Saag, Timothy Beukelman, Kevin L Winthrop. (United States)
- 268 Autoimmune, Neurologic, and Venous Thromboembolic Adverse Events Following Administration of a Quadrivalent HPV Vaccine to Adolescent Girls in Denmark and Sweden [887]**  
Lisen Arnheim-Dahlström, Björn Pasternak, Henrik Svanström, Pär Sparén, Anders Hviid. (Denmark)
- 269 A Novel Approach to Assessing the Real-World Effectiveness of the Human Papillomavirus Vaccine: The Regression Discontinuity Design [888]**  
Leah M Smith, Erin C Strumpf, Jay S Kaufman, Linda E Lévesque. (Canada)

▶ **END SESSION C**

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Monday, August 26</b>				
<b>Back to the Future: Methods in Time (Methods 1)</b>				
1		10:30 am	519 AB	Oral
2		10:45 am	519 AB	Oral
3		11:00 am	519 AB	Oral
4		11:15 am	519 AB	Oral
5		11:30 am	519 AB	Oral
6		11:45 am	519 AB	Oral
<b>Burden of Disease: Profiles and Prospects</b>				
7		10:30 am	524 AB	Oral
8		10:45 am	524 AB	Oral
9		11:00 am	524 AB	Oral
10		11:15 am	524 AB	Oral
11		11:30 am	524 AB	Oral
12		11:45 am	524 AB	Oral
<b>Opioids or NSAIDs: A Painful Choice</b>				
13		10:30 am	520 CF	Oral
14		10:45 am	520 CF	Oral
15		11:00 am	520 CF	Oral
16		11:15 am	520 CF	Oral
17		11:30 am	520 CF	Oral
18		11:45 am	520 CF	Oral
<b>Part Man - Part Machine, A Device Potpourri</b>				
19		10:30 am	518 AB	Oral
20		10:45 am	518 AB	Oral
21		11:00 am	518 AB	Oral
22		11:15 am	518 AB	Oral
23		11:30 am	518 AB	Oral
24		11:45 am	518 AB	Oral
<b>Pregnancy Session 1</b>				
25		10:30 am	520 AD	Oral
26		10:45 am	520 AD	Oral
27		11:00 am	520 AD	Oral
28		11:15 am	520 AD	Oral
29		11:30 am	520 AD	Oral
30		11:45 am	520 AD	Oral
<b>Use Your Heart</b>				
31		10:30 am	520 BE	Oral
32		10:45 am	520 BE	Oral
33		11:00 am	520 BE	Oral
34		11:15 am	520 BE	Oral
35		11:30 am	520 BE	Oral
36		11:45 am	520 BE	Oral
<b>Big Molecules, Big Problems?</b>				
37		1:30 pm	524 AB	Oral
38		1:45 pm	524 AB	Oral
39		2:00 pm	524 AB	Oral
40		2:15 pm	524 AB	Oral
41		2:30 pm	524 AB	Oral
42		2:45 pm	524 AB	Oral

Abstract #	Poster #	Presentation Time	Room	Format
<b>Gene Meets Drug</b>				
43		1:30 pm	520 CF	Oral
44		1:45 pm	520 CF	Oral
45		2:00 pm	520 CF	Oral
46		2:15 pm	520 CF	Oral
47		2:30 pm	520 CF	Oral
48		2:45 pm	520 CF	Oral
<b>Hot Topics in Diabetes: Pancreatitis and Cancer</b>				
49		1:30 pm	520 BE	Oral
50		1:45 pm	520 BE	Oral
51		2:00 pm	520 BE	Oral
52		2:15 pm	520 BE	Oral
53		2:30 pm	520 BE	Oral
54		2:45 pm	520 BE	Oral
<b>Methods in CER</b>				
55		1:30 pm	519 AB	Oral
56		1:45 pm	519 AB	Oral
57		2:00 pm	519 AB	Oral
58		2:15 pm	519 AB	Oral
59		2:30 pm	519 AB	Oral
60		2:45 pm	519 AB	Oral
<b>Respiratory</b>				
61		1:30 pm	518 AB	Oral
62		1:45 pm	518 AB	Oral
63		2:00 pm	518 AB	Oral
64		2:15 pm	518 AB	Oral
65		2:30 pm	518 AB	Oral
66		2:45 pm	518 AB	Oral
<b>Sounding All the Sources</b>				
67		1:30 pm	520 AD	Oral
68		1:45 pm	520 AD	Oral
69		2:00 pm	520 AD	Oral
70		2:15 pm	520 AD	Oral
71		2:30 pm	520 AD	Oral
72		2:45 pm	520 AD	Oral
<b>Benefit-Risk Assessment, Communication and Evaluation (BRACE): Embrace the Challenges and Opportunities (Submitted on Behalf of the BRACE SIG)</b>				
73		5:00 – 6:30 pm	520 BE	Sympos.
<b>Design and Methodological Considerations in Conducting Relative Effectiveness Studies of Newly Launched Products</b>				
74		5:00 – 6:30 pm	520 CF	Sympos.
<b>Drug Response in Diverse Populations: Role of Ethnicity</b>				
75		5:00 – 6:30 pm	518 AB	Sympos.
<b>Harmonizing Methods and Data across Multiple Databases: Beautiful Music or Cacophony?</b>				
76		5:00 – 6:30 pm	517 D	Sympos.
<b>Non-Database Pharmacoepidemiology in Low Resource Settings: Current Status and Unique Opportunities To Advance Methods</b>				
77		5:00 – 6:30 pm	524 AB	Sympos.
<b>Post-Marketing Pharmacoepidemiologic (PE) Database Studies to Assess Drug Safety</b>				
78		5:00 – 6:30 pm	519 AB	Sympos.
<b>Strategies to Enhance Validity in the Design of Comparative Effectiveness Studies</b>				
79		5:00 – 6:30 pm	520 AD	Sympos.

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Monday, August 26 continued</b>				
<b>POSTER SESSION A</b>				
<b>Classical Pharmacoepidemiology</b>				
80	1	8:00 am – 6:00 pm		Poster
81	2	8:00 am – 6:00 pm		Poster
82	3	8:00 am – 6:00 pm		Poster
83	4	8:00 am – 6:00 pm		Poster
84	5	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
85	6	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
86	7	8:00 am – 6:00 pm		Poster
87	8	8:00 am – 6:00 pm		Poster
88	9	8:00 am – 6:00 pm		Poster
89	10	8:00 am – 6:00 pm		Poster
90	11	8:00 am – 6:00 pm		Poster
91	12	8:00 am – 6:00 pm		Poster
93	13	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
94	14	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
95	15	8:00 am – 6:00 pm		Poster
96	16	8:00 am – 6:00 pm		Poster
97	17	8:00 am – 6:00 pm		Poster
98	18	8:00 am – 6:00 pm		Poster
99	19	8:00 am – 6:00 pm		Poster
100	20	8:00 am – 6:00 pm		Poster
102	22	8:00 am – 6:00 pm		Poster
103	23	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
104	24	8:00 am – 6:00 pm		Poster
105	25	8:00 am – 6:00 pm		Poster
106	26	8:00 am – 6:00 pm		Poster
107	27	8:00 am – 6:00 pm		Poster
108	28	8:00 am – 6:00 pm		Poster
109	29	8:00 am – 6:00 pm		Poster
110	30	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
111	31	8:00 am – 6:00 pm		Poster
112	32	8:00 am – 6:00 pm		Poster
113	33	8:00 am – 6:00 pm		Poster
114	34	8:00 am – 6:00 pm		Poster
115	35	8:00 am – 6:00 pm		Poster
116	36	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
117	37	8:00 am – 6:00 pm		Poster
118	38	8:00 am – 6:00 pm		Poster
119	39	8:00 am – 6:00 pm		Poster
120	40	8:00 am – 6:00 pm		Poster
121	41	8:00 am – 6:00 pm		Poster
122	42	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
123	43	8:00 am – 6:00 pm		Poster
124	44	8:00 am – 6:00 pm		Poster
125	45	8:00 am – 6:00 pm		Poster
126	46	8:00 am – 6:00 pm		Poster
127	47	8:00 am – 6:00 pm		Poster
128	48	8:00 am – 6:00 pm		Poster
130	49	8:00 am – 6:00 pm		Poster
131	50	8:00 am – 6:00 pm		Poster
132	51	8:00 am – 6:00 pm		Poster
133	52	8:00 am – 6:00 pm		Poster
134	53	8:00 am – 6:00 pm		Poster
135	54	8:00 am – 6:00 pm		Poster
136	55	8:00 am – 6:00 pm		Poster
137	56	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
138	57	8:00 am – 6:00 pm		Poster
139	58	8:00 am – 6:00 pm		Poster
140	59	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
141	60	8:00 am – 6:00 pm		Poster
<b>Comparative Effectiveness Research</b>				
142	61	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
143	62	8:00 am – 6:00 pm		Poster
144	63	8:00 am – 6:00 pm		Poster
145	64	8:00 am – 6:00 pm		Poster
146	65	8:00 am – 6:00 pm		Poster
<b>Drug Safety in Pregnancy and Lactation</b>				
147	66	8:00 am – 6:00 pm		Poster
148	67	8:00 am – 6:00 pm		Poster
149	68	8:00 am – 6:00 pm		Poster
<b>Other</b>				
150	69	8:00 am – 6:00 pm		Poster
151	70	8:00 am – 6:00 pm		Poster
152	71	8:00 am – 6:00 pm		Poster
153	72	8:00 am – 6:00 pm		Poster
154	73	8:00 am – 6:00 pm		Poster
155	74	8:00 am – 6:00 pm		Poster
156	75	8:00 am – 6:00 pm		Poster
157	76	8:00 am – 6:00 pm		Poster
158	77	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
159	78	8:00 am – 6:00 pm		Poster
160	79	8:00 am – 6:00 pm		Poster
161	80	8:00 am – 6:00 pm		Poster
162	81	8:00 am – 6:00 pm		Poster
163	82	8:00 am – 6:00 pm		Poster
164	83	8:00 am – 6:00 pm		Poster
<b>Pharmacovigilance</b>				
165	84	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
166	85	8:00 am – 6:00 pm		Poster
167	86	8:00 am – 6:00 pm		Poster
168	87	8:00 am – 6:00 pm		Poster
169	88	8:00 am – 6:00 pm		Poster
170	89	8:00 am – 6:00 pm		Poster
171	90	8:00 am – 6:00 pm		Poster
172	91	8:00 am – 6:00 pm		Poster
173	92	8:00 am – 6:00 pm		Poster
174	93	8:00 am – 6:00 pm		Poster
175	94	8:00 am – 6:00 pm		Poster
176	95	8:00 am – 6:00 pm		Poster
177	96	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
178	97	8:00 am – 6:00 pm		Poster
179	98	8:00 am – 6:00 pm		Poster
180	99	8:00 am – 6:00 pm		Poster
181	100	8:00 am – 6:00 pm		Poster
182	101	8:00 am – 6:00 pm		Poster
183	102	8:00 am – 6:00 pm		Poster
184	103	8:00 am – 6:00 pm		Poster
185	104	8:00 am – 6:00 pm		Poster
186	105	8:00 am – 6:00 pm		Poster
187	106	8:00 am – 6:00 pm		Poster
188	107	8:00 am – 6:00 pm		Poster
189	108	8:00 am – 6:00 pm		Poster
190	109	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Monday, August 26 continued</b>				
191	110	8:00 am – 6:00 pm		Poster
192	111	8:00 am – 6:00 pm		Poster
193	112	8:00 am – 6:00 pm		Poster
194	113	8:00 am – 6:00 pm		Poster
195	114	8:00 am – 6:00 pm		Poster
196	115	8:00 am – 6:00 pm		Poster
197	116	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
198	117	8:00 am – 6:00 pm		Poster
199	118	8:00 am – 6:00 pm		Poster
200	119	8:00 am – 6:00 pm		Poster
201	120	8:00 am – 6:00 pm		Poster
202	121	8:00 am – 6:00 pm		Poster
203	122	8:00 am – 6:00 pm		Poster
204	123	8:00 am – 6:00 pm		Poster
205	124	8:00 am – 6:00 pm		Poster
206	125	8:00 am – 6:00 pm		Poster
207	126	8:00 am – 6:00 pm		Poster
208	127	8:00 am – 6:00 pm		Poster
209	128	8:00 am – 6:00 pm		Poster
210	129	8:00 am – 6:00 pm		Poster
211	130	8:00 am – 6:00 pm		Poster
<b>Risk Management / Risk Minimization/Communication</b>				
212	131	8:00 am – 6:00 pm		Poster
213	132	8:00 am – 6:00 pm		Poster
214	133	8:00 am – 6:00 pm		Poster
215	134	8:00 am – 6:00 pm		Poster
216	135	8:00 am – 6:00 pm		Poster
217	136	8:00 am – 6:00 pm		Poster
218	137	8:00 am – 6:00 pm		Poster
219	138	8:00 am – 6:00 pm		Poster
220	139	8:00 am – 6:00 pm		Poster
221	140	8:00 am – 6:00 pm		Poster
<b>Adherence SIG</b>				
244	141	8:00 am – 6:00 pm		Poster
223	142	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
224	143	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
225	144	8:00 am – 6:00 pm		Poster
226	145	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
242	146	8:00 am – 6:00 pm		Poster
227	147	8:00 am – 6:00 pm		Poster
229	148	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
234	149	8:00 am – 6:00 pm		Poster
236	150	8:00 am – 6:00 pm		Poster
237	151	8:00 am – 6:00 pm		Poster
238	152	8:00 am – 6:00 pm		Poster
239	153	8:00 am – 6:00 pm		Poster
241	154	8:00 am – 6:00 pm		Poster
243	155	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
245	156	8:00 am – 6:00 pm		Poster
246	157	8:00 am – 6:00 pm		Poster
247	158	8:00 am – 6:00 pm		Poster
248	159	8:00am – 6:00pm		Poster
<b>Comparative Effectiveness Research (CER)</b>				
249	160	8:00 am – 6:00 pm		Poster
250	161	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
251	162	8:00 am – 6:00 pm		Poster
252	163	8:00 am – 6:00 pm		Poster
253	164	8:00 am – 6:00 pm		Poster
255	165	8:00 am – 6:00 pm		Poster
256	166	8:00 am – 6:00 pm		Poster
258	167	8:00 am – 6:00 pm		Poster
259	168	8:00 am – 6:00 pm		Poster
260	169	8:00 am – 6:00 pm		Poster
261	170	8:00 am – 6:00 pm		Poster
262	171	8:00 am – 6:00 pm		Poster
263	172	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
264	173	8:00AM – 6:00 pm		Poster
265	174	8:00 am – 6:00 pm		Poster
266	175	8:00 am – 6:00 pm		Poster
267	176	8:00 am – 6:00 pm		Poster
268	177	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
270	178	8:00 am – 6:00 pm		Poster
271	179	8:00 am – 6:00 pm		Poster
272	180	8:00 am – 6:00 pm		Poster
273	181	8:00 am – 6:00 pm		Poster
274	182	8:00 am – 6:00 pm		Poster
275	183	8:00 am – 6:00 pm		Poster
277	184	8:00 am – 6:00 pm		Poster
278	185	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
279	186	8:00 am – 6:00 pm		Poster
280	187	8:00 am – 6:00 pm		Poster
281	188	8:00 am – 6:00 pm		Poster
282	189	8:00 am – 6:00 pm		Poster
283	190	8:00 am – 6:00 pm		Poster
285	191	8:00 am – 6:00 pm		Poster
286	192	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
288	193	8:00 am – 6:00 pm		Poster
289	194	8:00 am – 6:00 pm		Poster
<b>Medications in Pregnancy SIG</b>				
290	195	8:00 am – 6:00 pm		Poster
291	196	8:00 am – 6:00 pm		Poster
292	197	8:00 am – 6:00 pm		Poster
293	198	8:00 am – 6:00 pm		Poster
295	199	8:00 am – 6:00 pm		Poster
296	200	8:00 am – 6:00 pm		Poster
297	201	8:00 am – 6:00 pm		Poster
298	202	8:00 am – 6:00 pm		Poster
300	203	8:00 am – 6:00 pm		Poster
302	204	8:00 am – 6:00 pm		Poster
303	205	8:00 am – 6:00 pm		Poster
304	206	8:00 am – 6:00 pm		Poster
305	207	8:00 am – 6:00 pm		Poster
306	208	8:00 am – 6:00 pm		Poster
307	209	8:00 am – 6:00 pm		Poster
309	210	8:00 am – 6:00 pm		Poster
310	211	8:00 am – 6:00 pm		Poster
311	212	8:00 am – 6:00 pm		Poster
312	213	8:00 am – 6:00 pm		Poster
313	214	8:00 am – 6:00 pm		Poster
314	215	8:00 am – 6:00 pm		Poster
315	216	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Monday, August 26 continued</b>				
316	217	8:00 am – 6:00 pm		Poster
317	218	8:00 am – 6:00 pm		Poster
318	219	8:00 am – 6:00 pm		Poster
319	220	8:00 am – 6:00 pm		Poster
320	221	8:00 am – 6:00 pm		Poster
321	222	8:00 am – 6:00 pm		Poster
322	223	8:00 am – 6:00 pm		Poster
323	224	8:00 am – 6:00 pm		Poster
325	225	8:00 am – 6:00 pm		Poster
326	226	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
327	227	8:00 am – 6:00 pm		Poster
328	228	8:00 am – 6:00 pm		Poster
329	229	8:00 am – 6:00 pm		Poster
330	230	8:00 am – 6:00 pm		Poster
331	231	8:00 am – 6:00 pm		Poster
333	232	8:00 am – 6:00 pm		Poster
335	233	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
336	234	8:00 am – 6:00 pm		Poster
337	235	8:00 am – 6:00 pm		Poster
338	236	8:00 am – 6:00 pm		Poster
339	237	8:00 am – 6:00 pm		Poster
340	238	8:00 am – 6:00 pm		Poster
341	239	8:00 am – 6:00 pm		Poster
342	240	8:00 am – 6:00 pm		Poster
343	241	8:00 am – 6:00 pm		Poster
345	242	8:00 am – 6:00 pm		Poster
346	243	8:00 am – 6:00 pm		Poster
347	244	8:00 am – 6:00 pm		Poster
348	245	8:00 am – 6:00 pm		Poster
<b>Adherence SIG Poster Walk Session</b>				
226	246	8:00 am – 6:00 pm		Poster
228	247	8:00 am – 6:00 pm		Poster
232	248	8:00 am – 6:00 pm		Poster
233	249	8:00 am – 6:00 pm		Poster
235	250	8:00 am – 6:00 pm		Poster
238	251	8:00 am – 6:00 pm		Poster
240	252	8:00 am – 6:00 pm		Poster
<b>Comparative Effectiveness Research (CER) SIG Poster Walk Session</b>				
254	253	8:00 am – 6:00 pm		Poster
257	254	8:00 am – 6:00 pm		Poster
268	255	8:00 am – 6:00 pm		Poster
269	256	8:00 am – 6:00 pm		Poster
276	257	8:00 am – 6:00 pm		Poster
284	258	8:00 am – 6:00 pm		Poster
287	259	8:00 am – 6:00 pm		Poster
<b>Medications in Pregnancy SIG Poster Walk Session</b>				
299	260	8:00 am – 6:00 pm		Poster
301	261	8:00 am – 6:00 pm		Poster
308	262	8:00 am – 6:00 pm		Poster
324	263	8:00 am – 6:00 pm		Poster
332	264	8:00 am – 6:00 pm		Poster
334	265	8:00 am – 6:00 pm		Poster
344	266	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 27</b>				
<b>Brain, Skin and Bones in Relation to CNS Drugs</b>				
349		8:00 am	520 CF	Oral
350		8:15 am	520 CF	Oral
351		8:30 am	520 CF	Oral
352		8:45 am	520 CF	Oral
353		9:00 am	520 CF	Oral
354		9:15 am	520 CF	Oral
<b>Money Matters</b>				
355		8:00 am	518 AB	Oral
356		8:15 am	518 AB	Oral
357		8:30 am	518 AB	Oral
358		8:45 am	518 AB	Oral
359		9:00 am	518 AB	Oral
360		9:15 am	518 AB	Oral
<b>Pediatrics</b>				
361		8:00 am	520 AD	Oral
362		8:15 am	520 AD	Oral
363		8:30 am	520 AD	Oral
364		8:45 am	520 AD	Oral
365		9:00 am	520 AD	Oral
366		9:15 am	520 AD	Oral
<b>PS, I Love You (Methods 2)</b>				
367		8:00 am	519 AB	Oral
368		8:15 am	519 AB	Oral
369		8:30 am	519 AB	Oral
370		8:45 am	519 AB	Oral
371		9:00 am	519 AB	Oral
372		9:15 am	519 AB	Oral
<b>That's Interesting...</b>				
373		8:00 am	524 AB	Oral
374		8:15 am	524 AB	Oral
375		8:30 am	524 AB	Oral
376		8:45 am	524 AB	Oral
377		9:00 am	524 AB	Oral
378		9:15 am	524 AB	Oral
<b>Up and Down the GI Tract</b>				
379		8:00 am	520 BE	Oral
380		8:15 am	520 BE	Oral
381		8:30 am	520 BE	Oral
382		8:45 am	520 BE	Oral
383		9:00 am	520 BE	Oral
384		9:15 am	520 BE	Oral
<b>Methods 3</b>				
385		10:00 am	519 AB	Oral
386		10:15 am	519 AB	Oral
387		10:30 am	519 AB	Oral
388		10:45 am	519 AB	Oral
389		11:00 am	519 AB	Oral
390		11:15 am	519 AB	Oral
<b>Potential Bias in Cardiovascular Studies</b>				
391		10:00 am	520 BE	Oral
392		10:15 am	520 BE	Oral
393		10:30 am	520 BE	Oral
394		10:45 am	520 BE	Oral
395		11:00 am	520 BE	Oral
396		11:15 am	520 BE	Oral

# ABSTRACT INDEX

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 27 continued</b>				
<b>Pregnancy Potpourri</b>				
397		10:00 am	520 CF	Oral
398		10:15 am	520 CF	Oral
399		10:30 am	520 CF	Oral
400		10:45 am	520 CF	Oral
401		11:00 am	520 CF	Oral
402		11:15 am	520 CF	Oral
<b>Psychotropics on Your Mind</b>				
403		10:00 am	518 AB	Oral
404		10:15 am	518 AB	Oral
405		10:30 am	518 AB	Oral
406		10:45 am	518 AB	Oral
450		11:00 am	518 AB	Oral
408		11:15 am	518 AB	Oral
<b>Sweet Spot on CER</b>				
409		10:00 am	520 AD	Oral
410		10:15 am	520 AD	Oral
411		10:30 am	520 AD	Oral
412		10:45 am	520 AD	Oral
413		11:00 am	520 AD	Oral
414		11:15 am	520 AD	Oral
<b>Vaccines: Benefits, Risks; Reducing the Unknowns</b>				
415		10:00 am	524 AB	Oral
416		10:15 am	524 AB	Oral
417		10:30 am	524 AB	Oral
418		10:45 am	524 AB	Oral
419		11:00 am	524 AB	Oral
420		11:15 am	524 AB	Oral
<b>Plenary Session: Edlavitch Award</b>				
421		2:30 – 4:00 pm	517 D	Plenary
<b>Advanced Topics on Database Algorithm Development and Validation</b>				
422		4:30 – 6:00 pm	517 D	Sympos.
<b>Best Practices and Areas of Future Research in the Development of Educational Material To Communicate Risk to Patients and Clinicians</b>				
423		4:30 – 6:00 pm	518 AB	Sympos.
<b>Impact of the Choice of Reference Set on Performance Testing of Signal Detection Methods</b>				
424		4:30 – 6:00 pm	524AB	Sympos.
<b>Importance of Sensitivity Analyses for Design Decisions in Comparative Effectiveness Research</b>				
425		4:30 – 6:00 pm	520 AD	Sympos.
<b>Looking for Efficient Solutions To Optimize Adherence to Drug Treatment: The Clinical, Health Services Research and Economics Perspectives</b>				
426		4:30 – 6:00 pm	520 BE	Sympos.
<b>New Approaches To Account for Selection Bias and Confounding by Frail Health Status</b>				
427		4:30 – 6:00 pm	520 CF	Sympos.
<b>Welcoming Advanced Methods into the World of Pregnancy Research</b>				
428		4:30 – 6:00 pm	519 AB	Sympos.
<b>POSTER SESSION B</b>				
<b>Benefit Risk Assessment and Risk Communication</b>				
429	1	8:00 am – 6:00 pm		Poster
430	2	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
431	3	8:00 am – 6:00 pm		Poster
432	4	8:00 am – 6:00 pm		Poster
433	5	8:00 am – 6:00 pm		Poster
434	6	8:00 am – 6:00 pm		Poster
<b>Methods</b>				
435	7	8:00 am – 6:00 pm		Poster
436	8	8:00 am – 6:00 pm		Poster
437	9	8:00 am – 6:00 pm		Poster
438	10	8:00 am – 6:00 pm		Poster
439	11	8:00 am – 6:00 pm		Poster
440	12	8:00 am – 6:00 pm		Poster
441	13	8:00 am – 6:00 pm		Poster
442	14	8:00 am – 6:00 pm		Poster
443	15	8:00 am – 6:00 pm		Poster
444	16	8:00 am – 6:00 pm		Poster
445	17	8:00 am – 6:00 pm		Poster
446	18	8:00 am – 6:00 pm		Poster
447	19	8:00 am – 6:00 pm		Poster
448	20	8:00 am – 6:00 pm		Poster
449	21	8:00 am – 6:00 pm		Poster
407	22	8:00 am – 6:00 pm		Poster
451	23	8:00 am – 6:00 pm		Poster
452	24	8:00 am – 6:00 pm		Poster
453	25	8:00 am – 6:00 pm		Poster
454	26	8:00 am – 6:00 pm		Poster
455	27	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
456	28	8:00 am – 6:00 pm		Poster
457	29	8:00 am – 6:00 pm		Poster
458	30	8:00 am – 6:00 pm		Poster
459	31	8:00 am – 6:00 pm		Poster
460	32	8:00 am – 6:00 pm		Poster
461	33	8:00 am – 6:00 pm		Poster
462	34	8:00 am – 6:00 pm		Poster
463	35	8:00 am – 6:00 pm		Poster
464	36	8:00 am – 6:00 pm		Poster
465	37	8:00 am – 6:00 pm		Poster
466	38	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
467	39	8:00 am – 6:00 pm		Poster
468	40	8:00 am – 6:00 pm		Poster
469	41	8:00 am – 6:00 pm		Poster
470	42	8:00 am – 6:00 pm		Poster
471	43	8:00 am – 6:00 pm		Poster
472	44	8:00 am – 6:00 pm		Poster
473	45	8:00 am – 6:00 pm		Poster
474	46	8:00 am – 6:00 pm		Poster
475	47	8:00 am – 6:00 pm		Poster
476	48	8:00 am – 6:00 pm		Poster
477	49	8:00 am – 6:00 pm		Poster
478	50	8:00 am – 6:00 pm		Poster
479	51	8:00 am – 6:00 pm		Poster
<b>Pediatrics</b>				
480	52	8:00 am – 6:00 pm		Poster
481	53	8:00 am – 6:00 pm		Poster
482	54	8:00 am – 6:00 pm		Poster
483	55	8:00 am – 6:00 pm		<i>Abstract Withdrawn by Author</i>
484	56	8:00 am – 6:00 pm		Poster
485	57	8:00 am – 6:00 pm		Poster
486	58	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 27 continued</b>				
487	59	8:00 am – 6:00 pm		Poster
488	60	8:00 am – 6:00 pm		Poster
<b>Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG</b>				
489	61	8:00 am – 6:00 pm		Poster
490	62	8:00 am – 6:00 pm		Poster
491	63	8:00 am – 6:00 pm		Poster
492	64	8:00 am – 6:00 pm		Poster
494	65	8:00 am – 6:00 pm		Poster
495	66	8:00 am – 6:00 pm		Poster
496	67	8:00 am – 6:00 pm		Poster
497	68	8:00 am – 6:00 pm		Poster
498	69	8:00 am – 6:00 pm		Poster
499	70	8:00 am – 6:00 pm		Poster
501	71	8:00 am – 6:00 pm		Poster
502	72	8:00 am – 6:00 pm		Poster
503	73	8:00 am – 6:00 pm		Poster
508	74	8:00 am – 6:00 pm		Poster
509	75	8:00 am – 6:00 pm		Poster
510	76	8:00 am – 6:00 pm		Poster
511	77	8:00 am – 6:00 pm		Poster
512	78	8:00 am – 6:00 pm		Poster
513	79	8:00 am – 6:00 pm		Poster
514	80	8:00 am – 6:00 pm		Poster
515	81	8:00 am – 6:00 pm		Poster
516	82	8:00 am – 6:00 pm		Poster
517	83	8:00 am – 6:00 pm		Poster
518	84	8:00 am – 6:00 pm		Poster
519	85	8:00 am – 6:00 pm		Poster
520	86	8:00 am – 6:00 pm		Poster
521	87	8:00 am – 6:00 pm		Poster
522	88	8:00 am – 6:00 pm		Poster
524	89	8:00 am – 6:00 pm		Poster
525	90	8:00 am – 6:00 pm		Poster
526	91	8:00 am – 6:00 pm		Poster
527	92	8:00 am – 6:00 pm		Poster
528	93	8:00 am – 6:00 pm		Poster
529	94	8:00 am – 6:00 pm		Poster
531	95	8:00 am – 6:00 pm		Poster
<b>Database SIG</b>				
532	96	8:00 am – 6:00 pm		Poster
533	97	8:00 am – 6:00 pm		Poster
534	98	8:00 am – 6:00 pm		Poster
535	99	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
536	100	8:00 am – 6:00 pm		Poster
537	101	8:00 am – 6:00 pm		Poster
538	102	8:00 am – 6:00 pm		Poster
539	103	8:00 am – 6:00 pm		Poster
540	104	8:00 am – 6:00 pm		Poster
541	105	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
543	106	8:00 am – 6:00 pm		Poster
544	107	8:00 am – 6:00 pm		Poster
545	108	8:00 am – 6:00 pm		Poster
546	109	8:00 am – 6:00 pm		Poster
547	110	8:00 am – 6:00 pm		Poster
548	111	8:00 am – 6:00 pm		Poster
549	112	8:00 am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
550	113	8:00 am – 6:00 pm		Poster
551	114	8:00 am – 6:00 pm		Poster
552	115	8:00 am – 6:00 pm		Poster
553	116	8:00 am – 6:00 pm		Poster
554	117	8:00 am – 6:00 pm		Poster
555	118	8:00 am – 6:00 pm		Poster
556	119	8:00 am – 6:00 pm		Poster
557	120	8:00 am – 6:00 pm		Poster
558	121	8:00 am – 6:00 pm		Poster
559	122	8:00 am – 6:00 pm		Poster
560	123	8:00 am – 6:00 pm		Poster
561	124	8:00 am – 6:00 pm		Poster
564	125	8:00 am – 6:00 pm		Poster
565	126	8:00 am – 6:00 pm		Poster
566	127	8:00 am – 6:00 pm		Poster
567	128	8:00 am – 6:00 pm		Poster
568	129	8:00 am – 6:00 pm		Poster
569	130	8:00 am – 6:00 pm		Poster
570	131	8:00 am – 6:00 pm		Poster
571	132	8:00 am – 6:00 pm		Poster
572	133	8:00 am – 6:00 pm		Poster
573	134	8:00 am – 6:00 pm		Poster
574	135	8:00 am – 6:00 pm		Poster
575	136	8:00 am – 6:00 pm		Poster
576	137	8:00 am – 6:00 pm		Poster
577	138	8:00 am – 6:00 pm		Poster
578	139	8:00 am – 6:00 pm		Poster
579	140	8:00 am – 6:00 pm		Poster
581	141	8:00 am – 6:00 pm		Poster
582	142	8:00 am – 6:00 pm		Poster
583	143	8:00 am – 6:00 pm		Poster
585	144	8:00 am – 6:00 pm		Poster
586	145	8:00 am – 6:00 pm		Poster
587	146	8:00 am – 6:00 pm		Poster
588	147	8:00 am – 6:00 pm		Poster
589	148	8:00 am – 6:00 pm		Poster
590	149	8:00 am – 6:00 pm		Poster
591	150	8:00 am – 6:00 pm		Poster
592	151	8:00 am – 6:00 pm		Poster
593	152	8:00 am – 6:00 pm		Poster
594	153	8:00 am – 6:00 pm		Poster
597	154	8:00 am – 6:00 pm		Poster
598	155	8:00 am – 6:00 pm		Poster
599	156	8:00 am – 6:00 pm		Poster
600	157	8:00 am – 6:00 pm		Poster
601	158	8:00 am – 6:00 pm		Poster
602	159	8:00 am – 6:00 pm		Poster
603	160	8:00 am – 6:00 pm		Poster
604	161	8:00 am – 6:00 pm		Poster
605	162	8:00 am – 6:00 pm		Poster
606	163	8:00 am – 6:00 pm		Poster
607	164	8:00 am – 6:00 pm		Poster
608	165	8:00 am – 6:00 pm		Poster
609	166	8:00 am – 6:00 pm		Poster
610	167	8:00 am – 6:00 pm		Poster
611	168	8:00 am – 6:00 pm		Poster
612	169	8:00 am – 6:00 pm		Poster
613	170	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 27 continued</b>				
614	171	8:00 am – 6:00 pm		Poster
615	172	8:00 am – 6:00 pm		Poster
616	173	8:00 am – 6:00 pm		Poster
617	174	8:00 am – 6:00 pm		Poster
618	175	8:00 am – 6:00 pm		Poster
619	176	8:00 am – 6:00 pm		Poster
620	177	8:00 am – 6:00 pm		Poster
621	178	8:00 am – 6:00 pm		Poster
622	179	8:00 am – 6:00 pm		Poster
623	180	8:00 am – 6:00 pm		Poster
624	181	8:00 am – 6:00 pm		Poster
625	182	8:00 am – 6:00 pm		Poster
626	183	8:00 am – 6:00 pm	<i>Abstract Withdrawn by Author</i>	
628	184	8:00 am – 6:00 pm		Poster
629	185	8:00 am – 6:00 pm		Poster
630	186	8:00 am – 6:00 pm		Poster
631	187	8:00 am – 6:00 pm		Poster
632	188	8:00 am – 6:00 pm		Poster
633	189	8:00 am – 6:00 pm		Poster
634	190	8:00 am – 6:00 pm		Poster
635	191	8:00 am – 6:00 pm		Poster
636	192	8:00 am – 6:00 pm		Poster
637	193	8:00 am – 6:00 pm		Poster
638	194	8:00 am – 6:00 pm		Poster
639	195	8:00 am – 6:00 pm		Poster
640	196	8:00 am – 6:00 pm		Poster
<b>Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG</b>				
654	197	8:00 am – 6:00 pm		Poster
643	198	8:00 am – 6:00 pm		Poster
644	199	8:00 am – 6:00 pm		Poster
646	200	8:00 am – 6:00 pm		Poster
647	201	8:00 am – 6:00 pm		Poster
649	202	8:00 am – 6:00 pm		Poster
651	203	8:00 am – 6:00 pm		Poster
652	204	8:00 am – 6:00 pm		Poster
653	205	8:00 am – 6:00 pm		Poster
656	206	8:00 am – 6:00 pm		Poster
658	207	8:00 am – 6:00 pm		Poster
<b>Pediatrics SIG</b>				
659	208	8:00am – 6:00pm		Poster
660	209	8:00am – 6:00 pm		Poster
696	210	8:00am – 6:00 pm		Poster
661	211	8:00am – 6:00 pm		Poster
663	212	8:00am – 6:00 pm		Poster
664	213	8:00am – 6:00 pm		Poster
666	214	8:00am – 6:00 pm		Poster
667	215	8:00am – 6:00 pm		Poster
668	216	8:00am – 6:00 pm		Poster
669	217	8:00am – 6:00 pm		Poster
670	218	8:00am – 6:00 pm		Poster
671	219	8:00am – 6:00 pm		Poster
672	220	8:00am – 6:00 pm		Poster
673	221	8:00am – 6:00 pm		Poster
674	222	8:00am – 6:00 pm		Poster
675	223	8:00am – 6:00 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
676	224	8:00am – 6:00 pm		Poster
677	225	8:00am – 6:00 pm		Poster
678	226	8:00am – 6:00 pm		Poster
679	227	8:00am – 6:00 pm		Poster
680	228	8:00am – 6:00 pm		Poster
682	229	8:00am – 6:00 pm		Poster
683	230	8:00am – 6:00 pm		Poster
684	231	8:00am – 6:00 pm		Poster
686	232	8:00am – 6:00 pm		Poster
687	233	8:00am – 6:00 pm		Poster
688	234	8:00am – 6:00 pm		Poster
689	235	8:00am – 6:00 pm		Poster
690	236	8:00am – 6:00 pm		Poster
691	237	8:00am – 6:00 pm		Poster
692	238	8:00am – 6:00 pm		Poster
693	239	8:00am – 6:00 pm		Poster
695	240	8:00am – 6:00 pm		Poster
697	241	8:00am – 6:00 pm		Poster
698	242	8:00am – 6:00 pm		Poster
<b>Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG Poster Walk Session</b>				
493	243	8:00 am – 6:00 pm		Poster
500	244	8:00 am – 6:00 pm		Poster
504	245	8:00 am – 6:00 pm		Poster
505	246	8:00 am – 6:00 pm		Poster
506	247	8:00 am – 6:00 pm		Poster
507	248	8:00 am – 6:00 pm		Poster
523	249	8:00 am – 6:00 pm		Poster
530	250	8:00 am – 6:00 pm		Poster
<b>Database SIG Poster Walk Session</b>				
542	251	8:00 am – 6:00 pm		Poster
562	252	8:00 am – 6:00 pm		Poster
563	253	8:00 am – 6:00 pm		Poster
580	254	8:00 am – 6:00 pm		Poster
584	255	8:00 am – 6:00 pm		Poster
595	256	8:00 am – 6:00 pm		Poster
596	257	8:00 am – 6:00 pm		Poster
627	258	8:00 am – 6:00 pm		Poster
<b>Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG Poster Walk Session</b>				
641	259	8:00 am – 6:00 pm		Poster
642	260	8:00 am – 6:00 pm		Poster
645	261	8:00 am – 6:00 pm		Poster
648	262	8:00 am – 6:00 pm		Poster
650	263	8:00 am – 6:00 pm		Poster
655	264	8:00 am – 6:00 pm		Poster
657	265	8:00 am – 6:00 pm		Poster
<b>Pediatrics SIG Poster Walk Session</b>				
662	266	8:00 am – 6:00 pm		Poster
665	267	8:00 am – 6:00 pm		Poster
681	268	8:00 am – 6:00 pm		Poster
685	269	8:00 am – 6:00 pm		Poster
694	270	8:00 am – 6:00 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Wednesday, August 28</b>				
<b>Around the World in 90 Minutes</b>				
699		8:30 am	518 AB	Oral
700		8:45 am	518 AB	Oral
701		9:00 am	518 AB	Oral
702		9:15 am	518 AB	Oral
703		9:30 am	518 AB	Oral
704		9:45 am	518 AB	Oral
<b>Chicken and Egg: Common Drugs, Cancer Risk and Outcome</b>				
705		8:30 am	524 AB	Oral
706		8:45 am	524 AB	Oral
707		9:00 am	524 AB	Oral
708		9:15 am	524 AB	Oral
709		9:30 am	524 AB	Oral
710		9:45 am	524 AB	Oral
<b>Effective Choices (CER)</b>				
711		8:30 am	519 AB	Oral
712		8:45 am	519 AB	Oral
713		9:00 am	519 AB	Oral
714		9:15 am	519 AB	Oral
715		9:30 am	519 AB	Oral
716		9:45 am	519 AB	Oral
<b>Risky Business</b>				
717		8:30 am	520 BE	Oral
718		8:45 am	520 BE	Oral
719		9:00 am	520 BE	Oral
720		9:15 am	520 BE	Oral
721		9:30 am	520 BE	Oral
722		9:45 am	520 BE	Oral
<b>Sexy Hormones</b>				
723		8:30 am	520 AD	Oral
724		8:45 am	520 AD	Oral
725		9:00 am	520 AD	Oral
726		9:15 am	520 AD	Oral
727		9:30 am	520 AD	Oral
728		9:45 am	520 AD	Oral
<b>The Down Side of Pregnancy</b>				
729		8:30 am	520 CF	Oral
730		8:45 am	520 CF	Oral
731		9:00 am	520 CF	Oral
732		9:15 am	520 CF	Oral
733		9:30 am	520 CF	Oral
734		9:45 am	520 CF	Oral
<b>ARITMO Final Results: Prediction of the Arrhythmogenic Risk of Antihistamines, Antipsychotics and Anti-Infectives by Integration of Translational Evidence</b>				
735		10:30 am – 12 pm	520 CF	Sympos.
<b>Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources</b>				
736		10:30 am – 12 pm	518 AB	Sympos.
<b>Confounding's Ugly Little Sister: Measurement Bias in Pharmacoepidemiology</b>				
737		10:30 am – 12 pm	517 D	Sympos.
<b>Improving Consistency in Findings from Pharmacoepidemiological Studies: The IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Project</b>				
738		10:30 am – 12 pm	520 BE	Sympos.

Abstract #	Poster #	Presentation Time	Room	Format
<b>Improving the Science of Regulatory Decision-Making – Advances in 2012/2013</b>				
739		10:30 am – 12 pm	520 AD	Sympos.
<b>Interpreting and Communicating Risk of Medications in Pregnancy, Using SSRIs as an Example</b>				
740		10:30 am – 12 pm	519 AB	Sympos.
<b>Unlocking the Secrets of Free Text through Natural Language Processing: An Introduction for Pharmacoepidemiologists</b>				
741		10:30 am – 12 pm	524 AB	Sympos.
<b>Elderly</b>				
742		1:30 pm	524 AB	Oral
743		1:45 pm	524 AB	Oral
744		2:00 pm	524 AB	Oral
745		2:15 pm	524 AB	Oral
746		2:30 pm	524 AB	Oral
747		2:45 pm	524 AB	Oral
<b>Methods 4</b>				
748		1:30 pm	519 AB	Oral
749		1:45 pm	519 AB	Oral
750		2:00 pm	519 AB	Oral
751		2:15 pm	519 AB	Oral
752		2:30 pm	519 AB	Oral
753		2:45 pm	519 AB	Oral
<b>Pediatrics: Potpourri</b>				
754		1:30 pm	520 CF	Oral
755		1:45 pm	520 CF	Oral
756		2:00 pm	520 CF	Oral
757		2:15 pm	520 CF	Oral
758		2:30 pm	520 CF	Oral
759		2:45 pm	520 CF	Oral
<b>Self-Controlled Studies</b>				
760		1:30 pm	520 BE	Oral
761		1:45 pm	520 BE	Oral
762		2:00 pm	520 BE	Oral
763		2:15 pm	520 BE	Oral
764		2:30 pm	520 BE	Oral
765		2:45 pm	520 BE	Oral
<b>Sticky Treatments &amp; Sticky Outcome</b>				
766		1:30 pm	520 AD	Oral
767		1:45 pm	520 AD	Oral
768		2:00 pm	520 AD	Oral
769		2:15 pm	520 AD	Oral
770		2:30 pm	520 AD	Oral
771		2:45 pm	520 AD	Oral
<b>Usefulness of Data Sources for CNS Drugs &amp; Diseases</b>				
772		1:30 pm	518 AB	Oral
773		1:45 pm	518 AB	Oral
774		2:00 pm	518 AB	Oral
775		2:15 pm	518 AB	Oral
776		2:30 pm	518 AB	Oral
777		2:45 pm	518 AB	Oral

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Wednesday, August 28 continued</b>				
<b>POSTER SESSION C</b>				
<b>Biologics, Including Vaccines</b>				
778	1	8:00 am – 1:45 pm		Poster
779	2	8:00 am – 1:45 pm		Poster
<b>Burden of Disease/Epidemiology of Illness</b>				
780	3	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
781	4	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
782	5	8:00 am – 1:45 pm		Poster
783	6	8:00 am – 1:45 pm		Poster
784	7	8:00 am – 1:45 pm		Poster
785	8	8:00 am – 1:45 pm		Poster
786	9	8:00 am – 1:45 pm		Poster
787	10	8:00 am – 1:45 pm		Poster
788	11	8:00 am – 1:45 pm		Poster
789	12	8:00 am – 1:45 pm		Poster
790	13	8:00 am – 1:45 pm		Poster
791	14	8:00 am – 1:45 pm		Poster
792	15	8:00 am – 1:45 pm		Poster
793	16	8:00 am – 1:45 pm		Poster
794	17	8:00 am – 1:45 pm		Poster
795	18	8:00 am – 1:45 pm		Poster
796	19	8:00 am – 1:45 pm		Poster
797	20	8:00 am – 1:45 pm		Poster
798	21	8:00 am – 1:45 pm		Poster
799	22	8:00 am – 1:45 pm		Poster
800	23	8:00 am – 1:45 pm		Poster
801	24	8:00 am – 1:45 pm		Poster
802	25	8:00 am – 1:45 pm		Poster
803	26	8:00 am – 1:45 pm		Poster
804	27	8:00 am – 1:45 pm		Poster
805	28	8:00 am – 1:45 pm		Poster
806	29	8:00 am – 1:45 pm		Poster
807	30	8:00 am – 1:45 pm		Poster
808	31	8:00 am – 1:45 pm		Poster
809	32	8:00 am – 1:45 pm		Poster
810	33	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
811	34	8:00 am – 1:45 pm		Poster
812	35	8:00 am – 1:45 pm		Poster
813	36	8:00 am – 1:45 pm		Poster
814	37	8:00 am – 1:45 pm		Poster
815	38	8:00 am – 1:45 pm		Poster
816	39	8:00 am – 1:45 pm		Poster
817	40	8:00 am – 1:45 pm		Poster
818	41	8:00 am – 1:45 pm		Poster
819	42	8:00 am – 1:45 pm		Poster
820	43	8:00 am – 1:45 pm		Poster
<b>Drug Utilization Research/Health Services Research</b>				
822	44	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
823	45	8:00 am – 1:45 pm		Poster
824	46	8:00 am – 1:45 pm		Poster
825	47	8:00 am – 1:45 pm		Poster
826	48	8:00 am – 1:45 pm		Poster
827	49	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
828	50	8:00 am – 1:45 pm		Poster
829	51	8:00 am – 1:45 pm		Poster
830	52	8:00 am – 1:45 pm		Poster
831	53	8:00 am – 1:45 pm		Poster
832	54	8:00 am – 1:45 pm		Poster
833	55	8:00 am – 1:45 pm		Poster
834	56	8:00 am – 1:45 pm		Poster
835	57	8:00 am – 1:45 pm		Poster
836	58	8:00 am – 1:45 pm		Poster
837	59	8:00 am – 1:45 pm		Poster
838	60	8:00 am – 1:45 pm		Poster
840	61	8:00 am – 1:45 pm		Poster
841	62	8:00 am – 1:45 pm		Poster
842	63	8:00 am – 1:45 pm		Poster
843	64	8:00 am – 1:45 pm		Poster
844	65	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
845	66	8:00 am – 1:45 pm		Poster
846	67	8:00 am – 1:45 pm		Poster
847	68	8:00 am – 1:45 pm		Poster
848	69	8:00 am – 1:45 pm		Poster
849	70	8:00 am – 1:45 pm		Poster
850	71	8:00 am – 1:45 pm		Poster
851	72	8:00 am – 1:45 pm		Poster
852	73	8:00 am – 1:45 pm		Poster
853	74	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
854	75	8:00 am – 1:45 pm		Poster
<b>Medical Devices</b>				
855	76	8:00 am – 1:45 pm		Poster
<b>Pharmacoeconomics / Outcomes Research in Pharmacology</b>				
856	77	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
857	78	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
858	79	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
859	80	8:00 am – 1:45 pm		Poster
860	81	8:00 am – 1:45 pm		Poster
861	82	8:00 am – 1:45 pm		Poster
862	83	8:00 am – 1:45 pm		Poster
<b>Asian Pharmacoepidemiology Network (AsPEN) SIG</b>				
864	84	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
<b>Biologics SIG</b>				
866	85	8:00 am – 1:45 pm		Poster
868	86	8:00 am – 1:45 pm		Poster
869	87	8:00 am – 1:45 pm		Poster
871	88	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
872	89	8:00 am – 1:45 pm		Poster
873	90	8:00 am – 1:45 pm		Poster
874	91	8:00 am – 1:45 pm		Poster
876	92	8:00 am – 1:45 pm		Poster
879	93	8:00 am – 1:45 pm		Poster
880	94	8:00 am – 1:45 pm		Poster
882	95	8:00 am – 1:45 pm		Poster
883	96	8:00 am – 1:45 pm		Poster
884	97	8:00 am – 1:45 pm		Poster
885	98	8:00 am – 1:45 pm		Poster
886	99	8:00 am – 1:45 pm		Poster
889	100	8:00 am – 1:45 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Wednesday, August 28 continued</b>				
<b>Drug Utilization/Health Services Research SIG</b>				
890	101	8:00 am – 1:45 pm		Poster
891	102	8:00 am – 1:45 pm		Poster
927	103	8:00 am – 1:45 pm		Poster
912	104	8:00 am – 1:45 pm		Poster
893	105	8:00 am – 1:45 pm		Poster
894	106	8:00 am – 1:45 pm		Poster
895	107	8:00 am – 1:45 pm		Poster
1017	108	8:00 am – 1:45 pm		Poster
896	109	8:00 am – 1:45 pm		Poster
897	110	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
898	111	8:00 am – 1:45 pm		Poster
899	112	8:00 am – 1:45 pm		Poster
900	113	8:00 am – 1:45 pm		Poster
901	114	8:00 am – 1:45 pm		Poster
902	115	8:00 am – 1:45 pm		Poster
903	116	8:00 am – 1:45 pm		Poster
904	117	8:00 am – 1:45 pm		Poster
905	118	8:00 am – 1:45 pm		Poster
906	119	8:00 am – 1:45 pm		Poster
907	120	8:00 am – 1:45 pm		Poster
908	121	8:00 am – 1:45 pm		Poster
909	122	8:00 am – 1:45 pm		Poster
910	123	8:00 am – 1:45 pm		Poster
911	124	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
913	125	8:00 am – 1:45 pm		Poster
914	126	8:00 am – 1:45 pm		Poster
915	127	8:00 am – 1:45 pm		Poster
916	128	8:00 am – 1:45 pm		Poster
917	129	8:00 am – 1:45 pm		Poster
918	130	8:00 am – 1:45 pm		Poster
919	131	8:00 am – 1:45 pm		Poster
920	132	8:00 am – 1:45 pm		Poster
921	133	8:00 am – 1:45 pm		Poster
922	134	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
923	135	8:00 am – 1:45 pm		Poster
924	136	8:00 am – 1:45 pm		Poster
925	137	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
926	138	8:00 am – 1:45 pm		Poster
928	139	8:00 am – 1:45 pm		Poster
929	140	8:00 am – 1:45 pm		Poster
930	141	8:00 am – 1:45 pm		Poster
931	142	8:00 am – 1:45 pm		Poster
932	143	8:00 am – 1:45 pm		Poster
933	144	8:00 am – 1:45 pm		Poster
934	145	8:00 am – 1:45 pm		Poster
936	146	8:00 am – 1:45 pm		Poster
937	147	8:00 am – 1:45 pm		Poster
938	148	8:00 am – 1:45 pm		Poster
939	149	8:00 am – 1:45 pm		Poster
940	150	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
941	151	8:00 am – 1:45 pm		Poster
942	152	8:00 am – 1:45 pm		Poster
943	153	8:00 am – 1:45 pm		Poster
944	154	8:00 am – 1:45 pm		Poster
945	155	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
946	156	8:00 am – 1:45 pm		Poster
947	157	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
948	158	8:00 am – 1:45 pm		Poster
949	159	8:00 am – 1:45 pm		Poster
950	160	8:00 am – 1:45 pm		Poster
951	161	8:00 am – 1:45 pm		Poster
952	162	8:00 am – 1:45 pm		Poster
953	163	8:00 am – 1:45 pm		Poster
954	164	8:00 am – 1:45 pm		Poster
956	165	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
957	166	8:00 am – 1:45 pm		Poster
959	167	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
960	168	8:00 am – 1:45 pm		Poster
962	169	8:00 am – 1:45 pm		Poster
963	170	8:00 am – 1:45 pm		Poster
964	171	8:00 am – 1:45 pm		Poster
965	172	8:00 am – 1:45 pm		Poster
966	173	8:00 am – 1:45 pm		Poster
967	174	8:00 am – 1:45 pm		Poster
968	175	8:00 am – 1:45 pm		Poster
969	176	8:00 am – 1:45 pm		Poster
970	177	8:00 am – 1:45 pm		Poster
971	178	8:00 am – 1:45 pm		Poster
972	179	8:00 am – 1:45 pm		Poster
973	180	8:00 am – 1:45 pm		Poster
974	181	8:00 am – 1:45 pm		Poster
975	182	8:00 am – 1:45 pm		Poster
976	183	8:00 am – 1:45 pm		Poster
977	184	8:00 am – 1:45 pm		Poster
978	185	8:00 am – 1:45 pm		Poster
979	186	8:00 am – 1:45 pm		Poster
980	187	8:00 am – 1:45 pm		Poster
981	188	8:00 am – 1:45 pm		Poster
982	189	8:00 am – 1:45 pm		Poster
983	190	8:00 am – 1:45 pm		Poster
984	191	8:00 am – 1:45 pm		Poster
985	192	8:00 am – 1:45 pm		Poster
986	193	8:00 am – 1:45 pm		Poster
987	194	8:00 am – 1:45 pm		Poster
988	195	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
989	196	8:00 am – 1:45 pm		Poster
990	197	8:00 am – 1:45 pm		Poster
991	198	8:00 am – 1:45 pm		Poster
992	199	8:00 am – 1:45 pm		Poster
993	200	8:00 am – 1:45 pm		Poster
994	201	8:00 am – 1:45 pm		Poster
995	202	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
996	203	8:00 am – 1:45 pm		Poster
997	204	8:00 am – 1:45 pm		Poster
998	205	8:00 am – 1:45 pm		Poster
999	206	8:00 am – 1:45 pm		Poster
1000	207	8:00 am – 1:45 pm		Poster
1001	208	8:00 am – 1:45 pm		Poster
1002	209	8:00 am – 1:45 pm		Poster
1003	210	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1004	211	8:00 am – 1:45 pm		Poster
1005	212	8:00 am – 1:45 pm		Poster
1006	213	8:00 am – 1:45 pm		Poster

29th ICPE-Final Program  
**ABSTRACT INDEX**

Abstract #	Poster #	Presentation Time	Room	Format
<b>Wednesday, August 28 continued</b>				
1008	215	8:00 am – 1:45 pm		Poster
1009	216	8:00 am – 1:45 pm		Poster
1010	217	8:00 am – 1:45 pm		Poster
1011	218	8:00 am – 1:45 pm		Poster
1012	219	8:00 am – 1:45 pm		Poster
1013	220	8:00 am – 1:45 pm		Poster
1014	221	8:00 am – 1:45 pm		Poster
1015	222	8:00 am – 1:45 pm		Poster
1016	223	8:00 am – 1:45 pm		Poster
1018	224	8:00 am – 1:45 pm		Poster
1019	225	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1020	226	8:00 am – 1:45 pm		Poster
1021	227	8:00 am – 1:45 pm		Poster
1022	228	8:00 am – 1:45 pm		Poster
1023	229	8:00 am – 1:45 pm		Poster
1024	230	8:00 am – 1:45 pm		Poster
1025	231	8:00 am – 1:45 pm		Poster
1026	232	8:00 am – 1:45 pm		Poster
1027	233	8:00 am – 1:45 pm		Poster
1028	234	8:00 am – 1:45 pm		Poster
1029	235	8:00 am – 1:45 pm		Poster
1030	236	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1031	237	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
1032	238	8:00 am – 1:45 pm		Poster
1033	239	8:00 am – 1:45 pm		Poster
1034	240	8:00 am – 1:45 pm		Poster
1035	241	8:00 am – 1:45 pm		Poster
1036	242	8:00 am – 1:45 pm		Poster
1037	243	8:00 am – 1:45 pm		Poster
1038	244	8:00 am – 1:45 pm		Poster
294	245	8:00 am – 1:45 pm		Poster
1040	246	8:00 am – 1:45 pm		Poster
<b>Medical Devices SIG</b>				
1045	247	8:00 am – 1:45 pm	<i>Abstract Withdrawn by Author</i>	
<b>Asian Pharmacoevidence Network (AsPEN) SIG Poster Walk Session</b>				
863	248	8:00 am – 1:45 pm		Poster
865	249	8:00 am – 1:45 pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<b>Medical Devices SIG Poster Walk Session</b>				
1041	250	8:00 am – 1:45 pm		Poster
1042	251	8:00 am – 1:45 pm		Poster
1043	252	8:00 am – 1:45 pm		Poster
1044	253	8:00 am – 1:45 pm		Poster
1046	254	8:00 am – 1:45 pm		Poster
1047	255	8:00 am – 1:45 pm		Poster
<b>Drug Utilization Research/Health Services Research SIG Poster Walk</b>				
839	256	8:00 am – 1:45 pm		Poster
911	257	8:00 am – 1:45 pm		Poster
935	258	8:00 am – 1:45 pm		Poster
955	259	8:00 am – 1:45 pm		Poster
958	260	8:00 am – 1:45 pm		Poster
1039	261	8:00 am – 1:45 pm		Poster
<b>Biologics SIG Poster Walk Session</b>				
867	262	8:00 am – 1:45 pm		Poster
870	263	8:00 am – 1:45 pm		Poster
875	264	8:00 am – 1:45 pm		Poster
877	265	8:00 am – 1:45 pm		Poster
878	266	8:00 am – 1:45 pm		Poster
881	267	8:00 am – 1:45 pm		Poster
887	268	8:00 am – 1:45 pm		Poster
888	269	8:00 am – 1:45 pm		Poster

